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ABSTRACT
ADIPOSE-DERIVED STROMAL VASCULAR FRACTION THERAPY IMPROVES
AGE-RELATED ADRENERGIC MEDIATED MICROVASCULAR DYSFUNCTION
AND INCREASES REVASCULARIZATION POTENTIAL FOLLOWING INJURY
Gabrielle Brown
May 14, 2022
The role of the microcirculation is to balance blood flow and oxygen delivery to
meet local metabolic and oxygen demands. With advancing age, the health of the
endothelium declines leading to improper augmentation of the microcirculation;
decreasing vasoreactivity and angiogenic potential which can further increase the risk of
ischemia. The multiple contributing factors that drive the decline in endothelial health
with age make traditional pharmacological interventions challenging whereas cell-based
therapies can exert multifactorial gains. Adipose-derived stromal vascular fraction (SVF)
is an emerging therapeutic for its easily accessible, autologous, anti-inflammatory, and
angiogenic properties. It is a heterogenous population comprised of leukocyte and
vascular cell populations as well as a small population of mesenchymal stem cells.
Coronary perfusion and isolated coronary microvessels from young, old, and old treated
with young SVF, female Fisher-344 rats were examined for health and functionality to
beta-adrenergic receptor agonists (b-AR). Advancing age decreases coronary perfusion
and vasoreactivity to b1-AR agonist norepinephrine (NE). A one-time tail vein injection
vi

of 10 million SVF cells 4 weeks prior reversed the age-related impairment in coronary
microvascular dysfunction. Furthermore, isolated coronary microvessels from young, old,
and old treated with SVF rats were examined for age- and SVF-related alterations in b1AR cell signaling. Advancing age reduced the expression of b1-ARs on coronary
microvessels and increased the expression of vasodilatory inhibitors, GRK2 and Gai.
While SVF fully restored the b1-AR population it only marginally mitigated the inhibitor
expression back to young control levels. Advancing age altered the cellular composition
of SVF promoting a more pro-inflammatory phenotype with increased M1 macrophages
and various types of T cells with a reduced mesenchymal stem cell population.
Intravenously injected SVF can disseminate and engraft into the microcirculation of
mesenteric windows; connective tissues located along the small intestines. SVF from
young donors can significantly increase vascularized area of an aged mesenteric window
subjected to a hypoxic-like injury compared to aged SVF which only marginally
improves vascular area. Advancing age can drive a decline in the functionality of the
microcirculation. SVF therapy offers a promising vascular therapeutic reversing the agerelated dysfunction, increasing organ perfusion, and promoting revascularization
following injury.
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CHAPTER 1
INTRODUCTION

The cardiovascular system is comprised of the heart and all the blood vessels of
the body. The vascular portion of the circulation can be divided into several categories
based upon anatomical structure: conducting arteries, resistance arterioles, capillaries,
venules and veins. The large conducting arteries such as the aorta and carotids have
multiple thick layers consisting of vascular smooth muscle, elastin, and collagen, all
contributing to their distensibility property. These components allow the large vessels to
dampen the pulse pressure derived from the left ventricle (LV) [1]. The vascular wall of
arterioles is primarily composed of smooth muscle cells which allow the vessels to dilate
or constrict over a considerable range in response to agonists and antagonists. These
vessels range from 20-100 µm in diameter [2, 3]. Capillaries are vessels consisting of a
single layer of endothelium and <10 µm in luminal diameter, which facilitate the
exchange of gases and metabolites [4]. Arterioles and capillaries are part of the
microcirculation (in addition to venules) [5] whose role it is to regulate blood flow to
tissues in response to tissue metabolites and neural innervation [6].
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Sympathetic Control of the Microcirculation
The myocardium and microcirculation are innervated and respond to
norepinephrine (NE), an adrenergic catecholamine released by the sympathetic nervous
system. NE initiates its effect by binding to G-protein coupled adrenergic receptors (ARs)
resulting in activation of the receptor through conformational change [7]. Families and
subcategories of ARs are grouped based upon their structure, associated intracellular
proteins, and elicited effect [8]. The expression of ARs varies based upon tissue and in
the case of the vasculature, expression can differ with branching order [9]. In the
myocardium, there is 4:1 ratio of beta-1 (β1-AR) to beta-2 AR (β2-AR), with minimal
expression of the beta-3 AR (β3-AR) [10, 11]. In the vasculature, β2-AR is more
abundant in the vascular smooth muscle cells (VSMCs) than on the endothelium of the
arterioles. In the coronaries, specifically, the endothelial cells predominantly express β1ARs while the VSMCs express β1-AR as well as alpha-1 ARs (a1-ARs) [12-14]. As
branching order increases, relative expression of β1- and α1-AR decreases whereas β2-,
β3-, and alpha-2 (α2-AR) adrenergic receptors increase [9]. While there is some β3-AR
expression in the vasculature, expression is minimal but, interestingly, it is found most
abundantly in white and brown adipose tissue [15, 16].
The major role of these receptors in the heart is to increase altering inotropy,
lusitropy, and chronotropy [17, 18] or to mediate vasorelaxation (β-ARs) or
vasoconstriction (α-ARs) via agonism. In the vasculature, all three β-ARs are associated
with a stimulatory G-protein (Gs) to activate adenylate cyclase which in turn converts
ATP into cyclic AMP (cAMP), leading to activation of protein kinase A to phosphorylate
the myosin light chain kinase, resulting in inactivation of the myosin light chain and
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inducing vasodilation [19, 20]. The α1-ARs activate a Gq alpha subunit and
phospholipase C to hydrolyze phosphatidylinositol 4,5-bisphosphate into diacylglycerol
and inositol triphosphate, which in turn activates its receptor in the endoplasmic
reticulum to release calcium and induce vasoconstriction. On the other hand, α2-ARs
induce vasoconstriction via activation of an inhibitory G-protein (Gai), thereby inhibiting
AC. In healthy vessels, there is a favoring of β-AR mediated vasodilation to α-AR
mediated vasoconstriction. The stimulatory proteins of β-ARs that induce vasodilation
are the main intracellular second messengers of this signaling cascade, though inhibitory
and regulatory proteins are also associated with the β-ARs. Of note, β2- and β3-ARs are
functionally distinct from β1-AR by their ability to also deactivate ACs by coupling to a
Gai subunit [8].
Another regulatory protein in the β-AR signaling cascade belongs to a family of
proteins called G-protein receptor kinases (GRKs). Upon catecholamine-receptor
binding, GRK2 causes phosphorylation of internal tail of the β-AR thereby sterically
hindering the Gs protein coupling [21]. In addition, GRK-mediated phosphorylation
recruits β-arrestin to the receptor-GRK complex, further causing steric hindrance and
desensitization [17]. β-arrestin primes the β-receptor for dynamin-mediated
internalization into clathrin-coated endosomes for storage, trafficking to lysosomes for
degradation, or eventual recycling to the plasma membrane [22-25]. These prodesensitization and internalization processes exist in a homeostatic balance with the
process of resensitization, where β-AR receptors are dephosphorylated at the plasma
membrane or predominantly in the endosome, then trafficked back to the plasma
membrane ready to receive agonistic signals and induce vasodilation again [20, 26-29].
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Resensitization is mediated by phosphatases, namely protein phosphatase 2A [30]. While
adrenergic-mediated vasorelaxation is one mechanism microvessels use to augment blood
flow, vasodilation can also be achieved through other adrenergic receptor agonists such
as dobutamine [31], or through endothelium-independent mechanisms such as nitric
oxide (NO) being produced in response to increased intraluminal flow [32, 33].
New Microvessel Development
The oxygen needs of a tissue are met through the regulation of blood flow, but
also through angiogenesis, or growth of new blood vessels, if more blood flow is needed.
The formation of new blood vessels stems from hypoxic regions of a given tissue
generating hypoxia inducing factor-a, followed by local endothelial cells producing
vascular endothelial growth factor (VEGF) and plasma derived growth factor (PDGF) in
response. This stimulates the differentiation of an endothelial cell into a tip cell which
forms a stalk, ultimately leading to the generation of a capillary sprout from existing
vasculature [34]. Not only does this process occur in areas of hypoxia but also in areas of
healing following injury. Microvascular regeneration or repair is a multistage process
involving progressive changes in microvessel phenotypes and microvascular networks.
Importantly, repairs leading to effective perfusion involve not only deriving new
microvessels and vessel segments, but the coordinated organization of these elements into
a new or existing network that now meets the perfusion, metabolic, and functional needs
of the tissue [35-37]. Adaptation of the neovessels in the context of this network reorganization is a dynamic, multi-cell process involving neovessel pruning or remodeling
into arterioles, capillaries, or venules [38]. Critically important to the vascularization

4

outcomes is the establishment of vasoactive regulation of the new microvasculature to
enable proper physiological responses to tissue function [39-42].
Microvascular Pathologies and Aging
Pathologies of the vasculature and microvasculature are often complex in nature,
leading to loss of physiological homeostatic regulation of patency and adequate perfusion
to match tissue metabolic demands. Contributing pathological factors include endothelial
dysfunction, oxidative stress, mitochondrial dysfunction, endoplasmic reticular stress,
loss of angiogenic potential and vascular density, and greater senescence and apoptosis.
In the setting of advanced age, many of the factors listed have already initiated and
pushed the tissue environment into a pathophysiological outcome when a remodeling
stimulus arises [43]. Aging has long been considered an unmodifiable risk factor for the
development of vascular pathologies [44, 45]. The age-related impairment in vascular
remodeling is most apparent in the microvascular networks and is caused by a decline in
the health of the endothelium [46].
As early as age 40, a decline in endothelial function can develop, with most
clinical manifestations apparent around 50 years of age followed by a steep decline in
function as age continues to advance [47]. With the world’s population of aged
individuals ever increasing, peripheral vascular disease (PVD) is a major cause of
ischemic injury and mortality [48, 49]. PVD is a broad disease that encompasses large
artery atherosclerotic plaque obstructions to non-occlusive microvascular disease (MVD).
In the periphery, MVD can lead to organ perfusion/demand mismatch and ultimately
organ failure or loss of limb [50, 51]. With advancing age, coronary perfusion is
compromised by ~43% which correlates negatively with myocardial flow reserve, all of
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which exacerbate coronary microvascular dysfunction (CMD) [52, 53]. To assess the
structure and functionality of the coronary microcirculation, a coronary flow reserve
(CFR) can be measured and obtained through non-invasive echocardiography testing.
CFR is calculated via dobutamine (Dob, β1-AR agonist) or adenosine infusion which
increases blood flow (BF) velocity through the left anterior descending (LAD) artery.
CFR is calculated as a ratio of LAD velocity during stress (Dob or adenosine) compared
to LAD velocity during rest, highlighting the adrenergic ties in CMD [54, 55]. Clinically,
CMD is defined as CFR ≤ 2.5, endothelial dysfunction with constriction to acetylcholine
(Ach), or <20% coronary dilation to nitroglycerin [56]. CMD represents significant
societal economic cost burden, similar to that of obstructive disease (~$750,000 vs.
~$1,000,000 lifetime cost burden), driven by repeat angiography, increased anti-ischemic
therapy costs and increased hospitalization, thus showcasing the significance of this
pathology and need for comprehensive management strategies [57].
Mechanisms of Microvascular Disease
Oxidative Stress. The decline in the health of the vasculature in advancing age
occurs through several mechanisms, including increased systemic oxidative stress [58],
cellular senescence [59], and inflammation [60], all of which drive endothelial
dysfunction and subsequent development of MVD [43, 61]. Oxidative stress is an
increase in reactive oxygen species (ROS) which can rapidly combine with NO
producing a reactive peroxynitrite [62] and reducing the bioavailability of NO.
Furthermore, the expression levels of endothelial nitric oxide synthase decrease as aging
progresses [63]. Cellular senescence refers to the limited number of cell divisions one cell
can undergo due to genetic and morphological changes [64, 65] which can be brought
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about through loss of telomeres, then DNA from repeated cellular divisions [66]. In
endothelial cells, cellular senescence can present as decreased endothelial cell
proliferation and impaired migration and dysfunction [67] which can be reversed through
induction of telomerase [68]. Cellular senescence is also characterized by the senescenceassociated secretory phenotype, whereby cells exhibit increased secretion of interleukins,
chemokines, growth factors, matrix metalloproteinases, insoluble proteins and
extracellular matrix [65]. This leads to a pro-inflammatory state with feedforward
mechanisms that further increase oxidative stress.
Inflammation. The term “inflammageing” refers to a pro-inflammatory state
associated with aging and is defined by increased blood markers of inflammation without
a triggering event, with simultaneous reduction of capacity to launch an appropriate
inflammatory response when a triggering event does occur [65, 69]. Inflammageing is a
dynamic process occurring with age as each individual cytokine increases at different
ages and with different slopes, and can vary greatly by individual [70]. At some unknown
point in the aging process, the increases of various cytokines/factors culminate in
pathological effects, thereby setting a pathological threshold. This threshold is lowest for
individuals 60-80 years old leading to a decline in vascular health. Chronic inflammation
has been shown to drive cellular senescence and increased apoptosis [71], decreasing
endothelial cell proliferation [72] which can lead to diminished tissue repair following an
injury [73, 74]. Specifically, normal aging-related increases include: interleukins (IL), IL1, IL-6, IL-8, IL-13, IL-15, IL-18, C-reactive protein, interferon α and β, transforming
growth factor β (TGFβ), tumor necrosis factor α (TNFα), monocyte chemoattractant
protein-1 (MCP-1), along with decreases in VEGF and IL-2 [65, 75-81]. The factors
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described above are part of the multifaceted pathologies of age-related generators of
endothelial dysfunction.
Endothelial Dysfunction. Age-related endothelial dysfunction can impact the
health of the microvasculature and regulation of blood flow through feed forwards
mechanism involving adrenergic receptor desensitization and impairments in
revascularization following injury. Aging leads to an overload of catecholamines released
from the sympathetic neurohormonal system; while initially protective against a declining
cardiac output, excess catecholamines can cause compensatory receptor degradation after
prolonged stimulation [82-85]. The β-AR has been shown to decrease in sensitivity and
density with age in the myocardium, aorta, mesentery, and coronary vasculatures [39, 8690]. The catecholamine mediated desensitization can reduce the population of the β1-AR
from 77% to 60% in the myocardium [10, 91-93] and results in a shift away from
coronary vasodilation and toward vasoconstriction as the α-ARs remain unchanged with
age [9, 92, 94-96]. Improper augmentation of blood flow in response to vasodilatory
stress can lead to poor perfusion and increased risk of ischemic injury [97, 98]. A
therapeutic that restored the beta-receptor sensitivity (Chapter 2) and population
(Chapter 3) back to youthful levels would be a desirable therapy in reducing the
ischemic risk of this aged population.
Angiogenic potential. Endothelial health parallels the capacity of a microvascular
network to sprout new vessels via angiogenesis and collateralization, the process of
forming vessels around ischemic areas. Thus, microvascular growth and network
remodeling are crucial for the maintenance of the overall health and functionality of an
organ [99]. Advancing age and endothelial dysfunction impairs angiogenesis by
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compromising endothelial cell proliferation, inducing endothelial cell apoptosis,
dampening cell migration, increasing endothelial cell senescence, and reducing levels of
VEGF and PDGF needed for stalk formation [100-103]. This results in the older
population being more susceptible to injury and illness [104], while also taking up to
twice as long to heal as measured by time for re-epithelization of subcutaneous wounds
[105]. Increasing the density of the microcirculation could serve as a preemptive measure
to increase blood flow to a tissue decreasing the ischemic risk and enhancement of
angiogenesis following an injury would serve as a valuable therapeutic for aged patients
(Chapter 4). Currently, no drug regimen of this nature exists as aberrant and
uncontrolled vascular growth is a hallmark within a tumor environment.
Collateralization, or the growth of new blood vessels to service a tissue because
existing networks cannot sufficiently supply blood flow, is significantly reduced after
injury in patients >70 years old [106]. Proper collateral vessel development is dependent
upon upregulation of PDGF on infiltrating cells [107] and endothelial function. PDGF
stimulates maturation of blood vessels by smooth muscle cell and pericyte recruitment
[108], as immature, uncoated vessels die in a process called rarefaction, a phenomenon
that is increased in aged vascular beds [109, 110]. Plasma samples from healthy
individuals showed that there is a reduction in basal levels of PDGF as early as 25 years
of age [111]. Taken together, those of advanced age experience endothelial dysfunction
which increases the risk of ischemic injury, exacerbated by reduced capacity to
revascularize the ischemic area, and once ischemia and cell death occur there is aberrant
repair. However, the rate of age-related deterioration can differ substantially across subpopulations and individuals [112]. This leads to a question for future consideration: do
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specific aging-related changes explain why some sub-populations are more prone to
certain CMDs, and can this association be amenable to manipulation in terms of
therapeutic targeting?
Post-menopausal Women and Coronary Microvascular Disease
A population at risk for aberrant cardiovascular remodeling are post-menopausal
women. Normally with advancing age, ovarian production of estrogen drops by 90%; the
conversion of androgens in adipose tissue then becomes the predominant source of
estrogen after menopause [113]. Post-menopausal women are at higher risk for CMD
compared to their age-matched male counterparts [74]. Furthermore, CMD manifest
differently in the sexes. Unlike men who predominately present with large vessel
atherosclerosis, as many as 50% of women referred for cardiac evaluation do not have
obstructive coronary disease but present with coronary microvascular
dysfunction/ischemia [114] representing ~ 90,000 cases per year, a lifetime cost burden
of $1 million, and up to an 8% 5-year mortality rate [57, 115]. Women presenting with
CMD show signs of heart failure with preserved ejection fraction [116]. This unique
presentation of microvascular mediated heart failure is also common in oophorectomized
young women, suggesting that estrogen plays an important role in the vitality of blood
vessel function [117]. Vascular dysfunction in postmenopausal women is prominent in
the resistance vessels of the heart [118]. Further, decreased CFR [119] and impaired
angiogenesis become apparent when circulating estrogen declines due to decreased
VEGF signaling from the estrogen receptor-2 [120]. Given the importance of the
microvasculature in tissue health, it is not surprising that compromised or dysfunctional
microvessels contribute to many disease conditions. In many instances, microvascular
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repair or regeneration to restore microcirculatory health are necessary components to
treating the disease. For example, instances of microvascular insufficiency, i.e. situations
of reduced perfusion due to low vascular densities and/or compromised vasodynamics,
contribute to or cause tissue ischemia, non-healing ulcers, limited tissue metabolism and
health, and further complications related to aging [39, 40, 43, 121-125].
Treating Coronary Microvascular Disease
Therefore, therapeutics to improve microvascular function target a tightly
controlled multi-cell process, and in the context of advancing age, pathophysiological
remodeling has taken hold. Unfortunately, the traditional pharmaceuticals currently
available for vascular diseases are targeted at mitigating one aspect of multifactorial
pathologies [126]. While helpful in preserving myocardial β-AR sensitivity by reducing
the workload of the myocardium, first-generation beta-blockers are non-specific [127]
and little is known of their consequence to the vasodilatory function of coronary
microvessels [128]. Although nitrates may provide acute relief of symptoms, there is little
evidence of reduced major adverse cardiac events or mortality [129, 130]. Further,
nitrates cause rebound angina and increase oxidative stress, and are difficult to manage.
Despite these limitations, they are still the recommended treatment for CMD focusing on
anti-ischemic protection via reduced inotropism and oxygen conservation [131].
Not only are the current treatments aimed at improving vascular function
superficial in their therapeutic capacity; targeting the age-related chronic inflammation
impairing revascularization following injury are unfavorable as well. Although
pharmacologic anti-inflammatories are used clinically, caution is warranted, as a robust
increase in inflammatory markers is the first critical step in tissue healing following
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injury. However, in older patients, this inflammatory spike is blunted [69]. Current antiinflammatory pharmacologics have shown no efficiency in improving age-related
microvascular endothelial dysfunction [132] and have also been shown to delay wound
healing by inhibiting angiogenesis [133]. In an acute setting of MI, nonsteroidal antiinflammatory agents such as ibuprofen may lead to delayed necrosis yet ultimately yield
expanded infarct regions, increased tendency for ventricular rupturing, and overall worse
clinical outcome including increased incidents and recurrent myocardial infarction (MI)
[134]. As a preemptive measure, hormone replacement therapy has been utilized to stave
off the declining effects from a lack of estrogen, but many clinical trials showed little to
no vascular benefit and even adverse effects of hormone replacement therapy in aged
females [135]. A novel strategy that can holistically treat each facet of CMD
pathophysiology by mending the pathologic microvessels themselves, rather than merely
treating their symptomatic consequences, is of significant clinical interest which parallels
the multi-faceted gains seen in cell-based therapies [126].
Cell-based Therapeutics
Potential Mechanisms. Initially used to treat leukemia in the 1950’s, cell-based
therapeutics are currently being utilized in 5,000 active clinical trials [136], with 900
focused on treating cardiovascular diseases (according to a search on March 2022 on
grants.gov). While stem cell therapies have been around for more than 70 years, the
scientific field is still exploring their enigmatic nature. They are thought to act by cellular
engraftment into the host tissues and/or delivering paracrine factors that promote
angiogenesis and modulate inflammation within the treated tissue [137-143]. The
“paracrine hypothesis” suggests stem cells exert much of their beneficial effect on
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damaged tissue through the paracrine action of their secretome (i.e. exocytosed contents
or vesicles) rather than engraftment of stem cells into damaged tissue [144]. Using cell
culture systems that prevent direct contact while allowing exchange of factors in the
shared media, it is established that stem cells can exert regenerative, differentiation
induction and pro-angiogenic effects via paracrine mechanisms [145, 146]. Exosomes are
membrane-bound vesicles ranging from 30-150 nm released from cells that function in a
paracrine manner transporting proteins, lipids, RNAs, microRNAs, mitochondria and
more between cells [144, 147, 148]. Although the majority of the field has moved to
identify the paracrine hypothesis as the prevailing theory for the majority of stem cell
mediated vascular regeneration, there is still relevance for the direct mechanism, i.e.
engraftment, such as differentiation and direct transfer of cellular contents which should
not be wholly discounted.
Ideal Donor. Given the biological complexity intrinsic to microvascular
regeneration, repair and tissue vascularization, many cell-based approaches are showing
great promise in regenerating or improving microvascular form and function. Here, these
cell therapies act mostly in a paracrine factor through secreted factors or exosomes, or
through direct cell interactions such as differentiation, or also through multiple cell
interactions such as interactions of donor perivascular niche with endothelial cells [148151]. There is current discussion about which strategy is most appropriate for stem cell
therapy, either using allogeneic cells that can be more readily obtained, or autologous
cells that better match host biologic and immunologic dynamics. This debate is often
referred to as “self or shelf”. If one were to imagine the “ideal stem cell donor candidate”,
its properties would include a young person with no prior disease history, healthy

13

lifestyle habits whose stem cells would be at no risk for causing rejection/immune
response, maximum potential for engraftment, survival, and proliferation, as well as
maximal and consistent secretion of therapeutic factors. Likewise, the ideal stem cell
recipient for most successful therapeutic benefit would be someone with minimal disease
progression (preventative care) with limited co-morbidities and healthy lifestyle habits. In
reality, patients often have multiple co-morbidities and progressive disease presentation.
Similarly, donor stem cells, even from an ideal stem cell donor candidate, can still
potentially elicit immune responses [152]. How would one choose the universal stem cell
donor that these allogeneic cellular therapeutics are based on?
Allogeneic stem cells are derived from a non-self-donor of the same species.
Potentially, allogeneic stem cells could be produced in enormous quantities and readily
available on a large pharmaceutical scale for clinical use, i.e. “off the shelf.” Issues of
collection, aging, and disease states can be avoided with use of an ideal donor, who may
be a young individual without chronic disease history and a healthy lifestyle [153]. The
challenges of allogeneic stem cell sources include immune reactions to the human
leukocyte antigens on donor cells, infection transmission from donor to patient, and
ethical concerns if the cells are isolated from an embryological source [153]. Pivoting to
autologous stem cells, their use dismisses the immunological concerns of non-self-tissue
and the ethical concerns that may come with use of embryological tissue. There is greatly
decreased risk of transmitting infection from donor to recipient. However, autologous
stem cell use can be complicated by cell age and disease states that cause cellular
dysfunction [154, 155]. Patients with disease caused by gene defects may not receive any
benefit via therapy with autologous cells. The vast number of cells necessary to collect
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for expansion ex vivo makes collection from autologous donors challenging especially in
aged or diseased states [153].
Mesenchymal Stem Cells
Due to the challenges presented above, mesenchymal stem cells (MSCs) are a
highly sought-after cell source as an allogeneic or autologous vascular therapeutic. MSCs
are relatively hypo-immunogenic [156] with approximately half of international clinical
trials from 2004-2018 using allogeneic MSCs as their source [157, 158]. These MSCs
exhibit a hypo-immunogenic property due to their capacity to be conditional antigen
presenting cells in the early phase of an immune response [159, 160] then
immunomodulate through secretion of soluble factors [161, 162]. Preclinical and clinical
trial evidence shows MSC therapy to have a multifactorial effect in immune modulated
reduction in fibrosis, reduction of hypoxia and oxidative stress, and non-pathological
extracellular matrix remodeling. In a setting of MI, MSCs have been shown to reduce
scar formation and improve cardiac functions as measured by echocardiography [163,
164]. However, there are conflicting results in MSC efficacy due to variable such as
autologous vs allogeneic, dose, and route of administration [165]. On the other hand,
MSCs have been shown to increase angiogenesis to further reduce hypoxia and hypoxiainduced oxidative stress [166-168]. A pre-clinical study utilizing a mouse model of MI
showed that administration of isogenic MSCs 3-hours post-ischemia resulted in a reduced
infarct size, improved LV function, and increased capillary density 4-weeks later [169].
These results were corroborated in a similar study but at a 12-week-endpoint [170].
Initially, the therapeutic mechanism behind some of the gains seen following
MSC therapy was due to their differentiation potential, as MSCs can differentiate beyond
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their biological blood/bone niche into various cells such as hepatocytes, epithelial cells,
or neural cells generated by co-culturing with cytokines during in vitro expansion for cell
therapy applications [171-173]. However, engraftment and direct differentiation does not
always lead to recovery of cardiovascular function. For instance, amnion-derived MSCs
can differentiate to cardiomyocyte and endothelial-like cells in a rat model of heart
failure, but this came without recovery of cardiac function or reduction in fibrosis [174].
The lack of long-term cell retention, low efficacy, and laborious task of harvest and
culture of bone marrow-derived cells led to the use of other sources of cell-based
therapies notably adipose-derived stromal vascular fractions (SVF).
Adipose-derived Stromal Vascular Fraction as a Therapeutic Candidate
SVF can be harvested from lipo-aspirate utilizing mechanical or enzymatic
digestion of the biological matrix [175]. Recently, medical equipment has been designed
and developed that perform this isolation in the operating suite [176]. With the ability to
leverage a real-time point-of-care therapeutic approach, specifically through ease of
isolation and the availability of autologous sources, SVF has become an ideal candidate
in vascular therapeutics [177, 178]. The isolation of adipose stromal cells with multilineage differentiation potential was first reported in the peer-reviewed literature in 2001
[179]. In recent years, the use of SVF has emerged as an alternative therapeutic strategy
with clinical trials for arthritis, stroke, pulmonary disease, inflammatory bowel, and
ischemic cardiomyopathy [180-183]. Further, SVF’s use in clinical trials aimed at
vascular therapies and vascular regeneration is growing exponentially [184].
SVF is inherently a heterogeneous cell population comprised of mostly
endothelial cells, smooth muscle cells, pericytes, fibroblasts, hematopoietic cells such as
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macrophages, B cells, and T cells, natural killer, and dendritic cells, and a small number
of MSCs [176, 185]. These various cell types are theorized to be an optimal milieu of
environmental cues to stimulate SVF engraftment or release of paracrine factors within a
tissue to enhance vascular function [186-188]. Further, the benefit of multiple anatomical
locations for harvesting and yielding more cell populations gives adipose tissue a greater
autologous benefit. Bone marrow-MSCs were initially hailed as the superior autologous
cell source to treat MI because of their differentiation potential [171, 172], but recent
studies have shown equal efficacy of adipose-derived SVF in improving cardiac function
after MI and in vitro induction into cardiomyocyte-like-cells, promoting angiogenesis and
reducing inflammation [189-195]. This greater efficacy was shown to be in part due to
SVF having greater cytokine production, secreting anti-inflammatory and angiogenic
growth factors [196-199]. Continuously, a single administration of SVF has been shown
to persist as far out as 8 weeks [200], and a single intravenous (i.v.) administration also
results in a wide biodistribution [42]. Interestingly, SVF cells can incorporate into the
vascular wall long-term [42] and are associated with normalization of inflamed large
vessels [201]. The significant potential of microvascular cell-based therapies is being
realized in ongoing and recently completed clinical trials, building on current levels of
understanding and highlighting future directions for investigation.
Despite these benefits of cell-based therapies, there are few studies conducted
using advanced age as the model of pathology. The studies presented in this dissertation
describe the use a female rat model of advanced age to understand how aging alters
microvascular function (Chapter 2-3) and vascular growth (Chapter 4). While these
clinical trials have shown beneficial effects of SVF administration, to date it is not
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approved by the Food and Drug Administration due to questions regarding therapeutic
mechanism along with treatment timing, cell dose, and duration. Regardless of the
growing number of studies proving SVF’s therapeutic efficacy in promoting healing as
described above, there is a gap in understanding SVF’s therapeutic contribution to an
aging vasculature. There is also a need to better understand how SVF cells spatially and
temporally contribute to neovascularization and blood flow within a vascular bed. The
ultimate goal is to deliver cells to influence and promote microvascular growth and
function. These intriguing questions discussed above frame the context of the studies
conducted in this dissertation.
The overall hypothesis of this proposal is that advancing age impairs vascular
function by reducing vasodilatory sensitivity and decreasing angiogenesis; both of which
are improved following SVF therapy. The knowledge of how age affects the
cardiovascular system is ever growing but the anatomic limitations of the
microvasculature have made examining it in situ/in vivo a challenge. Additionally, this
faction of the cardiovascular system is often overlooked in studies examining SVF’s
efficacy as a therapeutic. Here, we utilize an aged rat model in combination with adiposederived SVF therapy to examine the microvascular reactivity effects in the coronary
microcirculation, as well as the angiogenic and incorporation potential of SVF in the
mesenteric microcirculation for the reasons detailed above. The goals of this project were
the following:
1. To determine if there is an age-related impairment in coronary
microvascular vasodilation that can be reversed with SVF therapy
(Chapter 2). Coronary microvascular function in young (3 mo), old (24 mo),
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and old treated with a 1-time tail vein injection of 10 million SVF cells
(O+SVF, 24 mo) female Fisher 344 rats was assessed using
echocardiography, pressure-volume loops, and isolated coronary
microvascular preps. The impact of age and SVF therapy on microvascular
health and subsequent impairment in left ventricular function was measured
by pressure-volume loops and blood flow through the LAD during rest and
stress trial (coronary flow reserve, CFR). Individual isolated and pressurized
coronary microvessels were used to determine sensitivity to beta-adrenergic
agonists and antagonists.
2. To determine where in the intracellular beta-adrenergic signaling cascade
age-related impairment and SVF-related improvement occurs (Chapter
3). Coronary microvascular function in young (3 mo), old (24 mo), and old
treated with a 1-time tail vein injection of 10 million SVF cells (O+SVF, 24
mo) female Fisher 344 rats was assessed using isolated coronary microvessels
subjected to immunofluorescence, pressure myography, and Next Gen RNA
sequencing. Multiple proteins involved in the beta-adrenergic mediated
signaling cascade were probed for expression, functionality in contributing to
vasodilation, and transcriptional changes in response to age or SVF therapy.
3. To determine the effect of donor age on SVF’s angiogenic potential in an
aged and injured vascular bed (Chapter 4). The cellular populations of
SVF were examined for changes due to donor age in female Fisher 344 rats.
Mesenteric windows from old (24 mo) female Fisher 344 rats were examined
for SVF integration following i.v. injection with and without exteriorization
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injury. The administered SVF was from young (4-9 mo) or old (24 mo) donors
to examine age-related changes to angiogenic potential in revascularization.
The T cell population was isolated or depleted from SVF to determine if T
cells are a main cell type needed for promoting revascularization following
injury and responsible for SVF’s angiogenic gain.

Much of this chapter is from the published works referenced as follows:
Tracy, E. P., G. Rowe, and A.J. LeBlanc, Cardiac Tissue Remodeling in Healthy Aging:
The Road to Pathology. Am J Physiol Cell Physiol, 2020.
Tracy, E.P., et al., Aging Induced Impairment of Vascular Function - Mitochondrial
Redox Contributions and Physiological/Clinical Implications. Antioxid Redox
Signal, 2021.
Tracy, E.P., et al., State of the Field: Cellular and Exosomal Therapeutic Approaches in
Vascular Regeneration. Am J Physiol Heart Circ Physiol, 2022
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CHAPTER 2
ENHANCED BETA-1 ADRENERGIC RECEPTOR RESPONSIVENESS IN
CORONARY ARTERIOLES FOLLOWING INTRAVENOUS STROMAL
VASCULAR FRACTION THERAPY IN AGED RATS

Overview
Our past study showed that a single tail vein injection of adipose-derived stromal
vascular fraction (SVF) into old rats was associated with improved dobutamine-mediated
coronary flow reserve. We hypothesize that intravenous (i.v) injection of SVF improves
coronary microvascular function in aged rats via alterations in beta adrenergic
microvascular signaling. Female Fischer-344 rats aged young (3 months, n=32) and old
(24 months, n=30) were utilized, along with two cell therapies i.v. injected in old rats
four weeks prior to sacrifice: 1x107 green fluorescent protein (GFP+) SVF cells (O+SVF,
n=21), and 5x106 GFP+ bone-marrow mesenchymal stromal cells (O+BM, n=6), both
harvested from young donors. Cardiac ultrasound and pressure-volume measurements
were obtained, and coronary arterioles were isolated from each group for microvessel
reactivity studies and immunofluorescence staining. Coronary flow reserve decreased
with advancing age, but this effect was rescued by the SVF treatment in the O+SVF
group. Echocardiography showed an age-related diastolic dysfunction that was improved
with SVF to a greater extent than with BM treatment. Coronary arterioles isolated from
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SVF-treated rats showed amelioration of the age-related decrease in vasodilation
to a non-selective β-AR agonist. I.v. injected SVF cells improved β-adrenergic receptor
dependent coronary flow and microvascular function in a model of advanced age.

This chapter is from the published work referenced as follows:
Rowe, G., et al., Enhanced beta-1 adrenergic receptor responsiveness in coronary
arterioles following intravenous stromal vascular fraction therapy in aged rats.
Aging (Albany NY), 2019. 11(13): p. 4561-4578.
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Introduction
Coronary perfusion, reflective of coronary vascular function, is compromised by
as much as 43% in advanced age [52] and can contribute to the prevalence of
cardiovascular diseases (CVDs) such as heart failure (HF) and coronary microvascular
disease (CMD). There are several neurohormonal mechanisms that are activated in order
to maintain resting cardiac output (CO) in aging and HF, including sympathetic overdrive
[83]. As a result of this overactivation, a desensitization/downregulation of cardiac βadrenergic receptors (β-AR) occurs over time which leads to decreased cardiac
contractility and inotropic reserve [202, 203]. This age-related decrease in catecholamineresponsiveness in the elderly, as well as a decrease in β-AR vasorelaxation in both
animals and humans [94, 204, 205], results in a shift away from coronary vasodilation
and toward vasoconstriction [94].
In a healthy human heart, there is a 4:1 ratio of β1:β2-AR, with minimal
expression of β3-AR [10, 11]. All three β-ARs are associated with the stimulatory G
protein (Gs) activation and can have both stimulatory and inhibitory effects on the heart
by altering inotropy, lusitropy, and chronotropy [17, 18]. While β1-AR is present in all
cardiomyocytes, β2-AR is more abundant in endothelial cells and vascular smooth
muscle cells (VSMC) throughout the body [13, 14], while β3-AR is primarily expressed
in white and brown adipose tissue [15, 16]. Small coronary resistance arterioles, which
determine appropriate increases in vascular blood flow (BF) and can lead to CMD when
dysfunctional, exhibit a predominance of β2-AR [12]. Regardless, an age-associated
decrease in β-AR sensitivity and density, which is consistent across the species, has been
shown in cardiac muscle [87] and has mostly been attributed to a downregulation of β1-
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AR [206]. However, it is unknown if β1- and β2-AR signaling in coronary microvessels
is altered with age. Since b-AR signaling is abnormal in failing hearts as well as in aged
hearts, this pathway is a desirable diagnostic and therapeutic target.
Cell therapies such as mesenchymal stem/stromal cells (MSCs) are thought to act
by delivering paracrine factors that promote angiogenesis and modulate inflammation
within the treated tissue [137-140]. Our laboratory has described how an intravenous
(i.v.) injection of adipose-derived stromal vascular fraction (SVF) was associated with
improved dobutamine-mediated coronary flow reserve (CFR) and diastolic function in
aged rats in vivo compared to old control rats and those injected with an endothelial cell
population [42]. Even though we identified incorporated green fluorescent protein
(GFP+) SVF cells in the cardiac and coronary vascular tissue upon explant, isolated
coronary vasoreactivity to endothelin, bradykinin, and increases in pressure did not reveal
group differences in this study, which led us to explore changes in adrenergic-specific
signaling following SVF injection. Previously, MSCs have been shown to influence
adrenergic signaling in two models. In 2006, intramyocardial injection of bone-marrow
MSC (BM-MSC) led to β-AR upregulation and improved cardiac contractility in a model
of non-ischemic HF in rabbits [207], while a more recent study described the rescue of
cardiac function under adrenergic challenge in diabetic rats after i.v. injection of BMMSCs with concomitant restoration of β1-AR mRNA expression in the left ventricle
(LV) [208]. However, it is not known if either BM-MSC or SVF cell therapies restore
adrenergic signaling in the heart and coronary microvasculature in a model of advanced
age, and if this occurs through similar mechanisms.
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Therefore, based on the gaps in conclusions from the aforementioned studies, our
purpose was to determine if SVF and/or BM-MSC improve beta-adrenergic signaling in
the aged heart. Our hypothesis was that cell therapy (either BM-MSC or SVF) will
improve β1- and β2-AR-mediated vasodilation in coronary arterioles and this will be
associated with improved CFR in aged rats. We tested this hypothesis by comparing
young, old, and old rats injected intravenously with either BM-MSC or SVF and
evaluated cardiac and microvascular function using ultrasound, pressure-volume (PV)
loops, pressure myography, and immunofluorescence focused on adrenergic-specific
signaling.

Materials and Methods
Animal model, groups, and endpoint procedures.
All animal surgeries were performed in accordance with protocols approved by
the University of Louisville Institutional Animal Care and Use Committee and the
NIH Guide for the Care and Use of Laboratory Animals [209]. Young (3 mo) and old (22
mo) female Fischer-344 rats (Harlan Laboratories, Indianapolis, IN, USA and National
Institute on Aging, Bethesda, MA, USA, respectively) were housed in groups with free
access to food and water and were maintained on regular 12-hour light/dark cycles. Rats
were acclimated to facility conditions for a minimum of one week prior to endpoint
procedures. The remaining old rats were divided randomly into two cell injection groups:
old + GFP+ bone marrow stem cells (O+BM) and old + GFP+ SVF cells (O+SVF). Four
weeks later, old cell-injected rats were 23-24 months of age at endpoint. All animals were
utilized for PV loop data acquisition as well as isolated coronary arteriole experiments. A
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subset of animals from each group were utilized for echocardiography and
immunofluorescence. Animals were anesthetized deeply with a ketamine/xylazine
injection before euthanasia via removal of the heart.
Rat bone marrow cell isolation and culture.
BM-MSC were isolated from femur and tibia bones of young female and male
Fischer-344 GFP+ rats (colony maintained in house) using a protocol modified from
Barbash et al. [210] and Lennon et al. [211]. Briefly, 3-4 donor animals were anesthetized
deeply with 5% inhaled isoflurane balanced with 1 L/min O2 and then euthanized via
removal of the heart. Using sterile technique, femur and tibia bones were exposed and
disarticulated at the associated joints, and extraneous muscle and tissue removed leaving
only the bones of interest. Care was taken to obtain whole intact bones from each animal.
After removal of muscle and connective tissue, bones were stored in DMEM +
Penicillin/Streptomycin on ice. Bone cutters were used to remove the proximal and distal
end from each bone just below the marrow cavity. Whole bone marrow was then flushed
with 10mL sterile Complete Medium (DMEM + 15% fetal bovine serum + Glutamine +
Penicillin/Streptomycin) per bone using a 10 mL syringe and 27g needle; bone marrow
was collected into a sterile 70 µm filter screen fitted onto a sterile 50 mL conical tube.
After filtration, cells were centrifuged at 1400 rpm for 8 min at room temperature and
counted with a hemocytometer. Freshly isolated BM-MSC were cultured with an initial
seeding density of 7.5x107 cells per T75 culture flask in 10 mL Complete Medium; flasks
were placed in a 37°C incubator with 5% CO2 for 3 days, after which medium was
changed every 2-3 days until 95% confluence. Cells were then treated with 0.25% trypsin
at 37°C for 2 minutes and passaged into T75 culture flasks (1.5x106 cells/flask). Media
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was changed every 2-3 days and flasks passaged at 95% confluence; this method was
repeated until cells were harvested at passage 3 or 4 for infusion into O+BM rats.
SVF isolation.
SVF cells were isolated from a GFP+ Fischer-344 rat colony (maintained in
house) as previously described [41, 42]. Briefly, ovarian or epididymal fat pads from
young female and male rats respectively (3-6 mo) were harvested, washed, finely minced,
and digested in 0.75 mg/mL Type I collagenase solution (Vitacyte). Buoyant adipocytes
were removed via centrifugation, and the SVF cell pellet resuspended in 0.1% BSA-PBS
as previously described [41, 42]. Freshly isolated SVF cells were then prepared for
injection into O+SVF rats.
Cell injections.
BM-MSC populations were trypsinized. BM-MSC and SVF isolate were then
washed and filtered separately through a 20 µm screen to eliminate large cell and tissue
aggregates. Cell count was determined with a hemocytometer, and GFP+ fluorescence of
the cell population confirmed via fluorescence microscopy prior to injection. Old female
rats were randomly divided into the two cell injection groups, then injected intravenously
with either 107 GFP+ SVF cells or 5x106 GFP+ BM-MSC in 1 mL Lactated Ringer’s
solution (warmed to 37°C) via the tail vein.

Echocardiography.
Systolic and diastolic parameters.
LV systolic and diastolic function were evaluated by transthoracic
echocardiography using a Vevo 3100 with MS250D transducer with a frequency of 13-24
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MHz as previously described [42] (FUJIFILM VisualSonics Inc., Toronto, Ontario,
Canada). Briefly, rats were anesthetized and maintained with isoflurane (induction
chamber at 5% with 1.5–2.0 L/min O2 flow followed by 1.5% with 1.5 L/min O2 flow).
Rats were then placed in a supine position and the thorax was shaved. Body temperature
was maintained at 37–38°C, and heart rate was monitored using Vevo Imaging Station.
Variables that represent diastolic function - IVRT, E/A and E/e’ ratios - were obtained
during resting condition utilizing an apical four chamber view with conventional pulsed
wave Doppler and tissue Doppler. E/A ratio was calculated from the peak velocity flow
in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial
contraction (the A wave) during resting conditions [42]. Results from five cardiac cycles
during expiration were averaged together and used for between-group and within-group
comparisons.
Coronary flow reserve measurements.
In addition to the standard echocardiographic imaging of cardiac function, a
modified parasternal short-axis projection was used for Doppler recording of the LAD
during rest while animals were anesthetized with 1.5% inhaled isoflurane, and again
during two cardiac stress states induced via dobutamine (Dob, 20 µg/kg/min) and
adenosine (140 µg/kg/min) in a random order. The tail vein was cannulated with a 27gauge butterfly needle for drug administration. Dob and adenosine were infused for a
maximum of 5 minutes using an automated perfusion pump (KD Scientific, Holliston,
MA), with a recovery period between drugs to allow the heart to return to baseline LAD
velocity and heart rate. LAD BF velocity pre-stress and during the stress challenge were
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averaged from three consecutive cardiac cycles and CFR was calculated as the ratio of
the mean peak LAD BF velocity values during each stress condition and rest [212].

Hemodynamic measurements.
Rats were anesthetized with an intraperitoneal injection of ketamine (50 mg/kg) /
xylazine (12.5 mg/kg) / acepromazine (2.0 mg/kg) mix. Conductance readings were made
for ~35–60 min prior to harvesting heart tissue. Briefly, the rat was placed in a supine
position on a 37 °C pad, tracheotomized and connected to a ventilator to control
breathing. The right carotid artery was isolated using silk sutures. The cranial aspect of
the carotid artery was ligated, and a microsurgical clip was placed on the proximal
carotid artery for hemostasis. The chest cavity was opened between the right 5th and 6th
intercostal area and retracted to expose the inferior vena cava (IVC) near the diaphragm;
saline-soaked silk suture was placed under the IVC and left for later use during occlusion
measurements. An arteriotomy was performed with microsurgical scissors, and a 1.9 F
PV 6.00 mm conductance catheter (Transonic, London, ON, Canada) calibrated to
current atmospheric pressure was introduced into the carotid artery. The catheter was
then secured into the carotid artery with sutures and advanced retrograde across the aortic
valve into the LV; continuous hemodynamic monitoring insured proper catheter
placement in the LV. PV loops were recorded in the steady state with the ventilator off
for 8-10 seconds to reduce loop variability. The ventilator was turned on immediately
following baseline recording. After 2-3 minutes of recovery, the ventilator was again
turned off and the silk suture under the IVC was gently lifted to induce occlusion of the
IVC. Immediately following occlusion recording, catheter was removed, and the animal
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was humanely euthanized via vital organ removal. Data recording and analyses of both
baseline and occluded PV loops were performed using LabChart Pro software
(ADInstruments, Colorado Springs, CO).

Subepicardial arteriole isolation experiments.
The heart was removed from each animal and coronary arterioles from the LAD
artery distribution isolated and transferred to a vessel chamber. Arterioles were then
cannulated on both ends, pressurized to 45 mmHg [213], and allowed to develop
spontaneous tone (> 20% constriction from initial diameter) [42].
The following experiments were randomized in each vessel. Concentrationresponse curves to isoproterenol (non-specific β-AR agonist, Sigma-Aldrich I6504),
dobutamine (primarily a β1-receptor agonist with lower β2 activity, Sigma-Aldrich
D0676), NE (α1-, α2-, β1-, and β2-AR agonist, Sigma-Aldrich A9512), and salbutamol
(β2-AR agonist, Sigma-Aldrich S8260). Following the agonist responses, some vessels
were incubated in the β1-receptor antagonist CPG20712A (Sigma-Aldrich C231) prior to
a second concentration-response curve of isoproterenol or NE. Other vessels were
incubated in the β2-receptor antagonist ICI118551 (Sigma-Aldrich I127) prior to a
second concentration-response curve of isoproterenol. A third subset of vessels received
both CPG20712A and ICI118551 simultaneously prior to an additional concentrationresponse curve of isoproterenol. Upon completion of all response curves, vessels were
washed 2x15 min in Ca2+-free physiological salt solution followed by a single dose of
sodium nitroprusside (1e-4 [M]). Maximum diameter was determined as the largest
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diameter achieved throughout the experiment. Tone was calculated as 1-(initial
diameter/maximum diameter) x 100.

Immunofluorescence staining.
Coronary arterioles (750 µm-1 mm in length, < 250 µm in diameter) were isolated
and fixed in 2% paraformaldehyde in 48- well plates for 1-hour, washed 2x10 min in
DCF-PBS, and placed in 0.5% Triton-X/DCF-PBS for 20 minutes at room temperature
(RT). After treating with blocking solution for 1 hour at RT, arterioles were incubated in
a primary β1-AR antibody (Abcam, ab3442, 1:150) or β2-AR (Abcam, ab182136, 1:100)
solution in blocking solution at 4°C overnight with gentle rocking. Normal rabbit serum
replaced primary antibody solution for negative control tissues. A donkey anti-rabbit
IgG-Alexa Fluor 594 (Invitrogen, A21207, 1:300) blocking solution was added to the
tissues and incubated for 1-hour at RT. Nuclei were stained with Dapi. Tissues were
placed on slides with anti-fade mounting media, coverslip added, and imaged using a
Nikon ECLIPSE confocal microscope system (Nikon, Tokyo, Japan) with a 405 and 562
nm laser. Images were captured at 1024X1024 pixel density and 2 µm Z-step (minimum
10 stacks) with a 40X oil immersion objective. Immunofluorescence intensity of β1- or
β2-AR in the region of interest (ROI) boxes were determined by the Nikon NIS Elements
AR Analysis software (Nikon) using 20 µmx100 µm area and at least 8 µm in depth
[214]. ROI boxes were placed on the vascular wall overlapping both the endothelial and
smooth muscle cell layers but excluding the cardiomyocytes.
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Statistical analysis.
Statistical analyses were performed with SigmaPlot 14 (Systat), and the
significance level was set at p ≤ 0.05. Animal characteristics, catecholamine levels,
echocardiography and hemodynamic measurements, and immunofluorescence intensity
were analyzed using one-way ANOVA followed by Holm-Sidak or Dunn’s post hoc tests
where appropriate. When normality tests failed, one-way Kruskal-Wallia ANOVAs were
performed where appropriate. Concentration-response comparisons for between group
differences were analyzed with two-way repeated measures ANOVA. Pre- and postinhibition data were paired for analysis and inhibition of the concentration-response
comparisons for within group differences were analyzed with two-way repeated measures
ANOVA. All significant interactions were further investigated using Bonferroni post hoc
testing. Tone acquired pre- and post-inhibition were analyzed using a paired t-test for
within group difference. Between the groups, tone acquired pre- or post-inhibition were
analyzed using one-way ANOVA. Data are represented as means±SD or SEM as
indicated.

Results
Animal characteristics and circulating catecholamines.
To determine if systemic i.v delivery of SVF or BM-MSC affected fundamental
animal characteristics and circulating plasma catecholamine levels, we collected gross
anatomical measurements and sampled right ventricular blood; these data are presented in
Table 2.1. All aged groups (OC, O+SVF, and O+BM) exhibited increased body weight
(BW), total ventricular weight, and LV weight compared to YC (Table 2.1). There is a
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trend of increasing higher circulating plasma levels of norepinephrine (NE) and
epinephrine (EPI) in OC rats than in YC and O+SVF; although there is not significant
differences between groups (Table 2.1). The O+BM group has significantly lower NE
(0.2±0.03, n=6) and EPI (0.05±0.01, n=6) levels compared to OC (NE 3.32±0.96; EPI
2.12±0.5, n=15) (Table 2.1). There was no difference in plasma levels of serotonin (5HT)
between the groups. The OC (0.12±0.02, n=15) showed significantly higher dopamine
(DA) levels compared to YC (0.04±0.01, n=10) (Table 2.1).

Echocardiography and hemodynamic measurements.
Echocardiography.
To determine whether a cell therapy (SVF or BM-MSC) had any effect on cardiac
parameters in aged animals compared to control, echocardiography was performed during
rest and summarized in Table 2.2. OC rats exhibited a slight increase in stroke volume
(SV) due to increased LV end systolic and diastolic volumes (LVVs/d) and dimensions
(LVDs/d), but ejection fraction (EF) and CO were preserved, however these differences
are not statistically significant (Table 2.2). The O+SVF (2.58±0.44, n=10) and O+BM
(3.32±0.47, n=6) treated groups showed a significant increase in LVDs when compared
to OC (2.17±0.33, n=9, p < 0.05) but only the SVF treated group had a significant
increase in LV mass (500.49±46.39, n=10) when compared to YC (418.92±46.44, n=10)
(Table 2.2). Both cell treated (O+SVF and O+BM) groups demonstrated a statistical
difference when compared to YC in the following parameters: LVDs, LVDd, LVVs, and
LVVd (Table 2.2). The O+BM group had a significant decrease in EF and fractional
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shortening (FS) when compared to YC (Table 2.2). Additionally, the O+BM group had
significantly reduced SV, EF, and FS compared to OC and O+SVF (Table 2.2).
Hemodynamic measurements.
To determine whether a cell therapy (SVF or BM-MSC) had any effect on
hemodynamic variables in aged animals compared to control, PV loop experiments were
performed and summarized in Table 2.2. There were no significant differences regarding
a majority of the PV loop measurements. This is likely due to the differential anesthetic
effects of ketamine used for the PV loop measurements (ketamine is a known cardiac
depressor [215]) vs. isoflurane used during echocardiography. During periods of vena
cava occlusion, preload recruitable stroke work (PRSW) was measured as an index of
myocardial contractility. The O+BM (569.06±149.59, n=6) group showed a significant
loss in PRSW when compared to YC (-2127.74±865.62, n=13) (Table 2.2). Notably,
there were no differences in PRSW between the O+SVF (-1111.31±305.77, n =12)
treated group and YC (-2127.74±865.62, n=13).
Coronary flow reserve.
In order to evaluate the ability of the heart to respond to a stressor, Doppler
recordings of peak left anterior descending (LAD) artery BF velocity were measured
during a Dob or an adenosine infusion (Fig 2.1 A and B). The OC (1.77±0.4, n=9) group
had diminished Dob-induced CFR compared to YC (2.31±0.36, n=10) (Fig 2.1 A).
Treatment with SVF therapy (O+SVF) significantly improved Dob (2.7±0.68, n=10) and
adenosine- (2.6±0.41, n=10) induced CFR when compared to OC (Dob 1.77±0.4;
adenosine 1.61±0.26, n=9), achieving levels similar to YC (Dob 2.31±0.36; adenosine
2.08±0.55, n=10) (Fig 2.1 A and B). Adenosine-induced CFR was significantly lower in
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the O+BM (2.27±0.27, n=6) group when compared to O+SVF treated but was still
significantly higher than OC (Fig 2.1 B).
Diastolic function.
Echocardiographic measures of diastolic function are displayed in Figure 2.2,
including isovolumic relaxation time (IVRT), E/A ratio – representing the ratio of peak
velocity of blood flow from gravity in early diastole (the E wave) to peak velocity flow in
late diastole caused by atrial contraction (the A wave) – and E/e’ – representing the ratio
of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e').
All measures showed an age-related deterioration in diastolic function when compared to
YC (Fig 2.2 A-D). The O+SVF treated rats showed a statistically significant
improvement in E/A and E/e’ ratios when compared to OC (Fig 2.2 B C). The O+BM
group was similar to OC in that it had significantly decreased E/A and E/e’ ratios as
compared to YC, and E/A when compared to O+SVF (Fig 2.2 B and C). There is a
significant increase in the time constant of left ventricular relaxation measured by PV
relationship (tau) when comparing OC (19.16±0.83, n=16) and O+BM (19.01±0.74, n=6)
to YC (15.61±0.48, n=13) (Fig 2.2 D).

Subepicardial arteriole isolation experiments.
Arterioles under 150 µm in luminal diameter from the LAD distribution were
dissected and isolated to assess whether cell therapy or adrenergic inhibition altered basic
vessel characteristics such as spontaneous tone. Neither age (OC) nor a cell therapy
(O+SVF and O+BM) significantly altered the maximum diameter or average spontaneous
tone reached (Table 2.3). Average tone after incubation with ICI118551, CPG20712A, or
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both ICI118551+CPG20712A was not significantly different between the groups or when
compared to pre-inhibition (Table 2.3). β-AR agonists and antagonists were used to
assess if cell therapy altered microvascular reactivity to adrenergic stimuli.
Vasodilation to dobutamine (β1-AR) and salbutamol (β2-AR).
Dobutamine and salbutamol were used to examine if cell therapy alters β1(dobutamine) or β2-AR (salbutamol) responsiveness; data is represented in Figures 2.3 A
and B. At the highest concentrations (1e-6 and 1e-5 [M]), vasorelaxation to dobutamine is
significantly lower with age (OC) and in the O+BM group when compared to YC. At
concentration 1e-6 [M], O+SVF (26.96±4.7, n=11) vasorelaxation is significantly higher
when compared to O+BM (6.98±2.74, n=6) (Fig 2.3 A). There is no difference between
the groups at any dose of salbutamol (Fig 2.3 B).
Isoproterenol-induced vasodilation (non-selective β-AR agonist).
Isoproterenol alone or combined with a β1- or β2-AR antagonist (or both) was
used to examine whether receptor activity pre- and post-inhibition is altered with age, and
if receptor activity is restored with cell treatment; this data is summarized in Figures 2.4
A-D. The complete concentration response of isoproterenol-induced relaxation in O+BM
is significantly lower when compared to O+SVF (p < 0.05) (Fig 2.4 A). Pre-incubation
with ICI118551 (a β2-AR antagonist) revealed no difference between the groups. There
is a statistically significant reduction in isoproterenol relaxation after inhibition with
ICI118551 when compared to the uninhibited isoproterenol dose response for the YC,
O+SVF, and O+BM groups at various doses (^) (Fig 2.4 B). Preincubation with
CPG20712A (β1-AR antagonist) revealed no difference between the groups (Fig 2.4 C),
but there was a significant attenuation of the 1e-8 [M] response in YC and O+SVF
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compared to their isoproterenol response (^). For concentrations 1e-7 through 1e-4 [M],
all four groups showed a significant attenuation in relaxation when compared to their
corresponding pre-inhibitor isoproterenol concentration response (^) (Fig 2.4 C). Figure
2.4 D used both ICI118551 and CPG20712A to show potential β3-AR activity. There
was no difference between the groups, and every group showed a significant attenuation
in relaxation when compared to the corresponding isoproterenol concentration response
(^) (Fig 2.4 D).
Norepinephrine-induced vasodilation (β1-, β2-, a1-, a2-AR agonist).
NE and the β1-AR antagonist CPG20712A were used to show vasoreactivity to a
circulating catecholamine; data is represented in Figures 2.5 A and B. NE-induced
relaxation is significantly decreased in the OC group compared to YC and O+SVF (Fig
2.5 A). It is notable that there is no difference between YC and the O+SVF groups. When
CPG20712A was used to attenuate NE-induced relaxation, there was a significant
reduction in relaxation post-inhibition at concentrations 3e-7 through 1e-4 [M] for YC and
O+BM (^) (Fig 2.5 B).

Immunofluorescence staining.
To assess changes in populations of β1- or β2-AR with advancing age or cell
therapy treatment, immunofluorescence was performed on a subset of microvessels from
explanted hearts. Representative images from each group were used to show the
fluorescence intensity measured on the endothelial-vascular smooth muscle wall of each
microvessel (Fig 2.6 A). Quantification of β1- or β2-AR fluorescence is shown in Figure
2.6 B. Although not statistically significant, there is a slight decrease in both the β1- and

37

β2-AR with advancing age. Both cell therapies increased levels of β1-AR compared to
OC, while treatment with BM-MSC, but not SVF, increased levels of β2-AR.
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Table 2.1

Table 2.1: Animal characteristics and plasma catecholamine levels.
Gross anatomical measurements and catecholamine levels were measured and averaged.
p < 0.05 vs. Young Control (*), vs. Old Control (#), and vs. Old+SVF ($); data are
presented as means±SEM (n) and analyzed with one-way ANOVA followed by post hoc
tests where appropriate.

39

Table 2.2

Table 2.2: Summary of cardiac functional parameters during echocardiography and
pressure-volume loop recordings.
Data are presented as means±SEM, analyzed with one-way ANOVA followed by post
hoc test where appropriate. p < 0.05 vs. Young Control (*), vs. Old Control (#), and
vs. Old+SVF ($)
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Figure 2.1

Figure 2.1: Coronary flow reserve using doppler echocardiography in rats.
Stress test was performed on experimental groups using dobutamine (A) or adenosine (B)
and CFR was calculated. O+SVF group exhibited increased CFR vs. OC in both
adenosine and dobutamine conditions. p < 0.05 vs. Young Control (*), vs. Old Control
(#), and vs. Old+ SVF($); Data are presented as means±SDEV, analyzed with one-way
Kruskal-Wallis ANOVA followed by post-hoc Dunn’s (A) or with one-way ANOVA
followed by Holm-Sidak post-hoc analysis (B).
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Figure 2.2

Figure 2.2: Diastolic function assessment using echocardiography and pressurevolume loops.
Compared to YC rats, there was an age-related deterioration in diastolic function as
measured echocardiographically by IVRT (A), E/A ratio (B), E/e’ ratio (C), and
hemodynamically by Tau (D). Old rats treated with SVF significantly reversed this
dysfunction in measures of E/A ratio (B) and E/e’ ratio (C) compared to OC and
normalized diastolic function to YC levels in IVRT (A) and Tau (D). p < 0.05 vs. Young
Control (*), vs. Old Control (#), and vs. Old+SVF ($); Data are presented as
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means±SDEV, analyzed with one-way Kruskal-Wallis ANOVA followed by post-hoc
Dunn’s (A,C) test or one-way ANOVA followed by post-hoc Holm-Sidak (B, D) test.
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Table 2.3

Table 2.3: Isolated vessel characteristics.
Luminal diameters were measured. Tone was calculated as a percent of the maximum
diameter for pre- and post-incubation with an inhibitor. p < 0.05 vs. Young Control (*),
vs. Old Control (#), and vs. Old+SVF ($); data are presented as means±SEM (n) and
analyzed with paired t-tests for within group difference while between group difference
were analyzed using one-way ANOVA.
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Figure 2.3

Figure 2.3: Isolated coronary arteriolar vasoreactivity to b1- and b2-AR agonists.
Dobutamine, primarily a b1-AR agonist, induced vasorelaxation in all groups (A).
Coronary arterioles from YC animals exhibited a significantly greater dilation compared
to OC and O+BM at concentrations 1e-6 and 1e-5 [M] (*) (A). Salbutamol, a b2-AR
agonist, induced mild vasorelaxation that was similar between all the groups (B). p <
0.05 vs. Young Control (*) or vs Old+SVF ($); data are presented as means±SEM and
analyzed with two-way repeated measures ANOVA followed by post-hoc Bonferroni
test.

45

Figure 2.4

Figure 2.4: Contribution of b1- and b2-AR to isoproterenol-induced vasodilation
from isolated coronary arterioles.
Vasorelaxation to isoproterenol, primarily a non-selective b1-, b2-, and b3-AR agonist,
was significantly impaired in the O+BM group compared to O+SVF ($) (A).
Isoproterenol with ICI118551, a b2-AR antagonist, eliminated differences between the
groups. Compared to pre-incubation, all groups except OC (YC, O+SVF, and O+BM)
had significant attenuation in the inhibited dose response (^) at several concentrations
(B). Isoproterenol with CPG20712A, a b1-AR antagonist, also eliminated differences
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between the groups, and all groups exhibited significant attenuation in the response
compared to pre-inhibition (^) (C). No group differences to isoproterenol were noted
following inhibition with both ICI118551 and CPG20712A, and all groups exhibited
significant attenuation in the response compared to pre-inhibition (^) at every
concentration (D). p < 0.05 vs. Young Control (*), vs. Old Control (#), vs. Old+SVF, and
pre- vs. post-inhibition (^); data are presented as means±SEM and analyzed with twoway repeated measures ANOVA, paired for inhibitor analysis, followed by post-hoc
Bonferroni test.
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Figure 2.5

Figure 2.5: Contribution of b2-AR to norepinephrine-induced vasoreactivity in
isolated coronary arterioles.
Relaxation to NE was significantly impaired in OC animals compared to YC and O+SVF
groups at all concentrations (A). NE with CPG20712A, a b1-AR antagonist, attenuated
(^) the majority of the vasodilation response (3e-7 – 1e-4 [M]) in YC and O+BM treated
groups (B). p < 0.05 vs. Young Control (*) or vs. Old Control (#) and pre- vs. postinhibition (^); data are presented as means±SEM and analyzed with two-way repeated
measures ANOVA, paired for inhibitor analysis, followed by post-hoc Bonferroni test.
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Figure 2.6

Figure 2.6: b1- and b2-AR immunofluorescence in isolated coronary arterioles.
Representative images with ROI boxes used for fluorescent intensity analysis are shown
on isolated coronary arterioles stained for b1- or b2-AR (A). There is no significant
difference between the groups in the expression of b1- or b2-AR as measured by
quantification of fluorescent intensity (B). Data are represented as means+SEM and
analyzed with one-way ANOVA (n ≥ 4).
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Discussion
The major finding from this study is that aged rats treated with intravenous SVF
exhibit a restoration of cardiac β-AR responsiveness compared to untreated old controls.
This was realized four weeks following SVF treatment by improved CFR, diastolic
function, and coronary microvascular reactivity to adrenergic agonists, isoproterenol and
norepinephrine. Part of our original hypothesis was supported by the findings in this
study, as both SVF and BM-MSC cell therapies were associated with improved arteriolar
vasodilation to NE (a non-selective adrenergic agonist), but the BM-MSC group did not
show improvements in CFR, diastolic function, or vasodilation to isoproterenol or
dobutamine as described in the O+SVF group.
Although still controversial [216], the majority of evidence supports a beneficial
effect of cell therapy in treating ischemic and/or dysfunctional cardiac tissue, and this is
likely due to still not well-defined paracrine factors released by or in response to the
injected cells. Previous studies have shown that MSCs and adipose-derived SVF can be
anti-inflammatory and immune-modulatory [198, 199], possibly via influence from the
sympathoadrenal system [217]. Additionally, our past studies have shown that SVF cells
can incorporate into the vascular wall long-term [42] and are associated with
normalization of inflamed large vessels, possibly via alteration in reactive oxygen species
(ROS) signaling [201]. It’s well known that HF leads to enhanced release of
catecholamines [93, 218] and these levels are correlated to the severity of HF [219],
resulting in a desensitization of β-ARs which can ultimately promote more cardiac
dysfunction [93]. Catecholamine excess has also been demonstrated in advancing age
[85], shown to be partially consequent on ROS generation [220], and inversely linked to
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vascular endothelial function [221]. In 2006, Dhein and colleagues [207] demonstrated
for the first time that intramyocardial injection of BM-MSC normalized both circulating
catecholamine levels and β-AR density in the heart after four weeks in a model of nonischemic cardiomyopathy in rabbits. Although this was not statistically significant, our
data supports this trend, as we show an age-related increase in plasma catecholamines
that was decreased following BM-MSC or adipose-derived SVF injection (Table 2.1).
BM-MSCs were initially hailed as the superior autologous cell source to treat
myocardial infarction (MI) because of their differentiation potential [171, 172], but recent
studies have shown equal efficacy of adipose-derived SVF in improving cardiac function
after MI and in vitro induction into cardiomyocyte-like-cells and vascular elements [189192]. The present study shows that SVF but not BM-MSC therapy improved diastolic
function in aged rats, as measured by E/A, E/e’, and tau (Fig 2.2 B-D). It is worth
mentioning that some group differences observed by ultrasound (EF and SV) were not
present for hemodynamic outcomes, but this is likely due to the use of ketamine
anesthesia during hemodynamic measurements, which has been associated with
depressed LV function (Table 2.2) [215]. Regardless, our data stands in contrast to the
Monnerat-Cahli [208] study where 5x106 BM-MSCs improved left ventricular developed
pressure (LVDP) four weeks after injection in a diabetic rat model. Although we
purposefully utilized the same concentration and timeline of BM-MSC treatment in the
present study, we did not observe improved cardiac function in the O+BM group
compared to the O+SVF group (Fig 2.2 B-D), possibly due to the streptozotocin-model
of diabetes, use of young male Wister rats, or the method of LVDP measurement in an
isolated working heart as performed by Monnerat-Cahli and colleagues [208].
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Dobutamine and adenosine both increase cytosolic cAMP production [31] in the
coronary circulation to achieve hyperemic flow, but this occurs through different receptor
activation (β-AR and adenosine receptors, respectively). The age-related decrease in
dobutamine-induced CFR was significantly reversed after SVF treatment (Fig 2.1 A),
indicating SVF cell therapy improved cardiac β-AR responsiveness. Although age-related
deficits were not revealed during adenosine-induced CFR, both cell therapies (SVF and
BM-MSC) significantly improved CFR compared to OC (Fig 2.1 B). These disparate
results may be explained by the fact that β-AR-mediated accumulation of cAMP has been
shown to decrease with age, but alternate induction pathways of cAMP appear to be
preserved. To this end, relaxation to forskolin - a direct activator of adenylyl cyclase
(AC) - are normal in whole vessels [222] while basal levels of AC are increased with age
in rat aorta [223], suggesting that the AC enzyme and events distal to cAMP formation
are intact with age. Ross et al. [224] showed in vivo that infusion of propranolol (a β1and β2-AR inhibitor) decreased peak coronary blood flow in response to isometric
handgrip exercise in young men, whereas old men (67±4 years) exhibited no effect.
These studies support that SVF cell therapy in aged hearts increase CFR through
improvements in β-AR-cAMP signaling.
We found that there is a significant age-related decrease in β1-AR-mediated
vasodilation, as YC demonstrated increased vasodilation to dobutamine (Fig 2.3 A) vs.
OC. In this study, we believe SVF therapy worked by improving β-AR, specifically β1,
in the coronary microcirculation because vasodilation to dobutamine was increased
following SVF treatment vs. the O+BM group. Further, when β1-AR was inhibited using
CPG20722, age- and group-related differences were eliminated in the vasodilation to NE
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(Fig 2.5 B). Dobutamine can elicit differential effects depending on the tissue; in the
cardiac tissue it acts mostly via β1-AR stimulation versus in the vascular system it
stimulates β1- and β2-AR vasodilation, and also some minor α1-AR vasoconstriction
[225]. But the importance of β1-AR stimulation prevails, as Abdelkrim and colleagues
[226] demonstrated that immunization against the β1-AR in young rats produced
significant decreases in dobutamine and isoproterenol relaxations in small isolated
mesenteric arteries, and impaired endothelial-dependent nitric oxide (NO) signaling
pathways. As mentioned previously, there is decreased β-AR responsiveness with age
[86] and in HF [10, 93] and our findings support this conclusion.
Pretreatment with ICI118551, a β2-AR antagonist, abolished the difference in
vasodilation to isoproterenol between the cell-treated groups (Fig 2.4 A and B),
suggesting that there is some contribution of β2-AR activity and/or signaling following
SVF but not BM-MSC therapy. This link between SVF treatment and heightened β2-AR
activity is supported by the age-related decrease in relaxation to NE in coronary
arterioles, which was restored in the SVF cell-treated group (Fig 2.5 A). Historically, NE
effects on adrenergic receptors have been difficult to study because of the
multifaceted/opposing effects on vascular and cardiac tissues. Vasodilation to NE has
been previously shown to be primarily mediated through β2-AR on the VSMC of human
coronary arterioles [227]. However, we did not find a significant difference in
vasodilation between the groups using the selective β2-AR agonist, salbutamol (Fig 2.3
B). While β2:β1-AR ratio increases in failing human hearts [218] and in senescent hearts
[202, 228], we have a novel observation that the opposite occurs in β2-AR staining in
arterioles from OC, and this wasn’t altered with SVF treatment (Fig 2.6).
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If β1-AR undergoes prolonged stimulation, similar to chronic catecholamine
spillover in the elderly [229], β2-AR can undergo a cross-desensitization [85]. Schutzer et
al. [230] suggested that β2-AR actually achieves maximal desensitization with age,
resulting in β2-AR switching from Gstimulatory to Ginhibitory. To that end, β2-AR
stimulation with concomitant β1-AR inhibition has been shown to improve cardiac
function and myocardial O2 consumption post-operatively in aged male rats [231]. Of
note, β2- and β3-AR are functionally distinct from β1-AR by their ability to deactivate
ACs by coupling to the inhibitory G protein (Gai). Cardiac Gai levels and activity have
been shown to be increased with age in humans and in rodent models [232-234]. It’s
likely that aging may have a direct influence on β2-AR activity through indirect receptor
cross-desensitization due to circulating catecholamines and/or an increase in Gai activity,
and that SVF cell therapy reverses this, but further studies are required to explore this
possibility.

Conclusion
It’s important to consider the limitations of the present study: 1) radioligand
binding would be a more direct method of measuring β1- and β2-AR density and ratio in
isolated coronary arterioles compared to our immunofluorescence method, 2)
catecholamine levels were analyzed in plasma collected at the conclusion of PV loop
experiments while anesthetized with ketamine. Ketamine has been proven to decrease
plasma catecholamines whilst inhibiting the uptake of NE, resulting in a transient
increase [235]. This may have caused a dampening in the true catecholamine levels. 3) In
order to be consistent with a previous study [208], the concentration of cells between the
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two cell groups were not the same. 4) This study only utilized female rats as recipients.
Our rationale for this is because as age progresses in humans, CMD manifests in the
sexes differently. As many as 50% of women referred for evaluation of MI do not have
obstructive coronary disease, like most men, but are frequently associated with coronary
microvascular dysfunction/ischemia [236]. Follow-up studies suggest that CFR is a better
predictor of future adverse events compared to traditional angiographic methods in older
women [237]. 5) The present study utilized SVF and BM-MSC from young donor rats
only. Our lab and others have previously shown that the age of the donor significantly
depresses the angiogenic, vasculogenic, and overall mesenchymal potential of isolated
cells [238-240], but it’s unknown whether these factors would alter the outcomes in the
present study. Lastly, β3-AR plays a key role in the development of LV diastolic
dysfunction as recently shown by Yang et al. using a knockout mouse model [241]. The
role of β3-AR wasn’t directly explored in the current study but warrants investigation to
determine if aging and/or cell therapy alter its activity and/or expression.
Our previous study showed SVF incorporation into the cardiac and vascular space
four weeks post-injection in an aged rat [42].The field is still unsure if the beneficial
effects of injected cells are mediated via secreted factors being released from the cells or
if it is the incorporated cells themselves remaining in the circulation and populating the
peripheral tissue [242]. Regardless, this new data provides exciting evidence that SVF
cell treatment can improve vasodilation to adrenergic agonists and increase CFR
compared to old controls rats, providing a new strategy in managing sympathetic
desensitization that occurs in advancing age as well as diastolic dysfunction. These
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results lay significant groundwork into future studies on cell therapy and resultant
sympathoadrenal and β-AR signaling.
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CHAPTER 3
CELL THERAPY RESCUES AGING-INDUCED BETA-1 ADRENERGIC
RECEPTOR AND GRK2 DYSFUNCTION IN THE CORONARY
MICROCIRCULATION

Overview
Our past study showed that coronary arterioles isolated from adipose-derived
stromal vascular fraction (SVF)-treated rats showed amelioration of the age-related
decrease in vasodilation to β-adrenergic receptor (β-AR) agonist and improved β-AR
dependent coronary flow and microvascular function in a model of advanced age. We
hypothesized that intravenously (i.v.) injected SVF improves coronary microvascular
function in aged rats by re-establishing the equilibrium of the negative regulators of
internal adrenergic signaling cascade, G-protein receptor kinase 2 (GRK2) and G-alpha
inhibitory (Gai) proteins, back to youthful levels. Female Fischer-344 rats aged young (3
months, n=24), old (24 months, n=26) and old animals that received 1x107 green
fluorescent protein (GFP+) SVF cells (O+SVF, n=11) four weeks prior to sacrifice were
utilized. Overnight urine was collected prior to sacrifice for catecholamine
measurements. Cardiac samples were used for western blotting while coronary arterioles
were isolated for pressure myography studies, immunofluorescence staining, and RNA
sequencing. Coronary microvascular levels of the β1 adrenergic receptor are decreased
with advancing age, but this decreased expression was rescued by SVF treatment. Aging
57

led to a decrease in phosphorylated GRK2 in cardiomyocytes vs. young control with
restoration of phosphorylation status by SVF. In vessels, there was no change in genetic
transcription (RNA sequencing) or protein expression (immunofluorescence), however,
inhibition of GRK2 (paroxetine) led to improved vasodilation to norepinephrine in old
control (OC) and O+SVF, indicating greater GRK2 functional inhibition of β1-AR in
aging. SVF works to improve adrenergic-mediated vasodilation by restoring the β1-AR
population and mitigating signal cascade inhibitors to improve vasodilation.

This chapter is from the published work referenced as follows:
Rowe, G., et al., Cell therapy rescues aging-induced beta-1 adrenergic receptor and
GRK2 dysfunction in the coronary microcirculation. Geroscience, 2021.
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Introduction
The coronary microvasculature of aged individuals is unable to properly augment
blood flow (BF) in response to vasodilatory stressors [97], leading to poor coronary
perfusion and increased risk of heart failure (HF) [98]. In the aging heart, increased
circulating catecholamines combined with decreased sensitivity to adrenergic stress [229]
can lead to a loss in number and/or function of cardiac beta-adrenergic receptors (β-AR),
resulting in decreased cardiac contractility [87, 206]. Since β-AR in the heart and
vasculature primarily lead to vasodilation, this age-related decrease results in a
microvascular phenotypic shift from a dilatory state to a state of vasoconstriction [94]. It
is likely that the overactivation of the sympathetic neurohormonal system that occurs in
both advancing age and HF may share common signaling mechanisms [83]. In a failing
heart, the population of the β1-AR is reduced from 77% to 60% [91, 92] while the other
adrenergic receptors seem to be unaffected or even upregulated in the case of the alphaadrenergic receptors (a-AR) [92]. However, the status of β-AR-mediated signaling in the
coronary microvasculature in advanced age is currently unknown, as well as how this
signaling relates to coronary microvascular dysfunction.
Beta-blockers are the preferred treatment for HF to block the inotropic and
chronotropic effects of the sympathetic nervous system on the b1-AR [127], but chronic
beta-blockade to alleviate HF may be detrimental to the microvasculature [243].
Additionally, the myocardium and microvessels have β2- and β3-AR which are
functionally distinct from β1-AR as they both deactivate adenylyl cyclase (AC) by
coupling to the inhibitory G-protein (Gai) compared to a stimulatory G-protein (Gs) for
β1-AR signaling [39]. The activity and level of Gai increases in the myocardium in aging
59

humans [232], in HF [244, 245], and in rodent models [233, 234]. Aging is also
associated with decreased AC activity and cAMP levels in the myocardium [246], but
little is known about the role these factors play in the aging microvasculature of the heart.
The age-related decrease in β-AR-mediated vasorelaxation is thought to be due to
desensitization of the receptor, but the initial cause of desensitization has been identified
at various points of the adrenergic signaling cascade in myocardial tissue [127]: either
following a decrease in receptor density from transcriptional downregulation [247] and/or
due to the uncoupling of the Gs/AC unit from the adrenergic receptor [248]. In the
myocardium, uncoupling of the adrenergic receptor is protective against the increased
catecholamine onslaught and shown to be dependent upon G-protein receptor kinases
(GRK) [249] and Gai [250] which both increase with age [251, 252]. GRKs are unique in
their kinase function, controlling the affinity of the β-AR for its ligand and initiating
receptor internalization through phosphorylation of the internal tail [253]. However, it is
unknown if the age-related increase in these negative regulators of adrenergic signaling
also occurs in the coronary microcirculation. How GRK and Gai contribute to the overall
age-related decrease in catecholamine-responsiveness is also undetermined. The
involvement of β-AR signaling in aging hearts offers a unique diagnostic and therapeutic
opportunity to better understand this important pathway and the implications of age
within the coronary microcirculation.
Our laboratory has shown that a single intravenous (i.v.) injection of adiposederived stromal vascular fraction (SVF) improved β-AR-mediated coronary flow reserve
(CFR) and restored the vasodilatory capacity of isolated coronary microvessels to β-AR
agonists compared to old control rats [39, 42]. The purpose of the current study was to
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determine whether SVF cell therapy restores β-AR function in the coronary
microcirculation in aged females through reversal of the negative regulators of β-AR
signaling, resulting in improved sensitivity and vasodilatory responses to β-adrenergic
agonists. Our hypothesis was that cardiac β-adrenergic dysfunction in aging is due to
increased GRK2-dependent receptor phosphorylation that can be reversed through SVF
cell therapy, leading to increased receptor sensitivity to its ligand and decreased
internalization of the receptor, ultimately improving β-adrenergic function in the
coronary microcirculation.

Materials and Methods
Animals and experimental groups.
The Institutional Animal Care and Use Committee of the University of Louisville
approved this study, and all procedures followed the NIH Guide for the Care and Use of
Laboratory Animals [254]. Young control (YC, 4 months, equivalent to a 20-year-old
human [255], n=24) and old (23 months) female Fischer-344 rats (Envigo Laboratories,
Indianapolis, IN, USA and National Institute of Aging, Bethesda, MD, USA,
respectively) were group housed with free access to food and water and maintained on
regular 12-hour light/dark cycles. Young rats were acclimated to facility conditions for a
minimum of one week prior to endpoint procedures. Following one week acclimation, old
rats were randomly divided into old control (OC, equivalent to >70-year-old human
[255], n=26 or injected with green fluorescent protein positive (GFP+) SVF (O+SVF,
n=11) groups. Endpoint procedures were performed four weeks later (aged 24 months).
SVF isolation and cell injections.
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SVF cells were isolated from a GFP+ Fischer-344 rat colony (maintained in
house) as previously described [39, 41, 42]. Briefly, ovarian or epididymal fat pads from
young female and male rats respectively (3-6 months) were harvested, washed, finely
minced, and digested in 0.75 mg/mL Type I collagenase solution (Vitacyte 011-1030)
and 1 mg/mL Deoxyribonuclease-1 (Sigma DN25). Buoyant adipocytes were removed
via centrifugation, and the SVF cell pellet resuspended in 0.1% BSA-PBS as previously
described [39, 41, 42]. Freshly isolated SVF were then washed and filtered through a 20µm screen to eliminate large cell and tissue aggregates. Cell count was determined with a
hemocytometer, and GFP+ fluorescence of the cell population confirmed via
fluorescence microscopy prior to injection. Old female rats were injected intravenously
with 107 GFP+ SVF cells in 1 mL Lactated Ringer’s solution (warmed to 37°C) via the
tail vein as previously described [39, 42].

Urine collection and catecholamine analysis.
Prior to endpoint procedures, a subset of animals (n=6 per group) were
individually placed in metabolic cages with free access to food and water for overnight
collection of urine (18.5 hours). Frozen samples were sent to the University of Louisville
Bioanalytical Core for mass spectrometry analysis of excreted catecholamine levels as
previously described [256].

Subepicardial arteriole isolation experiments.
For endpoint procedures, animals were deeply anesthetized with inhaled 5%
isoflurane with 1.5-2.0 L/min O2 flow in induction chamber. After confirming lack of
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tactile reflex, the heart was removed and coronary arterioles from the left anterior
descending (LAD) artery distribution were isolated, cannulated on both ends and
pressurized to 45 mmHg in a 37°C bath containing physiological salt solution (PSS) plus
albumin [39, 42, 213]. Upon developing spontaneous tone (> 20% constriction from
initial diameter), arterioles were treated with β-AR- and/or intracellular signalingagonist/inhibitor protocols so that stimulation of the β-adrenergic signaling cascade
progressed from upstream to downstream. Vessels unable to initially establish
spontaneous tone were discarded and some arterioles did not reestablish tone following
one or more treatments. The drug/inhibitor protocols were randomized to the isolated
vessels:
•

Protocol 1 – BRL-37344 (β3-AR agonist, Sigma B169), Norepinephrine (NE)(α1-2,
and β1-2 AR agonist, Sigma-Aldrich A9512), and NE following 30 min incubation
with Paroxetine HCl (NE+Parox)(GRK-selective antagonist, VWR 89160-896),
Sodium Fluoride (NaF)(Gs activator, Sigma-Aldrich S6776).

•

Protocol 2 – NE, NE following 20 min incubation with CPG20712A (NE+CPG)(β1AR antagonist, Sigma C231), Forskolin (AC activator, VWR 89156-986).

•

Protocol 3 – Dobutamine (Dob)(primarily a β1-AR agonist with lower β2-AR
activity, Sigma-Aldrich D0676), NE, Dob following 20 min incubation with
ICI118551 (Dob+ICI)(β2-AR antagonist, Sigma I127), NE+ICI, 8-bromo-cAMP
(cAMP-dependent protein kinase activator, VWR 89157-000).

At the end of the protocol, arterioles were washed 2x15 min in calcium-free PSS
followed by a single high dose of sodium nitroprusside (SNP 1e-4 [M]) at the end of
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experiment. Maximal dilation for each vessel was determined as the largest diameter
achieved throughout the experiment. Data for spontaneous tone was calculated as (1[luminal diameter]/[max diameter])*100 while percent relaxation was calculated as
([luminal diameter-initial diameter]/[max diameter-initial diameter])*100.

Immunofluorescence staining.
Coronary arterioles (750 μm-1 mm in length, < 250 μm in diameter) were isolated
from each heart and fixed in 2% paraformaldehyde in 48-well plates for 1-hour, washed
2x10 min in DCF-PBS, and placed in 0.5% Triton-X/DCF-PBS for 20 minutes at room
temperature (RT) for permeabilization. After treating with blocking solution (10%
normal donkey serum/0.5% bovine serum albumin/0.1% Triton-X/DCF-PBS) for 1 hour
at RT, arterioles were incubated in a primary β1-AR (Abcam ab3442, 1:100), β2-AR
(Abcam ab182136, 1:100), β3-AR (Abcam ab59685, 1:200), a1-AR (Invitrogen PA130159, 1:100), a2-AR (Abcam ab3462, 1:100), GRK2 (Santa Cruz sc-13143, 1:100), Gs
(ThermoFisher PA5-115303, 1:100), Gai1 (Invitrogen MA5-12800, 2 ug/mL), or betaarrestin 2 (Invitrogen PA1-732, 2 ug/mL) antibody in blocking solution at 4°C overnight
with gentle rocking. Normal rabbit serum replaced primary antibody solution for isotype
control tissues. Donkey anti-rabbit IgG-Alexa Fluor 594 (Invitrogen A21207, 1:300 for
β1, β2, a1, a2, Gs, and beta-arrestin 2, 1:400 for β3 staining) and/or donkey anti-mouse
IgG-Alexa Fluor 647 (Abcam ab150207, 1:300 for GRK2 and Gai1 staining) antibody in
blocking solution were added to the tissues and incubated for 1-hour at RT. Arterioles
were washed 2x15 min in DCF-PBS, and nuclei were stained with DAPI. Samples were
placed on slides with anti-fade mounting media, coverslipped, and imaged using an
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Olympus FluoView 1000 confocal microscope (Olympus America, Center Valley, PA,
USA) with 405, and 543, and 635 nm lasers. Images of the adrenergic receptors were
captured with a 20X water immersion objective for β-ARs or a 40X objective for a-ARs
vessels at 1024x1024 pixel density and 1-1.92 µm Z-step with 6-18 slices (10.68-33.84
µm total image depth) being used for analysis. Immunofluorescence images of GRK2,
Gs, Gai1, and beta-arrestin 2 stained vessels were captured with a 20X water immersion
objective at 1024x1024 pixel density and 3.71 µm Z-step size with 3 slices (11.13 µm
total image depth) being used for analysis. Immunofluorescence intensity of the stained
protein in the region of interest (ROI) boxes were determined by the Nikon NIS Elements
AR Analysis software (Nikon Instruments, Melville, NY, USA) using at least 20 µm x
100 µm area and at least 8 µm of depth [39]. ROI boxes were placed on the left and right
vascular walls overlapping both the endothelial and smooth muscle cell layers but
excluding any cardiomyocytes, then averaged and normalized to the total image depth.

Western blotting.
Following subepicardial arteriole isolation, hearts were flash frozen and stored for
protein isolation. Protein was isolated from 3-mm sections of hearts of the LV regions of
the heart near the apical LAD by tissue homogenization in RIPA lysis buffer, 1X protease
inhibitor (Sigma P8340), and phosphatase inhibitor solution containing 1 mM sodium
orthovanadate (Sigma S6508) and 7.5 mM sodium fluoride (Sigma S6776). The
homogenate solution incubated at 4°C with gentle rocking for 30 min before being
sonicated on ice at 40% power 3 x10 sec each. Homogenate was then centrifuged at 4°C
and 12,000 rpm for 20 min. The supernatant was transferred to new tubes for protein
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concentration using BioRad DC protein assay (5000111) and a Biotek Synergy 4
spectrophotometer (Biotek Instruments, Highland Park, VT, USA). Protein stocks were
sampled and diluted 1:100 prior to concentration assay. BSA (Sigma A6003) from 0.1875
to 1.5 mg/mL in RIPA was used to generate a standard curve. Loading samples were
made at 50 µg of protein in 4X Lammelli (BioRad 161-0747) and RIPA buffers then
boiled at 95°C for 5 min. Samples were run on 4-20% gradient precast gels (BioRad,
4561095) at 200V for 30 min. Gels were placed in a wet tank transfer cassette with a
nitrocellulose membrane (BioRad, 1620112) for transfer at 100V for 1 hour surrounded
in ice. Membranes where then blocked in a 5% non-fat dry milk/1X TBS-T solution for 1
hour at RT with gentle rocking. The following primary antibodies were diluted 1:1000 in
a 5% non-fat dry milk/1X TBS-T solution and incubated with gentle rocking at 4°C
overnight to probe for: β1-AR (Abcam ab3442), β2-AR (Abcam ab182136), β3-AR
(Abcam ab59685), phosphorylated GRK2 (Abcam ab58520), GRK2 (Santa Cruz sc13143), Gs (ThermoFisher PA5-115303), Gai1 (Invitrogen MA5-12800), beta-arrestins
1&2 (Cell Signaling 4674S), beta-arrestin 2 (Invitrogen PA1-732), and GAPDH (Cell
Signaling 8884S, 1:3000). Secondary anti-rabbit (Cell Signaling 7074S) (β2-3-AR,
phospho-GRK2, Gs, beta-arrestins 1&2, and GAPDH) or anti-mouse (Cell Signaling
7076S) (GRK2 and Gai1) HRP conjugated antibodies were diluted in 5% non-fat dry
milk/1X TBS-T solution at 1:3000 for all the blots except the β1-AR, in which the antirabbit secondary was diluted 1:10,000 and incubated at RT for 1 hour with gentle
rocking. Chemiluminescence was performed using BioRad’s ECL clarity max solutions
(1705062) and imaged using a Chemidoc MP (BioRad, Hercules CA, USA). Intensity of
the bands was measured using ROI boxes in ImageJ (NIH). The band intensity of the
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protein of interest was normalized to its GAPDH band intensity, then the mean of this
ratio was calculated by group. For the phospho-GRK2 to total GRK2 analysis, band
intensity normalization was done using the following formula: ([phosphoGRK2/GAPDH]/[GRK2/GAPDH]).

RNA sequencing.
Coronary arterioles (750 μm-1 mm in length, <250 μm in diameter) were flash
frozen and stored at -80°C until samples from all groups were collected. Six isolated
vessels were pooled from two animals in the same group for an n=3 of biological
replicates/group. RNA was harvested with RNAqueous Micro kit (Invitrogen AM1931)
and quantified on a NanoDrop (ThermoFisher, Waltham MA, USA). Samples were sent
to the University of Louisville Genomics Core for quality control analysis using the
Agilent Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA) and quantified
using a Qubit fluorometric assay (Thermo Fisher Scientific, Waltham, MA) as previously
described [257]. Poly-A enrichments, barcoding, and Illumina Next-Gen sequencing for
library preparation was performed as previously described [257, 258]. Gene transcripts
were analyzed by the University of Louisville Bioinformatics Core for differential
expression analysis between group comparisons as previously described [259].

Statistical analysis.
Statistical analyses were performed in SigmaPlot 14.0 (Systat, San Jose,
California, USA) with p < 0.05 as the significance level. One-way ANOVA was
performed on animal characteristics, plasma catecholamine levels, and
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immunofluorescence intensity measurements of β-adrenergic receptors; either HolmSidak or Dunn’s post hoc analyses were performed where appropriate. One-way KruskalWallis ANOVAs were utilized in instances of failed normality. Concentration-response
curves as well as pre- and post-inhibition responses were analyzed via two-way repeated
measures ANOVA followed by Bonferroni post hoc analyses. Western blot data were
analyzed using One-way ANOVA with Holm-Sidak post hoc analysis or a KruskalWallis followed by Dunn’s method of post hoc analysis where appropriate. RNA
sequences were analyzed using Cufflinks-Cuffdiff2 with an absolute |log2FC| ≥ 1 to
determine differential expression as previously described [259].

Results
Animal characteristics and catecholamine metabolism.
To determine if systemic i.v. delivery of SVF altered animal characteristics and/or
excreted catecholamines in the urine, we collected gross anatomical characteristics and
sampled urine from overnight collection chambers; these data are presented in Table 3.1.
All aged groups exhibited increased body weight (BW), total ventricular weight, and left
ventricular (LV) weight when compared to YC animals (Table 3.1). With aging (OC,
138.31±10.09 ng/mg creatinine, n=6), significantly higher levels of NE excreted in the
urine were observed when compared to young animals (YC, 76.53±7.84 ng/mg
creatinine, n=6); this was not reversed by SVF treatment (O+SVF, 151.02±14.96 ng/mg
creatinine, n=6) (Table 3.1). In contrast, there were no age-related or group differences in
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urine levels of epinephrine (Epi), serotonin (5HT), dopamine (DA), or a metabolite of
serotonin (5-HIAA) between the groups (Table 3.1).

Myocardial and microvascular expression of β-adrenergic receptors.
To determine whether age (OC) or SVF cell-based therapy (O+SVF) affected the
β-adrenergic receptor population in the myocardium, western blotting was performed
(Fig 3.1). Measuring band intensity normalized to GAPDH, there was no significant
difference in the β1-AR or β2-AR levels in the myocardium across the groups (Fig 3.1).
To assess changes to the populations of all the adrenergic receptors (β1-3 ARs
and a1-2 ARs) within coronary microvessels with advancing age or following SVF
administration, immunofluorescence was performed on a subset of microvessels isolated
from explanted hearts. Images from each group were used to analyze the fluorescence
intensity measured on the endothelial/smooth muscle cell layer of each microvessel (Fig
3.2 A), and quantification of β1-3 ARs or a1-2 ARs fluorescence is shown in Figure 3.2
B. There was a significant decrease in the β1-AR with age, but the β1 receptor expression
is restored to young levels following SVF cell therapy (p < 0.05, n=9/group, Fig 3.2 B).
No other group differences were observed in β2-3 ARs or a1-2 ARs.

Isolated subepicardial vessel characteristics and β1-AR mediated vasodilation.
Arterioles under 150 μm in luminal diameter from the LAD distribution were
dissected and isolated to assess whether cell therapy or adrenergic inhibition altered basic
vessel characteristics such as spontaneous tone. Aged groups (OC, 16.50 ±0.73 µm, n=50
and O+SVF, 15.67±0.96 µm, n=27) had increased wall thickness compared to
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microvessels isolated from young animals (YC, 12.02±0.56 µm, n=40) (Table 3.2).
Maximum diameter (Dmax) achieved was significantly higher in OC vessels
(154.35±3.61 µm, n=55) when compared to YC (137.6±3.51 µm, n=42) and O+SVF cell
therapy (140±4.3 µm, n=31) (Table 3.2). Spontaneous tone at the beginning of the
experiment, post-GRK2 inhibition with Paroxetine HCl, post-β1-AR inhibition with
CPG20712A, and post-β2-AR inhibition with ICI118551 exhibited no significant
differences among the groups (Table 3.2).
The adrenergic agonist NE and β1-AR antagonist CPG20712A were used to show
β1-AR contribution to vasoreactivity via pressure myography; data is represented in
Figures 3.3 A-C. Following CPG20712A incubation, there was a significant attenuation
of NE-induced relaxation when compared to pre-inhibition at doses 1e-6 - 1e-4 [M] for all
groups (Fig 3.3 A-C).

GRK2 regulatory kinase expression in cardiac tissues.
To examine if age or SVF cell therapy alters the expression and/or functionality
of GRK2 in the myocardium and coronary microvessels, western blotting, IHC, and
pressure myography studies were performed (Fig 3.4 A-E). Myocardial samples from
each group were probed for phosphorylated and total GRK2 proteins (Fig 3.4 A). The
ratio of phosphorylated GRK2 (P-GRK2) to total GRK2 was significantly reduced in the
myocardium of OC animals compared to YC (Fig 3.4 A). In contrast, there was no
significant difference in the P-GRK2:GRK2 ratio comparing O+SVF to YC (Fig 3.4 A).
There was no difference in GRK2 protein expression in the OC group as measured by
immunohistochemistry on isolated coronary microvessels compared to vessels from YC
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and O+SVF (Fig 3.4 B). There was no significant difference in the vasorelaxation of YC
vessels to NE following GRK2 inhibition with Paroxetine HCl compared to the preinhibition response (n=10, Fig 3.4 C), but both the OC (Fig 3.4 D) and O+SVF (Fig 3.4
E) exhibited significant increases in vasorelaxation response to NE at lower doses when
compared to pre-inhibition response curves.

Intracellular signaling components and second messengers.
To determine if age or SVF therapy modifies intracellular transduction and/or
second messenger proteins of the β1-AR signaling cascade western blotting,
immunofluorescence, and pressure myography experiments were performed (Fig 3.5).
Myocardial samples from OC and O+SVF showed a significant reduction is Gs protein
when compared to YC (Fig 3.5 A). Coronary arterioles from each group were isolated
and immunofluorescently labeled for the Gs protein; ROI boxes were used to measure
fluorescent intensity, but staining showed no significant differences between the groups
(Fig 3.5 C). Using pressure myography on isolated coronary microvessels and direct Gs
activation with NaF, O+SVF exhibited significantly reduced relaxation when compared
to YC and OC (Fig 3.5 D). Western blotting of myocardial tissue showed a significant
increase in the amount of Gai protein in OC when compared to YC (Fig 3.5 B). There
was no difference in Gai protein expression between the groups when measured in the
coronary microvasculature (Fig 3.5 C). Using Forskolin on isolated vessels via pressure
myography, there were no differences between the groups when AC was directly
activated (Fig 3.5 E).
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Receptor endocytic proteins.
To determine if proteins mediating β-AR endocytosis and internalization were
altered with age or following SVF therapy, western blotting was performed on
myocardial tissue while IHC was done on isolated coronary microvessels (Fig 3.6).
Probing for beta-arrestins 1&2 via western blotting of myocardial tissues showed a
significant increase in the amount of beta-arrestins in the O+SVF group when compared
to YC samples (Fig 3.6 A). Probing the blot for just beta-arrestin 2 produced no
significant differences between any of the groups, although both aged groups (Fig 3.6 B).
Immunofluorescence of beta-arrestin 2 on isolated coronary arterioles showed no
difference between the groups (Fig 3.6 C).

Next-Gen RNA sequencing.
RNA sequencing was performed on isolated coronary microvessels, and
transcripts identified for adrenergic signaling and catecholamine processing; these data
are represented in a heat map (Fig 3.7). Catecholamine degradation enzyme monoamine
oxidase A was significantly increased with aging (log2FC(YC/OC) = -0.45, p < 0.001)
but not reversed by SVF therapy (log2FC(OC/O+SVF) = -0.24, p =0.16). However, there
is reduced expression of catechol-o-methyltransferase (responsible for catecholamine
degradation) in O+SVF when compared old (log2FC(OC/O+SVF) = 0.22, p = 0.046).
There was a significant increase in the β2-ARs in O+SVF vs. OC (log2FC(OC/O+SVF) =
0.43, p = 0.03) with no significant differences between groups for β1- and β3-ARs or a12 ARs (Fig 3.7). Transcription of GRK2 or GRKs 4-6 was not different between YC and
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OC (log2FC(YC/OC) = -0.08, p = 0.57) (Fig 3.7). Analysis revealed inhibitory G-protein
subunit ao1 (Gnao1) was increased in aging compared to youth (log2FC(YC/OC) =
-0.41, p = 0.024). There was no significant difference in Gnao1 between YC vs. O+SVF.
G-protein subunit ai2 (Gnai2) trended towards significance with aging relative to young
(log2FC(YC/OC) = -0.17, p = 0.054). In addition, positive regulation of GTPase activity
due to small G-protein signaling modulator 2 (Sgsm2) was downregulated with aging
(log2FC(YC/OC) = 0.34, p = 0.054). There was no significant difference between
O+SVF vs. YC or vs. OC for Gnai2 or Sgsm2 (Fig 3.7). However, AC isoform 6 (AC6)
was significantly downregulated in aging compared to youth (log2FC(YC/OC) = 0.28, p
= 0.016). AC6 expression was not restored to youthful levels following SVF therapy
(log2FC(YC/O+SVF) = 0.43, p < 0.001) (Fig 3.7). RNAseq analysis revealed a
significant increase in beta-arrestin 2 with aging compared to young (log2FC(YC/OC) = 0.47, p = 0.02) but no change in beta-arrestin 1 (log2FC(YC/OC) = 0.119, p = 0.55).
Beta-arrestin 2 was not significantly different in O+SVF vs. YC or vs. OC. On the other
hand, dynamin (responsible for endocytosis in concert with beta-arrestin) was
upregulated in O+SVF vs. old, but not young (log2FC(OC/O+SVF) = -0.46, p = 0.022)
(Fig 3.7).
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Table 3.1

Table 3.1: Animal characteristics and urine catecholamine levels.
Gross anatomical measurements and catecholamines levels in the urine from overnight
collection were measured and one-way ANOVAs followed by post hoc tests run where
appropriate. Urine catecholamine levels were normalized to mg creatinine. Data are
presented as means±SEM (n), p < 0.05 vs. YC (*).
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Figure 3.1

Figure 3.1: Expression of myocardial b1- & b2-AR with aging and following SVF
therapy.
Myocardial β1-AR protein expression is reduced (albeit not significantly) in aging and
not reversed by SVF therapy (A, B). There is no significant change in myocardial β2-AR
protein expression with age or with SVF therapy. Protein quantification for expression is
measured by band intensity normalized to GAPDH and data presented as means±SEM.
Significance determined by One-way ANOVA with Holm-Sidak post hoc analysis.
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Figure 3.2

Figure 3.2: Immunofluorescence detection of adrenergic receptors in coronary
microvessels.
In coronary microvessels, the β1-AR is significantly reduced in aging and reversed to
youthful levels by SVF therapy as measured by Mean Fluorescence Intensity (arbitrary
units) while β2-3 ARs and α1-2 ARs remain unchanged (A, B). Data is presented as
means±SEM, n’s above corresponding bar, and significance determined by One-way
ANOVA with Bonferroni post hoc testing, p < 0.05 vs. YC (*) and vs. OC (#). ROI
boxes are 10x100 µm. Scale bar equals 100 µm for the β-AR panels and 50 µm α-AR
panels.
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Table 3.2

Table 3.2: Isolated vessel characteristics.
Luminal diameters were measured. Tone was calculated as a percent of the maximum
diameter for pre- and post-incubation with an inhibitor. Data are presented as
means±SEM (n) and significance determined by One-way ANOVA followed by post hoc
tests where appropriate. p < 0.05 vs. YC (*) and vs. OC (#).
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Figure 3.3

Figure 3.3: Contribution of b1-AR to NE-induced vasorelaxation in isolated
coronary microvessels.
NE-mediated vasorelaxation is significantly attenuated by β1-AR inhibition with
CPG20712A at 1e-6 to 1e-4 [M] doses in YC (A), OC (B), and O+SVF (C). Data are
matched pre- to post-inhibition and presented as means±SEM. Significance determined
by Two-way Repeated Measures ANOVA with Bonferroni post hoc analysis. p < 0.05
when pre- vs. post-inhibition (*).
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Figure 3.4

Figure 3.4: Phosphorylation status and function of GRK2 in cardiac tissues.
Western blots of phosphorylated and total GRK2 protein expression, immunofluorescent
detection of GRK2 protein, and pressure myography with NE-mediated vasorelaxation
before and after exogenous inhibition of GRK2 with Paroxetine HCl. The ratio of
phosphorylated (naturally inhibited) GRK2 to total GRK2 is significantly higher in YC
when compared to OC myocardial samples, but there is no difference in either group
compared to O+SVF as measured by western blotting (A). Mean fluorescent intensities of
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GRK2 (green) expression as measured by immunofluorescence; representative images
from each group are shown with no significant difference between the groups (B). NEmediated vasorelaxation is improved by GRK2 inhibition with Paroxetine HCl in OC (1e8

to 1e-6 [M]) (D) and O+SVF (1e-9 to 1e-7 [M]) (e) while vessels from YC are unaffected

(C). Data are presented as means±SEM. Significance defined by Kruskal-Wallis Oneway ANOVA (A, B) and paired pre- to post-inhibition for analysis using Two-way
Repeated Measures ANOVA with Bonferroni post hoc testing (C-E). p < 0.05 when vs.
YC (*) (A, B) and pre- vs. post-inhibition (*) (C-E). ROI boxes are 5x100 µm. Scale bar
represents 100 µm (B).
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Figure 3.5

Figure 3.5: Intracellular G-proteins and AC contribution to adrenergic signaling.
Western blots and immunofluorescent detection of Gs and Gai protein expression as well
as pressure myography with Gs and AC-mediated vasorelaxation. Myocardial Gs is
significantly reduced in OC and O+SVF treated groups when compared to YC (A).
Myocardial Gai is significantly increased in OC as shown by western blot analysis (B).
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Isolated coronary arterioles from YC, OC, and O+SVF treated groups were
immunofluorescently stained for Gs (green), Gai (red), and DAPI (blue) to measure
mean fluorescent intensities; no differences between the groups were uncovered for either
protein, with representative images shown (C). Activation of Gs with sodium fluoride
leads to vasorelaxation in a dose-dependent manner which is significantly different in
O+SVF treated vessels compared to YC (1e-6 to 1e-2 [M] (*)) and OC (1e-5 to 1e-3 [M]
(#)) (D). Activation of AC with forskolin leads to concentration-dependent vasodilation
that is similar between all groups (E). Data presented as means±SEM. Significance
determined as p < 0.05 when vs. YC (*) and vs. OC (#) utilizing One-way ANOVA with
Holm-Sidak post hoc analysis (A-C) or Two-way Repeated Measures ANOVA with
Bonferroni post hoc analysis (D, E). ROI boxes are 5x100 µm. Scale bar represents 100
µm (C).
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Figure 3.6

Figure 3.6: Cardiac expression of β-arrestins in youth, aging and SVF therapy.
Western blotting and immunofluorescent detection of beta-arrestin proteins in
myocardium and isolated coronary microvessels. Internalization proteins beta-arrestins
1&2 are marginally increased with age (OC) and significantly increased in the O+SVF
relative to YC (A). Probing for beta-arrestin 2 showed no difference between the groups
(B). Immunofluorescently staining isolated coronary arterioles from each group for betaarrestin 2 (red) produced no significant differences between the groups and representative
images are shown below (C). Western blot expression reported relative to GAPDH, and
all data presented as means±SEM. Significance defined as p < 0.05 when vs. YC (*)
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determined by One-way ANOVA with Holm-Sidak post hoc analysis (A-C). ROI boxes
are 5x100 µm. Scale bar represents 100 µm (C).
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Figure 3.7

Fig. 7:RNA heat map.
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Heat map representing color-coded RNA expression levels of differentially expressed
genes involved in adrenergic signaling and receptor recycling in isolated coronary
microvessels from YC, OC, and O+SVF samples. In total, 119 genes are listed.
Significance defined as cuffdiff and DESeq2 for cutoff p < 0.05.
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Figure 3.8

Figure 3.8: Summary of adrenergic signaling with alterations due to aging and SVF
therapy.
In an aged coronary microvessel, there is a decrease in the β1-AR populations and
vasodilation to β1-AR agonists is reduced. Adrenergic signaling is inhibited through
GRK2 and Gai proteins which are significantly increased in the aged myocardium and
marginally increased in coronary microvessels. SVF cell therapy restores some
vasodilatory capacity via rescuing β1-AR populations through post-translational
modifications of GRK2 and the receptor recycling proteins beta-arrestins, as well as
diminution in Gai proteins. Green text represents activators whereas red text represents
inhibitors. The thicker arrow pointing from NE to the β-ARs indicates higher antagonism
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toward β1-AR compared to β2-AR. Solid black arrows indicate positive effects of cell
signaling while dashed lines indicate negative or inhibitory effects. A key and a summary
of findings are shown to the right. Image created with BioRender.com.
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Supplemental Figure 3.1

Supplemental Figure 3.1: Contribution of the β2- adrenergic receptor to adrenergicdependent vasodilation.
Using pressure myography, isolated coronary microvessels from YC, OC, and O+SVF
animals were subjected to β-AR agonism with NE with and without the β2-AR inhibitor
ICI118551 (A-C) or dobutamine with and without the β2-AR inhibitor ICI118551 (D-F).
Data are presented as means±SEM. Significance defined by paired pre- to post-inhibition
for analysis using Two-way Repeated Measures ANOVA with Bonferroni post hoc
testing. p < 0.05 when pre- vs. post-inhibition (*).
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Supplemental Figure 3.2

Supplemental Figure 3.2: Contribution of the β3- adrenergic receptor and cAMP to
adrenergic-dependent vasodilation.
BRL-37344, a β3-AR agonist (A), and 8-Bromo-cAMP, a cAMP donor (B), were added
in a dose-dependent manor to isolated coronary microvessels from YC, OC, and O+SVF
animals via pressure myography. Data presented as means±SEM. Significance
determined as p < 0.05 utilizing Two-way Repeated Measures ANOVA with Bonferroni
post hoc analysis.
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Discussion
In this study we hypothesized that SVF restored β1-AR function by blunting
downstream negative regulatory factors i.e. GRK2, Gai, and β-arrestin and promoting
positive regulatory factors i.e. Gs that are altered by aging. Although aging significantly
reduced positive and enhanced negative regulatory factors, SVF only partially restored
these to youthful levels. The major finding of this study is that i.v. administered SVF
restored the population of β1-AR in coronary microvessels compared to old controls.
Advancing age desensitized the β1-AR through increased GRK2-dependent
phosphorylation of the adrenergic receptor and increased Gai levels. Furthermore, when
AC was directly activated, neither age nor SVF treatment showed any difference from
young vessels, suggesting age-related microvascular dysfunction is above the level of AC
in the adrenergic signaling cascade. Additional findings are summarized in Figure 3.8.
This study assessed the functionality of the microvasculature in female rats. Our
rationale for this is that as age progresses in humans, coronary vascular disease (CVD)
and coronary microvascular disease (CMD) manifests in the sexes differently. Unlike
men who predominately present with large vessel-CVD, as many as 50% of women
referred for cardiac evaluation do not have obstructive coronary disease but present with
coronary microvascular dysfunction/ischemia [114]. Impairment in endothelial function
can begin developing as early as 40 years with most clinical manifestations apparent
around 50 years of age followed by a steep decline in endothelial function after
menopause [47]. The ages and strain of rat were chosen because the varying stages of
estrous have no effect on vasodilatory capacity in coronary arterioles from young female
Fisher 344 rats, but rather, advancing age and eventual loss of circulating estrogen
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impairs the coronary microvasculature in an endothelial-dependent fashion [260],
mimicking the clinical scenario. Since the small resistance arterioles of the
microvasculature govern the blood flow through an organ, impairment and/or improper
augmentation of blood flow to meet organ oxygen demand can result in tissue ischemia
which can progress to organ failure [39, 45].
The traditional pharmaceuticals currently available for HF and vascular diseases
are targeted at mitigating one aspect of multifactorial pathologies, which contrasts with
the multi-faceted gains seen in cell-based therapies [126]. The current paradigm is that
cell-based treatments provide therapeutic gains through the release of paracrine factors
[141], like exosome release [142], and/or cellular engraftment into the host tissues [143].
SVF administered via tail vein injection can disseminate and engraft into the myocardium
improving left ventricular function [42], while exosomes from mesenchymal cells have
also been shown to preserve cardiac function following a myocardial infarction (MI)
[261]. One possible mechanism for the therapeutic gains seen by mesenchymal-derived
exosomes is through mitigation of oxidative stress [262]. In recent years, studies have
demonstrated equal efficacy for SVF and bone marrow mesenchymal cells in treating
myocardial ischemia [192, 193], promoting angiogenesis [194], and reducing
inflammation [195]. SVF is inherently a heterogeneous cell population comprised of
mostly endothelial cells, smooth muscle cells, pericytes, hematopoietic cells such as
macrophages and T-cells, and a small number of mesenchymal stem cells (MSC) [176].
These various cell types are theorized to be an optimal milieu of environmental cues to
stimulate SVF engraftment or release of paracrine factors within a tissue [186]. Ease of
isolation and the availability of autologous SVF sources confer inherently minimal risk of
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rejection [177]. Despite these benefits of cell-based therapies, there are few studies
conducted using advanced age as the model of pathology as utilized in the current study.
An increase in sympathoadrenal catecholamines in response to HF correlates not
only with the severity of HF [219] but also with the severity of β-AR desensitization in
the myocardium with age [263]. We have shown that the catecholamine NE is increased
with age when measured in the urine (Table 3.1) as well as in the plasma [39]. While
initially protective against a declining cardiac output [84], chronic adrenergic stimulation
can cause desensitization of the vascular β-ARs [85]. Using immunofluorescence, we
measured a decline in β1-ARs with advancing age in isolated coronary microvessels
when compared to YC (Fig 3.2). While helpful in preserving myocardial β-AR
sensitivity, first-generation beta-blockers are non-specific [127] and little is known of
their consequence to the vasodilatory function of coronary microvessels. Coronary
microvessels are primarily dependent upon β1-AR contribution as shown by near
complete abrogation of vasodilation after receptor inhibition with CPG20712A in all
groups (Fig 3.3 A-C). In this study we show that SVF could be an ideal therapeutic for
age-related coronary vascular dysfunction as it did not increase β1-AR populations in the
myocardium (Fig 3.1) but did increase β1-AR populations in the coronary
microvasculature (Fig 3.2). Even though SVF was associated with restoring the β1-AR
population (Fig 3.2) and increasing coronary perfusion to adrenergic agonists [39], the
therapeutic action of SVF does not appear to be due to increased transcription of the
adrenergic receptors in a rat model (Fig 3.7). While β2- and 3-ARs are present in the
coronary microvasculature (Fig 3.2), we measured no age or group differences in
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vasodilation to β2-AR (Supplemental Fig 3.1) or β3-AR (Supplemental Fig 3.2 A)
agonists.
Following ligand binding to the β-AR, signal transduction is regulated first by
GRK2, which phosphorylates the internal tail of the receptor, initiating endocytosis [264].
GRK2 has different affinities for the β1- and β2-ARs, phosphorylating differing locations
on the receptor tail [265]. Ungerer and colleagues measured an increase in transcription
of GRK2 in myocardial samples from patients with HF averaging 50 years of age [251],
but this does not match our own assessments of mRNA transcripts of GRK2 in the
coronary microvasculature (Fig 3.7), highlighting the possible difference in expression
between myocardium versus microvessel tissues. Over the course of two studies,
Schutzer et. al showed that GRK2 increased activity in the aorta of aged rats [266], and
this was directly related to a decline in β-AR functionality in aged rat coronaries [249].
GRK2 phosphorylation of the β-AR initiates receptor endocytosis through beta-arrestinmediated binding and scaffolding, but the sequence differences between the β1- and β2AR result in the β2-AR having higher affinity for GRK2 and thus higher recruitment of
beta-arrestins when compared to the β1-AR [267]. In this study, we showed that SVF
treatment increased protein expression of both beta-arrestins 1&2 in the myocardium (Fig
3.6 A), and transcription of beta-arrestin 2 mRNA is higher in coronary microvessels in
OC (Fig 3.7). As previously described, the sequence differences in the adrenergic
receptors lead to the beta-arrestins binding at different affinities, with beta-arrestin 2
having a higher affinity for the β1-AR [268]. Once internalized, Liang and colleagues
showed that the β-ARs are sorted into different endosomal compartments where the β2AR is dephosphorylated and redistributed back to the membrane while β1-AR
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redistribution was not comparable [265]. Building off the literature as well as data
currently presented, one possible mechanism for the restoration of the β1-AR population
and gain in vasodilatory function following SVF therapy could be a redistribution of this
receptor through the beta-arrestin - receptor recycling axis.
The role of GRK2 in β-AR desensitization has led to study of its inhibition as a
potential therapeutic, both for treating HF [269] and for directing favorable myocardial
remodeling following MI [270]. Paroxetine HCl is a small molecule that binds and
stabilizes the active site of GRK2, leading to inhibition of kinase activity [271]. Utilizing
pressure myography, we showed an improvement in vasorelaxation to NE following
GRK2 inhibition with Paroxetine in our aged groups (OC and O+SVF) but not in YC
(Fig 3.4 C-E), as well as a reduction in the ratio of phosphorylated GRK2 (naturally
inhibited) to total GRK2 levels in the myocardium of OC vs. YC rats (Fig 3.4 A).
Further, we showed that SVF therapy shifted the naturally inhibited (P-GRK2) to active
(total) GRK2 ratio, resulting in levels returning to YC (Fig 3.4 A). It is interesting to note
that a study conducted by Eckhart and colleagues using a transgenic mouse model of
GRK2 overexpression led to increased vascular wall thickness and depleted
vasorelaxation to isoproterenol [272]. Similarly, we observed an increased wall thickness
in our aged groups (Table 3.2). Taken together these data suggest that with advancing
age there is an increase in GRK2 activity in coronary microvessels that SVF does not
reverse, but instead possibly alters the kinase activity via phosphorylation status of
GRK2.
The G-proteins associated with the adrenergic receptors elicit vasodilation or
vasoconstriction through the specificity of the associated G-proteins [273]. Unlike the β2-
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AR which is associated with a Gs and a Gai protein, the β1-AR is only directly
associated with a Gs [7]. We used the small molecule, NaF, to directly activate the Gs
protein in pressurized isolated coronary microvessels and observed significantly reduced
relaxation in vessels from SVF-treated rats compared to YC and OC throughout the lower
doses, but significantly higher relaxation compared to YC at the last dose (Fig 3.5 D).
This data fits into a mixed field as Weber and colleagues reported NaF promoting a
vasoconstriction response in mesenteric arteries from old rats [274] but is contrary to
Cushing and colleagues reporting NaF vasodilation as an endothelial-dependent
mechanism in porcine, bovine, canine, and human coronary arteries [275]. When
examining Gs levels in isolated coronary microvessels, there was no difference due to age
or SVF treatment (Fig 3.5 C). Yet in the myocardium, the Gs protein was reduced in both
the OC and the O+SVF treated groups (Fig 3.5 A). Even though the Gs protein initiates
the signaling cascade for vasodilation following β1-AR activation, crosstalk between Gs
and Gai can occur [276, 277], and both govern AC activity [278]. As previously
mentioned, the activity and levels of Gai have been shown to increase in the myocardium
with HF [244, 245]; furthermore, a study conducted by Janssen and colleagues showed
that adenovirus-directed overexpression of Gai2 attenuated β-AR signaling in rabbit
myocytes [279]. We measured an increase in Gai1 in the myocardium of OC rats that is
not reversed following SVF therapy (Fig 3.5 B). When we examined mRNA expression
of inhibitory G-proteins in isolated coronary microvessels, we found an increase in
Gnao1 and Gnai2 with age compared to young (Fig 3.7). While many studies have
examined the effect of age or HF on Gai levels in the myocardium and the ability of Gai
to cross-inhibit β1-AR mediated contractile response [280], few studies have examined
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the effect of age on Gai in the coronary microvasculature. It is important to note that
vasodilation is not only adrenergic-dependent, but can also be elicited through nitric
oxide (NO) production, which is more commonly associated with youth [281], and
endothelial-derived hyperpolarizing factors, which are more commonly associated with
age [282]. Gai and Gnao proteins can prompt vasodilation through the two alternative
aforementioned pathways [283]. These data lend consideration that SVF works to restore
microvascular health through shifting the vasodilatory mechanism back from
hyperpolarization and more toward NO in conjunction with increased β-AR sensitivity,
but future studies are needed to address this possibility.
Not only is cAMP production by AC the convergent point in β-AR and a2-AR
signaling [284], but it is a common second messenger in other intracellular signaling
cascades. Studies have shown that the myocardium expresses two main isoforms of AC,
isoforms 5 and 6 [285]. Disruption of the AC isoform 5 led to prolonged life and
increased resilience to apoptosis following MI [285], indicating its native deleterious
effects. On the other hand, AC6 has been shown to be cardio-protective [286].
Compellingly, we have shown that there is a significant age-related reduction in mRNA
transcription of AC6 in the coronary microvasculature, although SVF does not restore
AC6 transcription back to levels seen in YC (Fig 3.7). To examine the functionality of
AC in prompting vasorelaxation, we used forskolin to directly activate AC in isolated and
pressurized microvessels, but no differences between the groups were found (Fig 3.6 C).
While transcription of the cardio-protective AC isoform 6 may be reduced with age,
functionality is intact (Supplemental Fig 3.2 B), conveying that age-related
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microvascular dysfunction and improvement following SVF administration occur above
the level of AC.

Conclusion
Coronary vascular function is compromised by as much as 43% with advancing age
which can contribute to the prevalence of cardiovascular diseases (CVDs) and coronary
microvascular disease (CMD) [52]. Our previous studies have shown that i.v. injected
SVF incorporate into the cardiac and vascular spaces [42], improve vasodilation to
adrenergic agonists as measured by coronary flow reserve, and remain detectable in aged
rats four weeks post-injection [39]. At the present time, the field of cellular therapeutics
is still exploring if benefits of injected cell therapies are a result of secreted factors
through exosomes, the cells themselves engrafting into the tissues, or a combination of
these [287]. While the mechanisms of cell therapy, SVF in particular, are still being
evaluated, age-related beta-adrenergic desensitization has been targeted for
pharmacological therapeutics to treat declining function in the myocardium. The data
presented here investigated the effect of age on beta-adrenergic desensitization
throughout the signaling cascade in cardiac tissues. We examined the differences between
myocardial tissues and the microvascular tissue, and the effect age has on each signaling
component. To our knowledge, this is the first time that coronary arterioles isolated from
an aged rodent model have undergone RNAseq analysis to compare transcriptional
changes to youth and cell therapy regime. Furthermore, we provide exciting evidence that
SVF works to improve adrenergic-mediated vasodilation through re-establishing the β1
receptor population and reducing the aged effect of signal transduction inhibitors, GRK2
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and Gai, thereby improving vasodilation. These results lay significant groundwork for
future studies on cell therapy and resultant sympathoadrenal and β-AR signaling.

Limitations and Future Directions
It is important to consider the limitations of the present study: 1) All of the rats in
this study were females. Our rationale for this is that as age progresses, women more
often present with microvascular dysfunction. Specifically, as many as 50% of women
referred for evaluation of MI present with coronary microvascular dysfunction/ischemia
rather than obstructive coronary disease, like most men, due to the loss of the protective
effects of estrogen [114]. The males of the Fisher 344 strain have also been shown to
develop coronary microvascular reactivity impairments with age [288], but we do not
know if the findings in the current study persist in the male sex. 2) Data presented in this
study sought to examine age-and SVF-related changes of beta-adrenergic signaling
proteins in myocardial and microvascular tissues. Future studies will be needed to
explore both sides of the cell therapy paradigms, i.e. paracrine versus engraftment, to
elucidate the therapeutic mechanism of the SVF-mediated increase in beta-1 adrenergic
receptor population. 3) Myocardial tissue samples were used for western blotting due to
the anatomical limitations of the coronary microvasculature. Nonetheless, Next Gen
sequencing of mRNA isolated from the pooled coronary microvessels yielded an
extensive library of data (Supplemental Table 3.1) and immunofluorescence of specific
adrenergic signaling targets were used in place of western blotting. Further examination
of the RNA sequencing data and current literature could provide insight into SVFmediated changes to transcription factors for genes involved in regulating the beta-
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adrenergic receptor as part of SVF’s therapeutic mechanism. 4) Future studies will use
pertussis toxin to inhibit the Gai protein to examine its contribution in microvascular
functionality. 5) Furthermore, we also plan to inhibit beta-arrestin pharmacologically in
isolated coronary microvessels to examine if there is an improved adrenergic vasodilation
response in the OC group. The heterogeneous properties of the various cell populations
within the SVF provide more than one outlet for improving vascular function and health
within an aged microvascular network which the authors will continue to investigate in
subsequent studies.
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CHAPTER 4
REVERSAL OF AGING-RELATED IMPAIRMENT IN REVASCULARIZATION
FOLLOWING INJURY BY ADIPOSE-DERIVED STROMAL VASCULAR
FRACTION IS NOT WHOLLY T CELL MEDIATED.
Overview
Advancing age drives a decline in vascular function i.e. angiogenic potential
increasing ischemic risk and impairing revascularization following an ischemic injury.
Adipose-derived stromal vascular fraction (SVF) has emerged as a potential regenerative
therapeutic following injury, but few studies have been conducted in the setting of
advanced age. Importantly, which specific cell type(s) in SVF are responsible for
therapeutic gains are still unknown. We hypothesized that aging would alter the
composition of cell populations present in SVF and its ability to promote angiogenesis
following injury, a mechanism that is T cell mediated. SVF isolated from young (4-9 mo)
and old (24 mo) GFP+ Fischer-344 rats were examined with flow cytometry for cell
composition. Mesenteric windows from old rats were isolated with or without
exteriorization-induced (EI) hypoxic injury; upon surgical closure, animals received
intravenous injection of one of four cell therapies: SVF from young or old donors, and
SVF from old donors depleted or enriched of T cells. Three days later, mesenteric
windows were removed and cultured for up to 5 days. Advancing age increased the SVF
T cell population but reduced revascularization following injury. Both young and aged
SVF engrafted throughout the host mesenteric microvessels but only young SVF
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significantly increased vascular area following EI. T cell depletion did not affect the
angiogenic potential of SVF. This study highlights the effect of donor age on SVF
angiogenic efficacy and demonstrates how the ex vivo mesenteric window model can be
used in conjunction with SVF therapy to investigate its contribution to angiogenesis.

This chapter is from the published work referenced as follows:
Rowe, G., et al., Reversal of Aging-Related Impairment in Revascularization Following
Injury by Adipose-Derived Stromal Vascular Fraction is not Wholly T cell
Mediated. J Vas Res, 2022. in peer review
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Introduction
The microvasculature primarily control and regulate blood flow through an organ,
but impairment of blood flow can result in tissue ischemia [39, 40, 45]. As aging
progresses, aberrant physiological remodeling responses can serve as the foundation that
eventually limit tissue plasticity during pathophysiological remodeling following injury
[43]. The increase in systemic oxidative stress [58], cellular senescence [59], and chronic
inflammation [60] that are characteristics of advancing age have been linked to
endothelial cell dysfunction and a decline in the capacity of a microvascular network to
sprout new vessels via angiogenesis and collateralization.
Current medications and surgical interventions utilized after an ischemic event act
by decreasing organ workload, mitigating inflammation, or grafting of large vessels to
redirect blood flow, but none target the multifactorial pathology of endothelial cell
dysfunction to promote growth of the microvasculature [69]. These treatments stand in
contrast to the gains observed in cell-based therapies [126]. Adipose tissue contains an
abundant source of multipotent cell populations such as mesenchymal stem cells (MSCs),
endothelial cells, pericytes, and hematopoietic cells including macrophages, T cells, and
other cells of the perivascular niche [176, 185]. Of note, T cells have been shown to play
a role in stimulating angiogenesis in ischemic areas [289] due to migration to the area of
injury [290, 291] and collateralization specifically by homing to sites of active
angiogenesis [292]. In recent years, studies have demonstrated equal efficacy for SVF
and bone marrow MSCs in treating myocardial ischemia [192, 193], promoting
angiogenesis [194], and reducing inflammation [195]. Availability of autologous and
allogenic SVF sources confer inherently minimal risk of rejection [177], offering an ideal
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candidate in vascular therapeutics due to the ability to leverage an easy-to-harvest, realtime, point-of-care therapeutic approach [178]. Despite these benefits of cell-based
therapies, there are few studies conducted using advanced age as the model of pathology
and examining the impact of donor age on the vasculogenic properties of cell therapy as
utilized in the current study.
To investigate the effect of age on SVF cell populations as well the potential to
increase angiogenesis in an aged microvasculature, we utilized an ex vivo model
comprised of connective tissues located along the intestinal mesentery termed mesenteric
windows [293]. The ex vivo mesentery culture model developed by the Murfee laboratory
was utilized in this study for ease of access, time-lapse imaging capabilities, and
survivability in culture [294]. This model has shown the functional effect of pericytes on
tip cell formation and maintenance of in vivo-like endothelial cell phenotypes along
capillary sprouts during active angiogenesis [295-298]. Furthermore, exteriorization
injury (EI) of the tissue has been shown to be a reproducible model to induce acute
hypoxia and stimulate angiogenesis [299, 300], but has not been previously used in a
setting of advanced age. Prior studies from our laboratory have shown that systemically
delivered SVF from young donors can improve coronary microvascular perfusion in aged
rats [42]. Furthermore, a single intravenous (i.v.) injection of SVF from young donors
resulted in a biodistribution of cellular engraftment across various organs and blood
vessels [42]. However, the therapeutic potential of SVF from aged donors on tissue
perfusion was not studied nor were changes in vascular density as a result of cell
administration examined. This study aimed to leverage the benefits of the mesenteric ex
vivo prep to investigate the impact of donor age on vasculogenic potential in a setting of
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advanced age and injury with intravenously administered SVF therapy. We hypothesized
that SVF from aged rats would exhibit increased inflammatory cell populations (M1
macrophages and T cells), limit the ability of the microvasculature to collateralize
following hypoxic injury and reduce the angiogenic potential which is T cell mediated
compared to SVF isolated from young rats.

Materials and Methods
Animal model.
The Institutional Animal Care and Use Committees of the University of Florida
and the University of Louisville approved this study, and all procedures followed the NIH
Guide for the Care and Use of Laboratory Animals [254]. Young (3-9 months) and aged
(23-24 months) of male and female Fischer 344 rats (Harlan Laboratories, Indianapolis,
IN, USA and National Institute of Aging, Bethesda, MD, USA, respectively) were group
housed with free access to food and water and maintained on regular 12-hour light/dark
cycles. Green fluorescent positive (GFP+) transgenic Fisher 344 male and female rats,
maintained in house (Louisville), aged 3-9 and 24 mo were utilized as SVF donors. All
rats were acclimated to facility conditions for a minimum of one week then randomly
divided into the experimental groups described in detail below and depicted in Figure
4.1.
SVF isolation and experimental groups.
SVF cells were isolated as previously described [40, 298]. Briefly,
epidydimal/ovarian fat pads from young (4-9 mo) or aged (24 mo) Fischer 344 donor rats
were harvested, mechanically homogenized and digested with a collagenase and
deoxyribonuclease-1 enzymatic solution. Following centrifugation, the buoyant adipocyte
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layer was removed. SVF cells were washed, filtered through a 20 µm nylon screen to
remove large cell or tissue aggregates, then prepared for flow cytometry analysis,
treatment of cultured mesenteric windows (Experimental Group 1), intravenous (i.v.) tail
vein injection into experimental animals (Experimental Groups 2 and 3), or modification
using magnetic antibody cell sorting prior to i.v. injection into experimental animals
(Experimental Group 4).
Flow cytometry.
Following isolation, the fresh SVF from young and aged donors was incubated in
rat Fc Block Mix (BD Biosciences 550271) at 4°C for 20 min protected from light. Cells
were then stained for cell surface markers with the appropriate monoclonal antibodies at
4°C for 30 min also protected from light. Supplemental Table 4.1 contains the
antibodies included in each staining panel used in this study along with dilations. During
the incubation, anti-mouse IgG kappa compensation beads and negative control beads
(BD Biosciences 552843) were added to each compensation tube; antibodies (positive
compensation) or fluorophore-conjugated IgG (negative compensation) were added to the
appropriate tubes. Following antibody incubation, red blood cells were lysed with diluted
Lyse buffer (BD Bioscience 5558999) and tubes were vortexed, incubated for 3 min at
37°C, spun at 350 g for 5 min, then cells washed twice with wash buffer. For the tubes
requiring CD68 staining, cells were fixed and stained with MACS Inside Stain Kit
(Miltenyi Biotec 130-090-477) according to manufacturer’s instructions. Data was
collected on an LSR II cytometer (BD Biosciences) and analyzed with FlowJo 7.6
software (Tree Star, Ashland, OR, USA).
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Experimental group 1.
SVF was isolated as described [40, 298]. Young or aged Fisher-344 rats were
anesthetized with an intramuscular injection of ketamine (80 mg/kg body weight) and
xylazine (8 mg/kg body weight). Rat mesenteric tissues were harvested and cultured
according to a previously established protocol [301-303]. Briefly, an incision was made
along the linea alba, and the mesentery was placed onto a sterile plastic stage using cotton
tip applicators to first remove the cecum and subsequently the ileum and jejunum. The rat
was euthanized with an intracardiac injection of 0.2 ml Beuthanasia. Vascularized
mesenteric tissues were excised and rinsed once in sterile saline (Baxter 2B1324X) and
immersed in minimum essential media (MEM; Gibco 11095-072) containing 1%
Penicillin-Streptomycin (PenStrep; Gibco 15140122) at 37°C.
To determine the effects of age on SVF transplantation therapy the following
groups were utilized: young SVF + young tissue, young SVF + aged tissue, aged SVF +
young tissue, and aged SVF + aged tissue (n=8 tissues per group; tissues per group were
harvested from 2 rats). Freshly isolated SVF cells were suspended in 10% FBS + MEM
solution at a concentration of 10 million cells/mL. Tissues were the spread onto a
polycarbonate filter membrane (pore size = 5 µm) on a cell crown insert (Millipore
Z681792-3EA) where 100 µL of SVF cell solution was transferred to the surface of each
mesenteric window. Windows and cells were incubated for 20 min to allow attachment of
SVF cells to the tissue. Cell crowns were then inverted into 6-well culture dishes
(Cellstar 657 160) with the fat of the tissue pressing against the bottom surface. Three
milliliters of culture medium composed of 10% FBS + MEM was added to each well on
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top of the filter. Tissues were cultured in standard incubation conditions (5% CO2, 37°C)
for 3 days.
After 3 days in culture, tissues were spread on glass slides before being rinsed 3
times for 10 minutes in PBS +0.1% saponin (Sigma Aldrich S7900). Fat around window
was removed and a hydrophobic marker was applied around the tissue. The tissue was
then labeled with PECAM at 1:200 (BD Pharmigen555026) and cover slipped.
Images were acquired using 4x (dry, NA = 0.1), 10x (dry, NA = 0.3), and 20x
(oil, NA = 0.8) objectives on an inverted microscope (Nikon Eclipse Ti2) coupled with an
Andor Zyla sCMOS camera. Image analysis and quantification were done using ImageJ
2.0.0-rc-54 (U.S. National Institutes of Health, Bethesda, MD). Images were quantified as
percent vascularized area for each tissue in order to evaluate angiogenic effect of SVF
transplantation on networks. Vascularized areas were measured by drawing the perimeter
along the edge of the vascular networks. Avascular regions within the network smaller
than 130 µm2 were subtracted from the vascularized area metric. The final vascularized
area was divided by the total tissue area.
Two-way ANOVA with pairwise Tukey’s multiple comparisons post-hoc tests with
interactions were used to test for statistical significance between the groups (p < 0.05).
Statistical analysis was performed using SigmaStat ver. 3.5 (Systat Software, San Jose,
CA, USA). Values are presented as means±SEM.

Experimental group 2.
Previously isolated frozen GFP+ SVF cells were reconstituted 10 million/mL in 1
mL Lactated Ringer’s solution (warmed to 37°C) as previously described [39, 40]. Aged
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female rats were injected i.v. via tail vein with SVF from young donors (O+YSVF, n=4)
or SVF from aged donors (O+OSVF, n=4). Three days after injection, aged rats treated
with SVF were anesthetized with inhaled 5% isoflurane with 1.5-2.0 L/min oxygen flow
through an induction chamber. After confirmation of a lack of a tactile reflex, the thoracic
cavity was opened, and rat euthanized via cardiac removal. Mesenteric windows were
isolated (6 tissues per animal) and placed individually in a 6 well dish on a crown insert
with membrane as previously described [301-303]. Windows were then cultured in MEM
media + 1% Penicillin-Streptomycin (Sigma-Aldrich PO7881) and cultured for up to 5
days at 5% CO2 and 37°C.
After 1 or 3 days in culture, the windows were affixed to glass slides, fixed in 4%
paraformaldehyde overnight, then rinsed in 1xPBS before being dried and stored at 20°C. Windows were washed x3 with PBS before being permeabilized in 0.5% Triton X100/0.1 M glycine at room temperature (RT) for 30 minutes. After rinsing x3 in PBS
slides were blocked with 5% normal donkey serum (Jackson ImmunoResearch 017-000121) and 1.5% bovine serum albumin in 1xPBS at RT for 1 hour. Rabbit anti-rat CD3
(1:200, Abcam ab16669), and the fluorescent probe Griffonia (Bandeiraea) Simplicifolia
Lectin 1 (GS-1) rhodamine (1:100, Vector Laboratories RL-1102) were diluted in 1.5%
BSA-PBS to be incubated on the tissue at 4°C overnight. After x3 washes in PBS, the
slides were incubated in secondary antibody solutions made in 1.5% BSA-PBS
containing donkey anti-mouse IgG Alexa Fluor 647 (1:400, Abcam ab150111) or donkey
anti-rabbit IgG Alexa Fluor 647 (1:400, Abcam ab150063) for 1 hour at RT. Slides were
then washed, incubated with DAPI (Invitrogen P36962) and coverslipped using
Fluoromount-G (SouthernBiotech 0100-01).
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Image stacks were acquired using a Nikon C2+ confocal microscope (Melville,
NY) with 20x objective + Nyquist resolution (final magnification ~70x), and 0.85 µm Zstep size with 10 slices/stack. GFP signal was excited with 488 laser alone rather than
antibody detection. One mesenteric window from an old control (no cell injection) was
utilized as a negative control. Visualization of co-localization of GFP+, CD3+, and DAPI
(nuclei) was done using ImageJ (n=1/group).

Experimental group 3.
The methods for this surgical procedure have been adapted from the protocol
described by Yang et al. [299]. Aged female Fisher 344 rats were anesthetized with
inhaled 5% isoflurane with 1.5-2.0 L/min oxygen flow through an induction chamber.
The animal’s abdomen was prepped by shaving and then sterilized with 70% isopropyl
alcohol and animal placed on heating pad. Under sterile conditions, a 3-cm opening was
made through abdominal skin and muscle. Gently, a section containing 8-10 mesenteric
windows was removed from the body cavity and placed onto a sterile plastic stage placed
on top of the abdomen. This action exteriorizes the windows from the abdominal cavity
but leaves all blood flow to the intestines and mesentery intact, resulting in an
exteriorization injury (EI). The windows were bathed in sterile physiological salt solution
warmed to 37°C throughout the 20-minute exteriorization procedure. The borders around
the exteriorized zone were marked with 5-0 silk loops to ensure proper identification at
explant, then the intestines and windows were placed back into the abdominal cavity and
the incision closed with 5-0 silk sutures. A subset of animals was randomly allocated to a
no cell control (NCC) group (n=4). Previously frozen SVF cells were thawed and
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prepared as described above and injected via tail vein, at 10 million cells/mL in warmed
Lactated Ringer’s solution (O+YSVF and O+OSVF, n=4/group). The animals were
subcutaneously injected on-time with a 1.2 mg/kg body weight buprenorphine slow
release and monitored daily to evaluate post-operative recovery.
Three days after EI, mesenteric windows were isolated as described above both
from EI regions and non-exteriorized (NEI) regions of the mesentery (6 tissues per
condition per animal). Isolated windows were cultured individually in a 6 well dish on a
crown insert with membrane as previously described [301-303]. During the mesenteric
window culture, at days 0, 3, and 5, MEM + 1% PenStrep media was supplemented with
3mL of GSL-I Rhodamine (1:40 dilution) in MEM. Windows were incubated at 37°C for
20 minutes, rinsed with MEM media, then 3mL of fresh MEM+1% PenStrep was
replaced. The 6 well plates were imaged on a Zeiss Z.1 Axio Observer with a sterile
heated incubation chamber; 10x images were acquired in the same location for each
mesenteric window over time. Images were processed in ImageJ by thresholding and
conversion to binaries. Extraneous cells not a part of the microvascular network was
excluded based upon circularity. Percent vascular area, or the area the microvessels
occupy in the image, was measured via analysis of mean area. Conversion of the binary
to a skeleton allowed for pruning of false branches. Analysis of the pruned skeleton
images yielded total vessel length, average vessel length per segment, number of
segments, and number of branches. Image analysis protocol modified from Strobel et al.
[304]. Data are represented as box and whisker plots. Statistical analyses were performed
in SigmaPlot 14.0 (Systat, San Jose, California, USA) with p < 0.05 as the significance
level. Multiple Two-way repeated measures ANOVAs with Bonferroni pairwise
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comparisons allowed for comparison of group, day, and injury model on the following
angiogenic metrics: percent vascular area, total vessel length, average vessel length per
segment, number of segments, and number of branches.

Experimental group 4.
The methods for this cell sorting have been adapted from the protocol provided by
Miltenyi Biotec and as previously described in [200]. Previously frozen GFP+ SVF was
thawed, washed, counted, and resuspended in chilled MACS buffer with rabbit anti-rat
CD3 (1:500, Abcam ab16669) to incubate at 4°C for 30 min. The cell solution was then
washed and resuspended in MACS buffer with anti-rabbit IgG microbeads (1:10,
Miltenyi Biotec 130-048-602) and incubated at 4°C for 15 min. The cell solution was
then washed and added to MS columns (Miltenyi Biotec 130-042-201) which were
placed in the magnetic stand (Miltenyi 130-042-108). Once the flow through CD3
depleted fraction was collected, the magnetic column was washed with MACS buffer. To
collect the CD3 enriched fraction, the column was removed from the magnetic field, 500
uL MACs buffer added to the column, then the solution gently expelled using the
plunger. Once sorted, final cell counts of depleted and enriched populations were
performed.
Exteriorization injury and SVF injection was done as described above
(Experimental group 3). Sorted cells were reconstituted at 1.1 million cells/mL in 1 mL
Lactated Ringer’s solution (warmed to 37°C) as previously described [39, 40]. Aged
female rats were injected i.v., via tail vein with the CD3+ depleted SVF from aged donors
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(O+OSVF CD3-, n=4) or with the CD3+ enriched, 1.1 million CD3+ SVF cells, from
aged donors (O+OSVF CD3+, n=4).
Three days after EI, mesenteric windows were isolated as described above both
from EI regions and non-exteriorized (NEI) regions of the mesentery (6 tissues per
condition per animal). Isolated windows were cultured individually as previously
described [301-303]. During the culture on days 0, 3, and 5 the media was supplemented
with GSL-1 Rhodamine in MEM and imaged as described above.
Statistical analyses were performed in SigmaPlot 14.0 (Systat, San Jose,
California, USA) with p≤.05 as the significance level. Multiple Two-way repeated
measures ANOVAs with Bonferroni pairwise comparisons allowed for comparison of
group, day, and injury model on the following angiogenic metrics: percent vascular area,
total vessel length, average vessel length per segment, number of segments, and number
of branches.

Results
Effect of donor age on SVF cell composition.
SVF isolated from young donors has a significantly higher percentage of
hematopoietic stem cells (CD34+) and mesenchymal stem cells (CD45-/CD34-/CD90+)
(Fig 4.2 A). Young SVF had a significantly higher stromal fraction which can be
comprised of fibroblasts, pericytes, and pre-adipocytes (Fig 4.2 A). SVF from young
donors contained significantly larger populations of total macrophages, as well as
immature and transitional macrophages (Fig 4.2 B). SVF from old donors had a higher
percentage of lymphocytes (Fig 4.2 A) and M1 inflammatory macrophages (Fig 4.2 B).
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Young SVF shows a marked increase in thymocytes compared to SVF from aged rats
(approaches significance, p=.057) (Fig 4.2 A). SVF isolated from old donors has a
significantly higher percentage of CD3+ T cells , as well as helper and CD4+ memory T
cells compared to young SVF. Activated and CD8+ memory T cells are higher in aged
SVF compared to young SVF (approaches significance, p=.057) (Fig 4.2 C).

Effect of SVF donor age on vascular area.
The varying combinations of host and donor ages resulted in a significant increase
between young SVF on young mesenteric tissue compared to all other combinations
when seeded and co-cultured (Figs. 4.3 A and 4.3 E). There was a reduced level of
vascularized area in both aged SVF and aged tissue groups, but regardless of SVF age
and tissue age, no one group had strikingly lower vascularized area after three days in
culture (Figs. 4.3 B-D and 4.3 E).

Cellular engraftment of SVF into the vasculature of mesenteric windows.
Following i.v. injection of GFP+ SVF, engrafted cells from both donor groups
could be detected in and around the mesenteric microvasculature six days after
administration (Fig 4.4 A). Previously frozen SVF nor age of donor alters the ability of
SVF to engraft into host tissues. Furthermore, some engrafted SVF cells were co-positive
for the T cell marker CD3.

Effect of injury and SVF therapy on angiogenesis.
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To examine the effect of advanced age on vascular area following injury and the
angiogenic therapeutic effect of SVF, mesenteric windows subjected to EI from NCC,
O+YSVF, and O+OSVF treated animals were cultured and imaged for up to 5 days.
Representative images are shown in Figure 4.5 A. In the NEI control windows of the
NCC group, the aged and untreated tissue showed a significant increase in vascular area
by day 5 compared to day 0. By day 3 in the NEI windows of aged rats treated with
young SVF (O+YSVF), there was a significant increase in vascular area compared to day
0. However, in the EI windows of the NCC there is no change in vascular area between
any of the days. EI windows of aged rats treated with young SVF (O+YSVF) had a
significantly higher vascularized area compared to the NCC. While the O+OSVF treated
group showed a modest increase in vascular area in response to injury, it was not
significantly different compared to the other EI groups; however, the O+OSVF day 0 EI
was significantly higher than its NEI counterpart (*) (Fig 4.5 B). Supplemental Figure
4.2 displays further angiogenic metrics such as total vessel length (A-B) and average
vessel length per segment (C-D), number of vessel segments (E-F) and number of branch
points (G-H) in non-injured (NEI) and injured (EI) mesenteric microvascular networks.
Effect of modification of CD3+ cell population on SVF’s angiogenic potential.
The implication of modifying the T cell populations in SVF therapy was
examined by administering depleted or enriched CD3+ SVF to aged rats following injury,
and mesenteric windows were cultured and imaged for up to 5 days (Fig 4.6 A). In the
NEI condition CD3 depleted (CD3-) SVF had significantly higher vascular area
compared to day 0 at days 3 and 5 (Fig 4.6 B). Further, the CD3 depleted group at days 3
and 5 also had significantly higher vascular area than the CD3 enriched (CD3+) group at
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the same time points (Fig 4.6 B). Treatment with CD3 depleted or CD3 enriched SVF in
the setting of injury (EI) did not produce differences between the groups at any time
points. The CD3+ enriched group in the EI condition at day 5 had significantly higher
percent vascular area compared to day 0. This is in contrast to no difference in vascular
area observed in the CD3 depleted group for day 5 vs day 0 comparison (p=.126) (Fig 4.6
B). Supplemental Figure 4.3 displays further angiogenic metrics such as total vessel
length (A-B) and average vessel length per segment (C-D), number of vessel segments
(E-F) and number of branch points (G-H) in non-injured (NEI) and injured (EI)
mesenteric microvascular networks.
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Figure 4.1

Figure 4.1: Summary of methodology.
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Combinations of young or aged SVF cells seeded onto young or aged mesenteric
windows was utilized to assess SVF’s angiogenic properties influenced by age of donor
and/or host (Group 1). Young or aged SVF was administered to aged hosts via systemic
administration to assess SVF’s engraftment into the host mesenteric microvascular
network (Group 2). Exteriorization of the mesentery was utilized to induce injury in aged
rats treated with no cells or SVF from either young or aged donors. The microvascular
networks of injured windows and non-injured controls were imaged over time to quantify
angiogenic growth (Group 3). SVF from aged donors was subjected to magnetic
antibody cell sorting to generate CD3 depleted and CD3 enriched SVF fractions. The
modified SVF was then systemically administered following exteriorization injury
(Group 4). Angiogenic growth in the microvascular networks of injured and non-injured
windows was analyzed. Adipose-derived stromal vascular fraction (SVF), CD3+ (T cell
marker), cell membrane stain (Dil), exteriorization injury (EI), immunohistochemistry
(IHC), magnetic antibody cell sorting (MACS), months old (mo), non-exteriorized/noninjured (NEI). Aged rats treated with SVF from young donors (O+Y SVF), aged rats
treated with SVF from aged donors (O+O SVF), aged rats treated with SVF from aged
donors depleted of CD3+ T cells (O+O SVF CD3-), aged rats treated with SVF from
aged donors containing only CD3+ T cells (O+O SVF CD3+). Image created with
BioRender.com.

118

Figure 4.2
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Figure 4.2: Cell composition of SVF from young or aged donors.
Flow cytometry analysis of cell composition for SVF isolated from young or aged donors
(A-C). A) Lymphocytes (forward and side scatter), hematopoietic (CD45+/CD11b+),
hematopoietic stem cell (CD45+/CD34+), endothelial (CD31+), MSC (CD90+/CD45/CD34-), and stromal fraction (CD45-/CD31-/CD34+). B) All macrophages
(CD45+/CD11b+/CD68+), immature (CD45+/CD11b+/CD68+/CD86-/CD163-), M1
(CD45+/CD11b+/CD68+/CD86+/CD163-), M2 (CD45+/CD11b+/CD68+/CD86/CD163+) and transitional (CD45+/CD11b+/CD68+/CD86+/CD163+). C) All T cells
(CD3+), thymocytes (CD45-/CD90+), helper (CD3+/CD4+), cytotoxic (CD3+/CD8+),
activated (CD3+/CD25+), CD4 memory (CD3+/CD4+/CD44+), and CD8 memory
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(CD3+/CD8+/CD44+). Data are represented as percentage of cells in SVF mean+SEM,
n=3/group. p < 0.05 when vs young SVF (*).
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Figure 4.3
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Figure 4.3: Aging effects between donor SVF and host tissue on vascularized area.
Vascular coverage is greatest in young SVF + young tissue pairing (A) compared to aged
SVF on young tissue (B), young SVF on aged tissue (C) and aged SVF on aged tissue
(D). Quantitative analysis of percent vascularized area (E). Green outline indicates
vascularized area while red outline indicates avascular area. Scale bar = 2 mm. 8
mesenteric windows from 2 rats per group, p < 0.05 (*); values are shown as box and
whisker plots.
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Figure 4.4
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Figure 4.4: GFP positive SVF engrafted into mesenteric microvasculature following
intravenous injection.
GFP+ SVF (green) cells from young or aged donors were found in the perivascular space
and microvasculature (GSL-1 - red) of young host mesenteric windows six (A) days
following i.v. injection. GFP is co-localized (arrows) with CD3+ (T cell marker, pink),
and DAPI (blue). An old control animal not treated with SVF was used as a negative
control for GFP signal and secondary antibody control for CD3 (B). Scale bar = 20 µm.
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Figure 4.5
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Figure 4.5: SVF rescues age-related impairment in revascularization following
injury.
Representative images of injured (EI) and non-injured (NEI) mesenteric windows from
NCC, O+YSVF, and O+OSVF groups at days 0, 3, and 5 of culture. Vascular networks
stained with GSL-1 and scale bar = 200 µm (A). Quantitative analysis of percent vascular
area (B). Data are shown as box and whisker plots (n=4/group), brackets indicate p <
0.05 when comparisons are between days or groups. p < 0.05 when EI vs NEI within
group comparison (*).
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Figure 4.6
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Figure 4.6: Modification of T cell population in SVF does not alter angiogenic
potential following injury.
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Representative images of injured (EI) and non-injured (NEI) mesenteric windows from
O+OSVF animals that received CD3 depleted (CD3-) SVF or CD3 enriched (CD3+) SVF
at days 0, 3, and 5 of culture. Vascular networks stained with GSL-1 and scale bar = 200
µm (A). Quantitative analysis of percent vascular area (B). Data are shown as box and
whisker plots (n=4/group), brackets indicate p < 0.05 when comparisons are between
days or groups.
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Supplemental Table 4.1
Stromal and Mesenchymal Stem Cell
Marker Vendor
Catalog #
CD90 Novus Biologicals NB100-65543V
CD146 Novus Biologicals FAB3250G
CD34 Abcam
ab187284
CD31 BioRad
MCA1334A647
CD45 eBioscience
47-0461-82
Immune Cells
Marker Vendor
Catalog #
CD45 BioRad
MCA43A488
CD163 BioRad
MCA342PE
CD86 Miltenyi Biotec
130-109-178
CD3
eBioscience
46-0030-82
CD11b BioRad
MCA275A647
CD68 Miltenyi Biotec
130-103-366
CD8
BD Biosciences
561614
CD44 BioRad
MCA643FA
CD25 BioRad
MCA273PE
CD4
BD Biosciences
561578
CD3
eBioscience
46-0030-82

Clone
OX-7
404722
ICO115
TLD-3A12
OX1

Fluorophore
Dylight405
Alexa488
PE
Alexa647
APC-eFluor780

Dilution
1:200
1:100
1:20
1:50
1:40

Clone
OX-1
ED2
24F
eBioG4.18
OX-42
REA237
OX-8
OX-50
OX-39
OX-35
eBioG4.18

Fluorophore
Alexa488
PE
PE-Vio770
PerCP-eFluor710
Alexa647
APC-Vio770
V450
FITC
PE
PE-Cy7
PerCP-eFluor710

Dilution
1:10
1:10
1:20
1:40
1:200
1:5
1:100
1:20
1:20
1:200
1:40

Supplemental Table 4.1: Complete list of all antibodies utilized in this study for flow
cytometry.
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Supplemental Figure 4.1
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Supplemental Figure 4.1: The mesenteric microvasculature from aged animals
exhibits impaired angiogenesis to serum stimulation.
Mesenteric windows were harvested from young (YC) and aged (OC) Fisher 344 animals
to be cultured for 5 days. The media was supplemented with 10% fetal bovine serum to
stimulate angiogenesis. The vasculature was stained for time-lapse images for vascular
areas measurements. Representative images of mesenteric microvascular networks (A).
Vascular areas were measured and normalized to total area for days 0 and 5 (B). Scale
bar = 100 µm. Data are mean±STDEV. YC vs OC at p < 0.1.
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Supplemental Figure 4.2
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Supplemental Figure 4.2: Quantification of vascular morphology in response to
injury and SVF therapy.
Quantitative analysis of total vessel length (A-B) and average vessel length per segment
(C-D), number of vessel segments (E-F) and number of branch points (G-H) in noninjured (NEI) and injured (EI) mesenteric microvascular networks. Data are shown as
box and whisker plots (n=4/group), brackets indicate p < 0.05 when comparisons are
between days or groups. p < 0.05 when EI vs NEI within group comparison (*).
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Supplemental Figure 4.3
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Supplemental Figure 4.3: Quantification of vascular morphology in response to
injury and T cell modification of SVF therapy. Quantitative analysis of total vessel
length (A-B) and average vessel length per segment (C-D), number of vessel segments
(E-F) and number of branch points (G-H) in non-injured (NEI) and injured (EI)
mesenteric microvascular networks. Data are shown as box and whisker plots
(n=4/group), brackets indicate p < 0.05 when comparisons are between days or groups. p
< 0.05 when EI vs NEI within group comparison (*).
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Supplemental Figure 4.4
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Supplemental Figure 4.4: Injury promotes homing of T cells in aged SVF.
Quantitative analysis of GFP+, CD3+ or co-localization of both GFP+ and CD3+ cells in
NEI and EI windows 6 days post-injury and administration of SVF therapy from young
and aged donors. Data is represented as cell counts normalized to micrometers2 and
plotted as means±SEM (n=4/group). Brackets indicate p < 0.05 when comparisons are
between groups. p < 0.05 when EI vs NEI within group comparison (*).
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Supplemental Figure 4.5
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Supplemental Figure 4.5: Levels of inflammatory markers and growth factors as a
result of injury or SVF therapy.
Concentrations of pro- and anti-inflammatory cytokines as well as mediators of
inflammation and growth factors as measured from media. Data is shown as means+SEM
in ng/mL (n=4/group), brackets indicate p < 0.05 when comparisons are between groups.
Interleukin (IL), tumor necrosis factor alpha (TNFa), Interferon gamma (IFg), monocyte
chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF),
transforming growth factor beta (TGFb).
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Discussion
The first major finding from this study is that aging affects the cellular
composition of SVF in adipose tissue, leading to increased T cell and decreased
mesenchymal stem cell populations in older animals. Secondly, SVF can increase the
vascular area of the mesenteric microvasculature via in vitro co-culture as well as in vivo
when i.v. injected; in both conditions, SVF cells can engraft into these networks. Lastly,
there is an age-related impairment in revascularization following injury; i.v. SVF therapy
from young SVF donors improves angiogenic potential over non-cell-treated controls.
While SVF from aged donors showed a gain in percentage of vascularized area compared
to non-cell-treated controls, this was not significant. Contrasting our initial hypothesis,
SVF increases revascularization following injury, but this therapeutic potential is not lost
when T cells are removed from the fraction. In fact, there appears to be a T cell-mediated
impedance on in vitro angiogenesis in the non-injured windows, as the CD3- group
exhibited increased vascular area compared to the CD3+ group.
The overall goal of this study was to examine how composition in cell
populations of SVF is altered with age of donor, it’s impact on angiogenic potential in an
aged vasculature, and to determine whether T cells contribute to this regenerative effect
as part of a broader effort to elucidate which cell population is responsible for the
therapeutic gains seen in SVF treatment. The cell(s) of most interest in the field of
adipose-derived cellular-therapeutics remains a mystery, albeit this study provides
evidence against T-cell mediated recovery. Importantly, this study utilized the ex vivo
mesenteric window prep in a novel way to elucidate cell therapy testing in conjunction
with injury and advancing age to visualize changes in the microvasculature as a response
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over time. The applications of this model with differing cell populations and conditions
represents an avenue towards further narrowing of candidate cells and/or cellular
products responsible for vascular regenerative effect of SVF and other regenerative cell
populations.
A novel strategy that can holistically mend the pathologic microvessels themselves or
promote new growth, rather than merely treating the symptomatic consequence, is of
significant clinical interest which parallels the multi-faceted gains seen in cell-based
therapies [126]. Being easily isolated from lipo-aspirate, SVF therapy offers the ability to
leverage a real-time autologous point-of-care therapy with inherently minimal risk of
rejection, suggesting it is an ideal candidate in vascular therapeutics [177, 178, 305]. The
heterogenous cell population containing both immune cell and vascular cell components
is thought to be an optimal milieu of environmental cues to enhance vascular function
[186-188]. Adipose-derived SVF is comprised of an array of cell populations including a
small number of mesenchymal stem cells (MSC), endothelial cells, pericytes, and
hematopoietic cells such as macrophages and T cells [176, 306]. While a few studies
have examined how age of the SVF donor [154] or the culturing of SVF to confluency
[307] affected cell surface markers, these studies did not examine cell populations. We
show age-related changes to the cellular composition of SVF such as age-related
decreases in the mesenchymal stem cell and stromal cell populations with increases in
lymphocytes, M1 macrophages, and various T cells (Fig 4.2). Our results from young
SVF donors are congruent with current literature in total macrophage [308] and total T
cell percentages [309] with the current data showing the breakdown of the constituents
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(Fig 4.2). The-age related changes to cell populations within SVF are important to
consider for use as an autologous cell therapy or its application in an aged setting.
The ex vivo mesenteric window model was selected for its ease of access,
comprisal of an intricate microvascular network, and sustainability in culture. While the
mesenteric window model is not an established model for studying vascular diseases, it
has demonstrated age-related decreased angiogenesis [310] (Supp Fig 4.1) and
impairments in vascular function [311] indicating that this model can be beneficial to
studying an intact, aged, microvascular network. Previously, it has been shown that SVF
from young donors, when seeded and co-cultured with mesenteric windows from young
hosts, forms aggregates and demonstrates the beginnings of vasculogenesis within 36
hours of plating [191]. Furthermore, the SVF formed vessels indicating the presence of
endothelial cells and vascular pericytes and integrated into the mesenteric tissue in vitro
(Hodges et al. 2022, Microcirculation). The presence of young SVF on a young window
stimulated angiogenesis compared to a window without SVF (Hodges et al. 2022,
Microcirculation). Here we show co-culture with SVF from young and aged donors has
similar angiogenic potential resulting in comparable vascularized areas of aged
microvascular networks (Fig 4.3). This is in contrast to our previous study which
examined angiogenic potential of young vs. old SVF-laden collagen gels and reported
decreased vessel formation and host perfusion after subdermal implantation with those
containing aged SVF [154]. However, it is important to note that these age variable SVF
constructs were both implanted into young mice, emphasizing that the age of the
environment primarily determines angiogenic capability of SVF.
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With clinical applications of cell therapies typically involving systemic
administration, it is important to examine the biodistribution and engraftment potential of
the therapy. Our previous study showed that four weeks following a one-time i.v.
injection of 10 million young SVF cells into an aged rat resulted in the largest percentage
of SVF being retained in the aorta and carotid arteries (50% and 40 % respectively) [42].
However, the microcirculation was not examined for SVF retention nor was the
engrafting cell type. Scherberich et al. showed that SVF injected subcutaneously was able
to physically contribute to the vasculature as endothelial cells [312] and were further
supported by SVF-derived pericytes [313], but these experiments were not conducted in
an aging model. Here we show that i.v. injection of 10 million GFP+ SVF cells from
young and aged donors resulted in engraftment into the microvasculature within and
around vessels, and that T cells from the donor fraction can also be found in the
microvasculature (Fig 4.4). Understanding what cell types are retained in the host tissues
could aid in improving efficacy of administered cell therapies. Similar studies with
chronic cell therapies such as mesenchymal stem cells administered via i.v. injection
demonstrated that incorporation is as low as 10%, but this cell type was not shown to
aggregate and form new vessels [314, 315]. Future studies will be needed to quantify the
percentage of integration per host vessel, the percentages of integration of the various cell
types found in SVF, and what cytokines may be altered as a result of administering SVF.
In vitro studies have shown that SVF has an intrinsic angiogenic potential [191]
which when added to mesenteric windows increases the host vasculature (Hodges et al.
2022, Microcirculation) (Fig 4.3). While SVF therapy has been utilized in models of
ischemic injury and showed functional improvements, few studies integrate ischemic
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models with aged models [41]. Exteriorization of mesenteric windows has been shown to
be a stimulus for angiogenesis in young rats [299]. We showed that exteriorization injury
in aged rats produced little change in vascular area of the mesentery in aged control rats,
but i.v. administration of young SVF therapy markedly increased vascular area, while
aged SVF administration was non-significant (Fig 4.5). Aging has long been considered
an unmodifiable risk factor for the development of vascular pathologies [44, 45, 105]. In
the periphery, microvascular dysfunction can lead to organ perfusion/demand mismatch
and ultimately organ failure or loss of limb [50, 51]. Therefore, an autologous cell
therapy that could be administered to increase angiogenesis in an area following an
ischemic injury is of significance. Despite this, a better understanding of how cell
therapies achieve their gains either through paracrine release or cell engraftment and
which cell types are crucial to their function still needs to be explored further.
T cells have been implicated as crucial cells needed for tissue and vascular repair
following injury, as they activate other cells such as macrophages and fibroblasts,
stimulate apoptosis and clearance of dead cells, and are responsible for switching from a
pro-inflammatory state to a reparative state [316]. T cells have also been shown to
migrate to the injured area [290], secrete factors that enhance angiogenesis [289] and be
present at the angiogenic front following injury [291, 292]. In a knockout mouse model
depleted of regulatory T cells, there was a marked reduction in angiogenesis following
lung ischemia [317]. When we depleted aged SVF of the CD3+ T cells and administered
during exteriorization injury, we measured no difference between T-cell depleted and Tcell enriched SVF at increasing vascular area following injury (Fig 4.6). Interestingly, we
did see differences between the T-cell depleted and enriched groups in the non-injured
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windows with the SVF depleted of T cells having higher vascular area at days 3 and 5 of
culture post-injury compared to the enriched group (Fig 4.6). These data suggest that
while T cells may not be responsible for the increase in angiogenesis following injury, a
lack of T cells in SVF appears to be beneficial in a non-injury setting via increased
microvascular angiogenesis. This is especially applicable to aging populations whose
density of microvascular networks is decreased with age [318, 319]. Whether T-cell
depleted SVF might preserve organ function after an ischemic insult is an important
future direction. Of note, CD11b+ macrophages from young SVF donors administered
systemically can engraft into large conducting arteries, reduce the vasomotor tone, and
promote dilation following insult [200], albeit this was not in the microcirculation of an
aged model and revascularization following insult was not analyzed.
We hypothesized that T cells may mediate the regenerative effect of SVF. On the
contrary, our results show that vascular regeneration occurs steadily over 5 days with
SVF even when depleted of CD3 cells. In fact, CD3 depleted SVF outperformed CD3
enriched SVF for vascular recovery in non-injurious settings. It is possible that a
multitude of cells confer vascular regenerative properties to SVF (MSCs, fibroblasts,
pericytes, other immune cells, etc.), which would explain why vascular regeneration still
occurred in the CD3- SVF group during EI. Interestingly, with onset of injury, the ability
to achieve significant vascular regeneration is lost in the CD3- group but is preserved in
the CD3+ enriched group. This could signify that CD3+ T cells are a contributing
component of SVF-mediated vascular regenerative response to injury. Correspondingly,
potential angiogenic contributions of other SVF cells cannot preserve significant
angiogenic response after injury. Contrasting this notion, we found that aged SVF has a
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significantly greater proportion of T cells than young SVF, yet this increased T cell
population did not confer significant vascular regenerative ability to aged SVF donation.
Aged SVF yielded less stem cells, fibroblasts, and pericytes. Therefore, also examining
changes in these cell populations would be warranted. It is possible that synergy between
regenerative potential of multiple heterogenous cell types is required for optimal
angiogenic response to SVF. Further elucidating this complex symphony of cells within
SVF represents an important future direction. Additionally, future studies could employ
the methods detailed in this study to isolate other cell populations in SVF to assess their
contribution to SVF’s angiogenic potential by measuring vascular changes over time in
conjunction with cell tracking. Taken together this study presents novel insight into agerelated changes to cell populations isolated from the adipose-derived stromal fraction,
visualization of immune cells in SVF present in and around the microcirculation after i.v.
injection, effects of SVF therapy from young and aged donors on microvasculature after
ischemic injury, and evidence that the angiogenic effects of SVF cell therapy are not
wholly T-cell mediated.

Conclusion and Future Directions
The aging population are at greater risk of ischemic injury with less capacity for
vascular repair following injury. Therefore, the elderly stands to benefit greatly from cell
therapies as a remedy for vascular dysfunction. The field of cellular therapeutics is in its
relative infancy with current emphasis on optimization. In the context of this study, SVF
represents a heterologous cell population shown to increase angiogenic regeneration in
our novel aged mesenteric injury model. This study provides others with a new tool for
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tracking vascular recovery and can be used in conjunction with study of cell therapies or
pharmacologics in a setting of advanced age. Furthermore, we show how age of the donor
should be considered not only for cellular differences but functionality as a vascular
therapeutic. Age-related changes to cell dynamics and function in providing therapeutic
gains - i.e., secretion of anti-inflammatory cytokines, increasing sensitivity to VEGF,
increasing migration of injected cells, and endothelial cell division - are further avenues
to be explored in cellular therapeutics that could be done using the aged mesenteric
model.
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CHAPTER 5
DISCUSSION

The idea of stem cells was first proposed back in the 1860s by Dr. Ernest Heckle,
but stem cells did not enter into the realm of therapeutics until the 1950s [320]. Since
then, their use has soared with over 5,000 registered clinical trials today (based on a
search on clinicaltrials.gov in 2022). While almost every organ in the body contains a
type of stem cell, mesenchymal cell sources have proven to be a better cell therapy in
treating ischemic injury compared to hematopoietic stem cells, despite their longer
history [321]. Within their organ niche, mesenchymal stem cell sources provide
functional and structural support to the parenchymal cells of the organ by differentiating
into connective cell types such as endothelial cells, pericytes, fibroblasts, etc. Their
connective lineage also allows for harvesting from many regions throughout the body and
their sustainability in culture [322]. One source of mesenchymal cells that has eclipsed
the others is the stromal vascular fraction, found in adipose tissue - SVF. Recent studies
have shown that SVF has equal efficacy in improving cardiac function following MI,
reducing inflammation, differentiating into vascular elements, and promoting
angiogenesis compared to BM-MSCs [189-195]. Our results echo these findings in that
i.v. administration of BM-MSCs only partially rescued coronary flow reserve (CFR), left
ventricular (LV) diastolic dysfunction, and vasoreactivity to beta-adrenergic agonists in
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an aged rat model while SVF showed restorations in all of the metrics listed (Chapter 2).
SVF contains mesenchymal stem cells (MSCs), endothelial cells, pericytes, and
hematopoietic cells including macrophages, T-cells, and other cells of the perivascular
niche [176, 185] (Chapter 4). The ease of harvest, real-time use, and low
immunogenicity confer SVF either as an autologous or allogeneic cell therapy [159-162,
177, 178].
Therapeutic gains seen following SVF administration are thought to be due to
cellular engraftment and incorporation of the donor cells into the host tissues, however,
pre-clinical studies have shown that there is a markedly rapid decline in retained cells in
as little as 24 hours, 1 week, and 30 days after administration [323-327]. Further,
administration of exosomes harvested from mesenchymal cells can increase endothelial
cell density following a dermal wound and preserve cardiac function following an MI, all
of which support the current paracrine hypothesis of cell therapy mechanisms [261, 328].
However, long term studies have shown that SVF cell therapy can provide long term
sustained improvements as measured at a few months, 3-years, and even a 6-year follow
up even though cellular engraftment at the site of injury is low [329-332]. Intravenous
administration of cell therapies results in a wide biodistribution of cells being retained in
other non-target organs such as the spleen, where they were they may play a role in
modulation of the hosts’ immune cells [42, 329]. While the generally accepted paradigm
is that cell therapies work via paracrine secretion, long term improvements suggest that
engraftment of donor cells, while perhaps not in the organ of interest, cannot be wholly
discounted. Therefore, increasing the degree and/or duration of cell engraftment and thus
increasing exposure time to paracrine benefits would improve the efficacy of the cell
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therapy and would be a value to the cell therapies field [330]. However, to do this, greater
understanding of how cell therapy, specifically SVF, achieves its therapeutic gains is
needed.
The safety and efficacy of SVF as a therapeutic for osteoarthritis [181],
inflammatory bowel disease [180], idiopathic pulmonary fibrosis [182], chronic ischemic
cardiomyopathy [183], and coronary artery disease [332] have been vigorously
scrutinized. Ongoing studies exploring the long-term benefits and mechanism behind the
efficacy of SVF have yet to examine SVF’s therapeutic benefit or use as preventative
measure in the microvasculature highlighting future directions for investigation.
Clinical trials employing SVF therapy in combination with transplantation during
reconstruction, as well as preclinical trials showing SVF mitigating improvement in
wound healing following diabetic or ischemic injury emphasizes SVF as a therapeutic
approach to increase blood flow to a tissue via angiogenesis [333-335]. However,
preclinical trials do not often use models of advancing age, and while some clinical trials
do have populations of older patients, they are restricted in obtainable measurements such
as organ function at set time points which can overlook the mechanism behind the
improvement. The aged population is ever increasing and would benefit the most from
cell-based therapies. The Women’s Ischemia Syndrome Evaluation found that postmenopausal women are at greater risk for coronary microvascular dysfunction (CMD),
presenting with angina, compared to their male counter parts [47, 57, 114]. Impairment in
vascular dysfunction can begin developing as early as 40 years, with most clinical
manifestations apparent around 50 years of age followed by a steep decline in function
after menopause [47]. Previous studies have shown an age-related impairment in flow-
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mediated dilation (FMD), an endothelial-dependent mechanism, in brachial, [47, 336],
mesenteric [337], and coronary [260] arteries demonstrating that age-related vascular
impairment occurs in the resistance arterioles of the microcirculation. We utilized a
female rat model of advanced age, the Fisher 344 strain from the National Institute of
Aging colony. Aging coupled with the eventual loss of circulating estrogen in these rats
impair the coronary microvasculature in an endothelial-dependent fashion [260],
mimicking the clinical scenario. Utilizing this rodent model, we showed an age-related
decrease in CFR which is a functional and structural measure of the health of the
coronary vasculature and subsequent LV diastolic dysfunction (Chapter 2). Second, we
showed an age-related impairment in the vasodilatory capacity of coronary microvessels
to response to b-AR agonist, NE, due to a reduced b-AR population (Chapter 2 and 3).
Lastly, we found reduced capacity of the microvessels to undergo angiogenesis in
response to hypoxic injury with advanced age (Chapter 4). Since the small resistance
arterioles of the microvasculature govern the blood flow through an organ, impairment
and/or improper augmentation of blood flow to meet organ oxygen demand can result in
tissue ischemia which can progress to organ failure in a setting of advanced age with
further impairment of revascularization in an ischemic area [39, 45]. As previously
discussed, SVF could be a potential vascular therapeutic and be applicable to the aged
population working to increase function and growth of the vessels through its antiinflammatory, anti-oxidative, and angiogenic properties. However, the mechanism by
which SVF achieve these gains in an aged vascular bed is an area that still needs to be
explored.
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Our studies conducted in aged vascular beds in combination with SVF therapy
sought to explore several facets of its therapeutic paradigm. We administered SVF via the
tail vein, as an intravenous injection would be the most clinically applicable
administration route. Furthermore, we administered 10 million SVF cells systemically, as
clinical trials have shown 10-20 million cells was found to be the beneficial range while
preclinical trials have shown 3-250 million is beneficial with as little as 1 million exuding
a vasculogenic effect in culture [320, 338]. Because improper blood flow to meet/match
organ demand is most apparent in the coronary circulation, we used coronary
microvessels from aged rats with and without i.v. SVF therapy. With this methodology
we observed SVF rescuing CFR when stressed with a b-AR agonist, as well as improved
LV diastolic dysfunction. Upon isolating coronary microvessels, we showed SVF
increased vasodilatory sensitivity to a b-AR agonist compared to untreated age-matched
controls. Interestingly, we also showed that the coronary microcirculation is heavily
dependent upon b1-AR stimulated dilation, as inhibition of this receptor ablates
vasodilation to NE in all groups including young controls (Chapter 2). Upon further
exploration of how SVF improved b1-AR sensitivity, we probed coronary microvessels
from SVF and age-matched control rats to show that SVF therapy reversed the agerelated reduction in the b1-AR population back to young control levels. This therapeutic
gain was in part due to modest reduction in the negative regulatory inhibitors of the b-AR
signaling cascade, GRK2 and Gai (Chapter 3). Systemic inhibition of GRK2 with
paroxetine improved cardiac contractility and heart function in advanced age as well as
improved myocardial repair following MI [270, 271, 339]. However, GRK2 knock down
was shown to lead to hypertension and altered adrenergic signaling [340]. Inhibition of
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GRK2 in aged-isolated coronary microvessels significantly improved vascular dilation of
NE compared to an un-inhibited dose response in the same aged vessels. This effect also
occurred in aged rats treated with SVF therapy. When expression of active and
phosphorylated GRK2 were probed in myocardial samples, SVF improved the ratio of
phospho : active GRK2 to levels seen in young control hearts. Transcription of GRK2
was not altered with age, therefore this data suggests that SVF therapy modulated
GRK2’s activation status in coronary microvessels. GRK2 being the first step in b-AR
recycling, reduced activity of this kinase as a result of SVF therapy would increase b-AR
dilation sensitivity (Chapter 3). Gai is another b-AR regulator but is more commonly
associated with the b2-3-ARs. Overexpression of Gai in the myocardium leads to
decreased b2-AR sensitivity and heart function [279, 341]. We showed that advancing
age increases Gai myocardial expression. Furthermore, subtypes Gnao1 and Gnai2 were
significantly and markedly higher in aged coronary microvessels compared to young
control (Chapter 3) contrary to Shimokawa et als. findings [342]. While extended b2-AR
stimulation can lead to G-protein switching, stimulatory to inhibitory [343], the effect of
extended b1-AR stimulation and subsequent inhibition by Gai has not been explored in
the microcirculation.
Potential mechanisms that are supported by findings presented in this manuscript
and current literature in the field suggest that SVF-mediated gains are multifaceted and
would employ multiple mechanisms. One theory of aging is that reactive oxygen species
(ROS) increases as age advances, reducing protein function and impairing vasodilation in
resistance vessels [32]. Coronary microvessels from aged rats were shown to have
increased ROS which resulted in impaired b-AR mediated dilation and reduced the
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bioavailability of NO. In a youthful setting, plentiful NO levels naturally inhibit GRK2s
action to begin internalization of the b-AR. Incubating OC vessels with a NO donor,
sodium nitroprusside, returned vessel function to YC levels. Furthermore, inhibiting a
protein needed for internalization of the b-AR also improved vasodilation in OC vessels
(Appendix 3). With SVF therapy, although NO bioavailability is not restored, ROS
levels are reduced to alleviate β-AR thiol oxidation-mediated
desensitization/internalization and restored receptor recycling back to the plasma
membrane (Appendix 3). Secondly, while initially protective against failing cardiac
output, increased levels of systemic catecholamines can lead to decreased β-AR
sensitivity [94, 204, 205]. In measuring systemic plasma catecholamine levels, we
showed an age-related increase in NE with some reduction following SVF therapy
(Chapter 2). However, when measuring urine catecholamine levels, SVF did not reduce
the level of NE present (Chapter 3). This may be in part due to SVF having catabolic
action against catecholamines [344]. We measured a significant reduction in transcription
of catechol-o-methyltransferase and modest reduction in catecholamine degradation
enzyme monoamine oxidase A due to SVF therapy compared to aged-controls (Chapter
3). SVF therapy may contribute to the metabolism of catecholamines that begin the b-AR
desensitization [345]. Thirdly, microvessels isolated from animals with inflammatory
diseases such as irritable bowel and obesity exhibit impaired dilation to endotheliumdependent agonist acetylcholine compared to control animals [346, 347]. Chronic
inflammation impairing endothelial function has been linked to advancing age [348].
Aged patients that received an NF-kB inhibitor demonstrated improved brachial artery
FMD (+74%) compared to the age-matched placebo control group [348] and inhibition of
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TNFa improved FMD in aged female mesenteric arteries [337]. Both NF-kB and TNFa
are mediators of inflammation. Examining the transcriptome in young, aged, and SVF
treated coronary microvessels we showed an age-related increased in transcription of
inflammatory activators such as caspase 12, the IL-1 receptor kinase, and TNFa induced
protein. SVF therapy was shown to increase a NF-kB inhibitor to levels comparable to
YC (Chapter 3). The studies presented in this manuscript examine SVF’s therapeutic
mechanism to reverse age-related b1-AR desensitization and subsequent development of
LV diastolic dysfunction by decreasing the presence of negative regulators, GRK2 and
Gai, and alleviating ROS induced internalization, thereby promoting receptor recycling
back to the cell membrane and restoring the b1-AR population, improving sensitivity to
vasodilators (Chapter 2-3 and Appendix 3). While these findings represent a novel
therapeutic pathway to be targeted in patients advanced in age, it also presents a novel
mechanism by which SVF can be a promising microvascular therapeutic. However, it is
still unknown which cells constitute this improvement, what cell fractions such as RNA,
cytokines or exosomes may be released from SVF to drive these changes, and if this gain
is only in the existing vasculature or if SVF therapy promotes angiogenesis through
active integration and proliferation promoting increased tissue perfusion in an aged
vascular bed.
With aged patients being more susceptible to ischemic injury with reduced
revascularization following injury, we used a model of the mesentery to visualize
angiogenesis in the vasculature and SVF’s potential for integration into this vasculature.
Mesenteric windows are clear connective like tissues located along the length of the
small intestines which constitute a complete microcirculation and supporting divisions
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such as lymphatics and nerves that are capable of being taken out for culture over 7 days
[349]. While the ex vivo mesenteric window model is not an established model for
studying microvascular disease, it has demonstrated age-related decreased angiogenesis
[310] (Chapter 4) and age-related impairments in vascular function [311], mimicking the
clinical scenario. Additionally, this model is beneficial to studying an intact
microvascular network in combination with SVF therapy and it’s been shown that brief
exteriorization of a section of mesentery results in a hypoxic-like injury that can stimulate
angiogenesis in young rats [293]. We utilized the ex vivo mesenteric window model in
combination with SVF co-culture to examine the spatial-temporal interactions of SVF
with an aged microvascular network. When SVF from young donors is seeded onto and
co-cultured with a mesenteric window, SVF can form central hubs with endothelial cell
markers and active branching by day 3 (Appendix 4) [298]. The presence of SVF on the
window can increase the total vascularized area compared to an untreated control and
form connections with the host microvasculature (Appendix 4). Pivoting to a more
clinically relevant delivery, we showed that i.v. administration of SVF can disseminate
and engraft into the mesenteric microvasculature 3 days after injection (Chapter 4).
SVF’s inherent ability to form microvascular constructs was utilized in a left anterior
artery ligation MI model where SVF - Matrigel constructs were sutured and implanted
over the ischemic area, leading to improved scar healing, vascularization, and perfusion
of the SVF construct [41, 350]. While these studies show the angiogenic potential of SVF
in a young model and even following injury, we wanted to examine the impact of age and
injury in the mesenteric microvasculature.

151

Inducing a hypoxic-like exteriorization injury in aged rats resulted in an
angiogenic impairment which was not present in non-injured aged control windows.
Intravenous SVF therapy reversed this angiogenic impairment, significantly increasing
vascular area following injury (Chapter 4). Unlike pharmaceuticals typically affecting
only one therapeutic target; cell therapies can exert an influence on the multifaceted
pathology seen in aging and vascular dysfunction. The caveat being autologous cell
sources may not be more advantageous therapy due to their “aged nature”. When SVF
from young or aged donors was integrated into a Matrigel construct placed over the
infarcted area of a young heart, the aged SVF construct had lower microvascular
formation and less perfusion compared to the young SVF [154]. SVF taken from aged
human donors has a reduced capacity to restore cutaneous blood flow in a mouse
hindlimb ischemia model, reduced capacity for endothelial cell differentiation, and
reduced secretion of pro-angiogenic factors. The age-related angiogenic discrepancy
could be mitigated with pre-conditioning in hypoxic conditions [351]. We sought to
examine the effect of the donor’s age on SVF angiogenic potential in the mesentery and
in combination with injury compared to age-matched no cell controls. We showed that
when young SVF is co-cultured with a mesenteric window harvested from a young rat, it
resulted in the highest vascularized area compared to other young/aged combinations of
SVF donor and tissue. Interestingly, SVF from a young donor and an aged SVF donor
resulted in comparable vascularized areas of aged tissues following co-culture. This
highlights the equal efficacy in SVF either as an allogeneic or autologous vascular
therapy. In response to injury, i.v. injected SVF from young donors did significantly
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increase vascularized area of aged tissues while aged SVF only had a modest
improvement compared to the non-treated group (Chapter 4).
During the course of these studies, we also examined the impact that
freezing/thawing has on SVF’s angiogenic potential. Freshly isolated SVF fractions were
utilized in the vascular function experiments showing improvements in coronary flow
(Chapter 2-3) and the co-culture experiments showing improvements in vascular area in
aged tissues (Chapter 4 and Appendix 4) [298]. When SVF is cultured to confluency
(P0) then added to a construct that was implanted subdermally, the cultured SVF, while
not cultured to senescence, showed a reduced capacity to be perfused by the host [307].
Although in the last decade there have been developments in medical equipment to take
freshly isolated lipo-aspirate and automate the SVF isolation process so that it can be
done within the operating suite for immediate use or to be frozen and stored for later use
or as a potential allogeneic use [176]. A comparison between freshly isolated and frozen
SVF in bone healing revealed that both therapies promoted bone healing through
angiogenesis and osteogenesis with no difference between the groups [352]. Our results
showed similar findings in that fresh and frozen SVF, from either young or aged donors,
can increase angiogenesis in co-culture or following i.v. injection, but SVF from young
donor’s fares better compared to the aged SVF in increasing vascularized area following
injury (Chapter 4 and Appendix 4).
Exploring why SVF’s angiogenic potential may be lower when harvested from
aged patients, we examined the cell populations within SVF and their characteristics.
Using flow cytometry with multiple staining and gating steps, we have identified 18
populations of cells in SVF and measured their percentage within the fraction. Most
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notably, lymphocytes, M1 macrophages, CD3+ T cells, helper, activated, and memory T
cells are all found in higher concentrations in aged SVF compared to young. However, in
aged SVF there are fewer hematopoietic progenitor cells, mesenchymal stem cells, and
total, immature, and transitional macrophages (Chapter 4). Our findings are consistent
with the field where one study measured transcriptomic changes in SVF taken from preand post- menopausal patients; differences were found in the fertility-, sex hormone-,
immune-, aging-, and angiogenesis-related terms and pathways. Additionally, SVF from
post-menopausal donors could induce M1 polarization of macrophages, while their premenopausal counterparts facilitate T cell proliferation [353], although we found both of
these cell populations to be higher in our aged female rat model. A potential rationale for
SVF’s age-related impairment in angiogenesis is that it contains fewer mesenchymal
stem cells (Chapter 4). Furthermore, MSCs taken from aged patients were significantly
compromised in their ability to support vascular network formation in vitro, with
impaired migration and an inability to rescue age-associated impairments in cutaneous
wound healing in vivo [354, 355]. Regardless of processing and administration, SVF’s
mechanism to promote angiogenesis in the mesentery, and following injury, needed to be
explored.
Intravenous administration of a cell therapy can lead to a wide distribution
throughout all the body’s systems. It has been shown that an i.v. injection of 6 million
SVF cells results in a majority being retained in the carotid, aorta, lungs, and spleen 4weeks after injection [42]. We confirmed that i.v. injection of SVF can also result in
retention of these cells in the mesenteric microvasculature, resulting in cells within and
around microvessels (Chapter 4). Mounting evidence suggests that despite a wide
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biodistribution from intravenous cell injection, there is a beneficial effect on organs with
low engraftment, possibly due to cell therapy regulating the host’s immune cells via
homing in lymphoid organs such as the spleen; this observation needs to be explored
further [356-358]. Following injury, immune cells migrate out from lymphoid organs and
travel to the site of repair. When injury occurs in an aged patient, there is less infiltration
of the immune cells compared to young leading to diminutive repair [359]. In 2007 it was
reported that the i.v. administered MSCs homed to the infarcted region of the
myocardium [360]. Six days after exteriorization injury and SVF injection in our
mesenteric windows, we examined windows for GFP+ SVF engraftment and showed that
injury significantly increases homing of aged SVF in an injured aged window compared
to a non-injured control and an aged window treated with young SVF (Chapter 4). This
evidence suggests that the increased angiogenesis seen following SVF therapy may be
due to different effects depending on age of SVF donor, which cells are contributing to
this effect needs to be explored.
Age-related endothelial dysfunction can impair microvascular functionality as
well as angiogenesis. SVF contains a large population of endothelial cells which can
physically contribute to a host’s subdermal vasculature [312]. Although, injecting only
endothelial cells is not a sufficient therapy in improving poor age-related microvascular
perfusion, as we have previously shown [42]. Despite SVF’s promising potential to form
its own microvascular networks or contribute as endothelial cells, unprotected capillaries
are subject to rarefaction (pruning) if not surrounded by pericytes. SVF is an abundant
source of pericytes. When SVF is co-cultured with mesenteric window, SVF can form
vascular hubs expressing endothelial cell pericytes markers (Appendix 4). Additionally,
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MSCs within the SVF are capable of differentiating into pericytes, and SVF-derived
pericytes have been found around mature vessels [313, 314, 361]. While important in
protecting the endothelium, their use as a homogenous cell therapy is unknown. Although
age decreases the macrophage population found in SVF, macrophages are the major
contributors to the secretome [362] and host macrophages have been shown to be heavily
involved in vascular formation in an ischemic tissue [363]. In a model of hindlimb
ischemia, depletion of macrophages from SVF resulted in little change to
revascularization but depletion of host macrophages resulted in impaired
revascularization of the limb [364]. Contrary to this, administration of CD11b+
macrophages isolated from SVF improved vasomotor tone in a mouse model of hind limb
ischemia [200]. The two distinct subpopulations of macrophages present in SVF, M1 and
M2, can drive T cell function to either a pro-inflammatory state or a pro-regenerative
state, respectively [365]. The polarization of macrophages and subsequent T cell
implication has been shown to occur in aged tissues with macrophages being
predominantly M1 (Chapter 4) leading to an inflammatory environment [366]. However,
SVF therapy has been shown to promote tissue regeneration via M2 polarization of the
macrophages [367, 368]. T cells are a critical part of the immune system, bridging the
adaptive and innate divisions [369], activated via macrophages through the CD40
ligand/receptor axis [370], and have been shown to be crucial for the success/survival of
a bone marrow graft. Furthermore, T cells also play a role in stimulating angiogenesis in
ischemic areas [289] due to migration to the area of injury [290, 291] and
collateralization specifically by homing to sites of active angiogenesis [292]. Upon
probing for T cells in 6-day post injured mesenteric windows after SVF therapy, we
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found that the injured group treated with aged SVF had a significantly higher number of
donor GFP+ T cells (Chapter 4) consistent with others findings that T cell populations
do increase around post-infarct days 6-7 [371] concurrently when we measured an
increase in angiogenesis (Chapter 4). When T cells are depleted from SVF and
intravenously injected following injury, the T cell depletion does not affect SVF’s
revascularization potential. Interestingly, the depletion of T cells from the fraction
significantly increases the vascularized area in non-injured windows compared to
treatment with only T cells. Taken together this data suggests that SVF’s angiogenic
potential does not solely lie in one cell type, despite being a large portion, and rather
modification of SVF may be necessary in regard to when treatment is occurring. Our data
suggests that SVF with the T cells removed T cell depleted SVF could be utilized as a
preventative therapy to increase angiogenesis in a tissue prior to an ischemic event.
Whereas utilizing only the T cells from SVF or even unmodified SVF would be more
beneficial therapeutic following injury (Chapter 4). Nonetheless, many researchers still
examine the mesenchymal stem cell contribution to angiogenic repair despite the low
numbers found in SVF. While MSCs can differentiate into endothelial, pericytes,
fibroblasts and other supporting cells of the stromal fraction [372, 373], they only
comprise 5-10% of the SVF population; the percentage of MSCs is even lower when
harvested from an aged patient (Chapter 4). Each cell type described above has been
shown to have a promising therapeutic potential in one niche, but the amalgamation of all
of these cell types within SVF lend to a superior therapeutic potential. A heterogeneous
cell population may be more beneficial than the homogenous cell preparations, providing
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the unknown optimal milieu of environmental cues, in which the environmental cues
have yet to be examined [186, 374].
During embryogenesis, vascular endothelial growth factor (VEGF) is the
predominant factor in the regulation of new blood vessel formation, stimulating new
blood vessels to sprout from existing vasculature via angiogenesis. Hypoxic regions of a
given tissue generate VEGF gradients to stimulate the differentiation of an endothelial
cell into a tip cell which forms a stalk, ultimately leading to the generation of a capillary
[34]. Together, the process of angiogenesis (growth of new vessels from existing ones)
and vasculogenesis (single cells coming together to form a vessel) lead to a mature,
perfused microvessel network. When exogenous VEGF is added onto mesenteric
windows it stimulates angiogenesis in culture [301]. In a collagen matrix interface, SVF
was placed in the core and microvascular migration, crosslinking, and density was
examined in response to exogenous VEGF-A in the culture media. Exogenous VEGF-A
promoted angiogenesis, increasing vascular density, but not neovessel guidance out from
the core. Interestingly, when microvascular fragments were within the collagen core and
SVF in the surrounding outer field, microvessels formed towards the SVF compared to
when both the microvessels and SVF were located within the core. This data suggests a
diffusion gradience cue exists due to SVF in directing microvascular growth [304]. A
study utilizing several genetic and pharmacologic gain and loss of function models
demonstrated that VEGF-A distribution in the extra cellular space guides tip cell
migration (VEGF gradient) and cell proliferation (VEGF concentration) [375]. SVF cells
appear to secrete VEGF in optimal spatiotemporal gradients to promote angiogenesis in
microvessels.
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Advancing age has been shown to reduce the circulating levels of VEGF [75].
Furthermore, advancing age reduces VEGF expression and reduces its dilation potential
in the coronary microcirculation [288]. SVF has been shown to secrete growth factors
such as VEGF and TGFb in vitro [197]. In our aged-injury model, we measured various
levels of cytokines in the media on day 3 of culture, 6 days post-injury. There were few
changes in the levels of inflammatory markers between any of the groups. Interestingly,
non-SVF-treated non-injured aged windows had comparable levels of VEGF to young
SVF-injured windows which showed a significant increase in vascularized area at this
time point. The non-treated non-injured aged windows had significantly higher levels of
VEGF compared to the aged SVF non-injured windows (Chapter 4). Another group
measured serum levels of VEGF in aged control, young control, aged treated with young
SVF, and young to young. The aged group had higher levels of serum VEGF compared
to the other groups [376]. Application of SVF following endometrial injury was
associated with a 29% reduction in endometrial vascular endothelial growth factor
(VEGF) expression 4-weeks after administration [377]. Our results fall between those of
the two studies presented. We propose that young SVF, with greater angiogenic potential,
improves endothelial sensitivity to VEGF while aged SVF increases angiogenesis
through engraftment of immunomodulatory cells such as T cells following injury. To
further support this, an in vitro study using HUVEC cells showed that mitochondrial
ROS, hydrogen peroxide, increases in the presence of VEGF [378]. Studies from our lab
showed that advancing age increases levels of hydrogen peroxide within coronary
microvessels but FMD is impaired. Four weeks following an i.v. administration of young
SVF, FMD was restored by switching the acute signaling mediator from hydrogen
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peroxide to peroxynitrite, a molecule similar to the nitric oxide used in young vessels
(Appendix 3). Overexpression of a mitochondrial enzyme catalases which converts ROS
to hydrogen peroxide inhibits the effects of VEGF [378]. SVF therapy was shown to
relatively decrease catalase levels compared to aged controls despite higher gene
expression compared to young controls, this would shunt more ROS to become the
peroxynitrite rather than hydrogen peroxide (Appendix 3). Although SVF from young
donors reduces hydrogen peroxide in coronary vessels, we measured moderately high
levels of VEGF being produced in response to injury and increase angiogenesis,
suggesting SVF may increase vascular sensitivity to VEGF albeit through angiogenic or
vasoreactivity mechanisms needs to be explored (Chapter 4). Further changes in how the
secretome and transcriptome are altered in an aged vascular bed and following SVF
therapy are future directions.
In summary, advancing age is an unmodifiable risk factor for the development of
vascular pathologies developing in a complex and multifactorial manor [44, 45]. The
findings presented in this study demonstrated that age decreases coronary perfusion and
correlates with left ventricular diastolic dysfunction. Second, we showed that coronary
microvessels are dependent upon the b1-AR to produce an adequate vasodilatory
response but as chronological age advances the sensitivity of this receptor decreases
(Chapter 2). A decrease in the b1-AR was due to a decline in the receptor population
with age. Further exploration into why the b1-AR levels on coronary microvessels was
decreased with age is due to increased activity of the negative regulator GRK2, which
initiates receptor internalization following substrate binding, (Chapter 3) and increased
ROS which correlated with impaired b-AR dilation (Appendix 3). In young control
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animals, GRK2 can be both phosphorylated and nitrosolated, both contributing to natural
inhibition of GRK2 [379]. With age and a decline in nitric oxide bioavailability, GRK2
becomes more active (Chapter 3 and Appendix 3). A decline in nitric oxide with age
only adds to a decreased vascular dilative function (Appendix 3), and this effectively
puts aged patients at increased risk for an ischemic injury. Third, we showed advancing
age decreases the angiogenic potential to revascularize following an ischemic injury. SVF
has been an emerging therapeutic due to its ease of access, autologous and allogeneic
potential, angiogenic, immune modulatory, and anti-oxidative properties. A caveat being
we have shown that age can alter the cellular composition of SVF, lending more to a proinflammatory cellular phenotype. While aged SVF can increase angiogenesis following
ischemic injury, it does not significantly perform better like SVF from young donors
(Chapter 4). SVF from young donors was shown to improve all of the age-related
alterations previously described above. Briefly, SVF therapy improved coronary
perfusion and LV diastolic function, b1-AR sensitivity via restoring receptor population,
modulating dilatory inhibitors, receptor recycling, and also by increasing angiogenesis in
hypoxic areas of an aged vascular bed via engraftment and possible improvement in
sensitivity to VEGF (Chapter 2-4 and Appendices 1-2). Taken together this data
provides substantial support for SVF’s use as a therapeutic for the aged patient
population whilst exploring mechanisms behind the therapeutic benefit.
Further age-related alterations driving the decline in vascular health with
advancing age need to be explored. Current therapeutics aimed at preserving heart
functionality e.g., paroxetine or beta-blockers do not consider the impact on the
microvasculature often reliant on similar signaling cascades. Therapeutic targets
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following an injury, e.g., non-steroidal anti-inflammatories, do not consider that a spike
in inflammation is crucial for temporal control of healing and revascularization. The
impact of how age affects cells involved in vascular function and healing following
injury are future directions in the field of gerontology and biomedical sciences [35]. More
studies utilizing SVF and examining its constituent’s contribution to its therapeutic
potential will only advance SVF’s application in more disease states beyond advanced
age.
Specifically, if I could continue within this field of research I would further
examine SVF’s impact on catecholamine metabolism in improving dilation in the
resistance vessels [345]. The anti-oxidative properties of SVF warrant much further
investigation as it ties into dilation, angiogenesis, immune, and cell survival pathways.
The vascular hierarchy expresses many other receptors contributing to vasodilation and
constriction, being stimulated by other bioactive molecules. Some examples of receptors
to examine the impact of age, SVF therapy, and contribution to dilation are prostaglandin,
estrogen, and bradykinin receptors. If drugs such as BEZ235 or okadaic acid are used
systemically to inhibit b1-AR internalization and increase vasodilation; then the impact
on the b-AR populations in the heart and increase in inotropy needs to be considered
[121]. Interestingly we showed that SVF increased translation of the adenylyl isoform 6
in the coronary microvessels, albeit they were not completely free of myocytes. Isoform 6
is cardioprotective and has a role in the PKA/STAT3 pathway [285, 286]. During
myocardial ischemia, an increase in IL-6 activates STAT3 which has a protective role in
infarct size [380] and regulates transcription of VEGF [381]. Aberrant activation of
STAT3, such as in a chronic inflammatory state like advanced age, contributed to the
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development of atherosclerosis [382]. I believe the AC6/IL6 to STAT3 pathways in the
myocardium and microvasculature needs further research as potential pathways SVF
further provides therapeutic gains. I would also like to examine the potential of the Gai
subunit, normally associated with the b2-3-ARs, to cross-inhibit the Gs unit of the b1-AR
after prolonged stimulation, like seen with the age-related increase in catecholamines.
Lastly, I would continue utilization of the ex vivo mesenteric window model to assess
what cell types in SVF persist infiltrate during the remolding process; what changes to
the secretome correlate to this? How does remodeling of the vasculature look different to
that of young animals?
SVF’s contribution to angiogenesis and active vascular remodeling have
unanswered questions. For example, of SVF’s many cell types, which are the most
beneficial? Can SVF therapy be altered, say from an aged patient, to be a better
therapeutic i.e., pre-conditioning with growth factors or increasing one cellular
component over another? The area of SVF research with the least knowledge is how
advanced age of the donor modifies its therapeutic mechanism; the difference in
cytokines being released, the functionality of the cells being administered, and its overall
potential to be an effective therapeutic. How long can the therapeutic benefit of either an
autologous or allogeneic therapy last as it is being introduced into a potential “hostile”
aged environment? It would be pertinent if trials utilizing SVF as a therapeutic, when
measuring organ function, also examined vascular functionality and density, as the health
of the vasculature would only support the health of the organ. The data presented within
this study add to the discussion of how SVF can be used as a vascular therapeutic,
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potential mechanisms, reason for inclusion of aged subjects, and introduction to models
that can be employed for further investigation to SVF’s therapeutic gains.
The future of the cell therapies field is exploring these questions and more to
bring cell therapies, specifically SVF, to the front as a valuable vascular therapeutic to a
population that currently has little clinical remedies. Trending topics in the cell therapies
field, beyond the vasculature, include CRISPER Cas 9 modification of human leukocyte
antigens for reduced rejection, cellular reprograming to a more pluripotent state, 3-D bioconstructs with stem cells to bridge ischemic regions, further investigation into dosing
strategies, and organ regeneration from tissue scaffolds [320]. The pace the scientific
field is moving is an exceptional rate, only hindered by innovation, need, and technology.
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APPENDIX 1
LIST OF ABBREVIATIONS

a1-AR
a2-AR
β1-AR
β2-AR
β3-AR
5-HIAA
5HT
AC
AR
BF
BM-MSC
BW
cAMP
CFR
CMD
CO
CPG
CVD
DA
Dmax
Dob
EF
EI
Epi
FS
Gai
GFP+
GRK
Gs
GSL-1
HF
i.v.
ICI
IVC
IVRT

alpha-1 adrenergic receptor
alpha-2 adrenergic receptor
beta-1 adrenergic receptor
beta-2 adrenergic receptor
beta-3 adrenergic receptor
metabolite of serotonin
serotonin
adenylyl cyclase
adrenergic receptor
blood flow
bone-marrow mesenchymal stem cells
body weight
cyclic adenosine monophosphate
coronary flow reserve
coronary microvascular disease
cardiac output
CPG20712A
cardiovascular disease
dopamine
maximum diameter
dobutamine
ejection fraction
exteriorization-induced hypoxic-like injury
epinephrine
fractional shortening
inhibitory G-protein
green fluorescent protein
G-protein receptor kinase
stimulatory G-protein
griffonia (bandeiraea) simplicifolia lectin 1
heart failure
intravenous
ICI118551
inferior vena cava
isovolumic relaxation time
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LAD
LV
LVDP
LVDs/d
LVVs/d
MFI
MI
MSC
NaF
NE
NEI
NO
P-GRK2
Parox
PRSW
PSS
PV
RNS
ROI
ROS
RT
SNO
SNP
SV
SVF
VSMC

left anterior descending
left ventricle
left ventricular diastolic pressure
left ventricular dimensions systolic or diast
left ventricular volume systolic or diastolic
mean fluorescence intensity
myocardial infraction
mesenchymal stem cell
sodium fluoride
norepinephrine
non-exteriorized control
nitric oxide
phosphorylated G-protein receptor kinase 2 (inhibited)
paroxetine HCl
preload recruitable stroke work
physiological salt solution
pressure-volume
reactive nitrogen species
region of interest
reactive oxygen species
room temperature
S-nitrosolation
sodium nitroprusside
stroke volume
adipose-derived stromal vascular fraction
vascular smooth muscle
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APPENDIX 2
LIST OF GROUPS

NCC

no cell control

O+BM

old i.v. injected with 5 mil GFP+ bone-marrow mesenchymal stem
cells

O+OSVF

old i.v. injected with 10 mil GFP+ adipose-derived stromal vascular
fraction from old donors

O+OSVF CD3-

old i.v. injected with 1.1 mil GFP+ adipose-derived stromal vascular
fraction from old donors depleted of CD3+ T cells

O+OSVF CD3+ old i.v. injected with 1.1 mil GFP+ adipose-derived stromal vascular
fraction from old donors consisting of only CD3+ T cells
O+SVF

old i.v. injected with 10 mil GFP+ adipose-derived stromal vascular
fraction

O+YSVF

old i.v. injected with 10 mil GFP+ adipose-derived stromal vascular
fraction from young donors

OC

old control

YC

young control
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APPENDIX 3
STROMAL VASCULAR FRACTION RESTORES VASODILATORY FUNCTION BY
REDUCING OXIDATIVE STRESS IN AGING-INDUCED CORONARY
MICROVASCULAR DISEASE

Overview
The objective is to identify mechanisms for stromal vascular fraction’s (SVF)
previously reported restorative effects on vasodilative function in aging-induced coronary
microvascular disease (CMD). We hypothesize that aging-induced reactive oxygen
species (ROS) diminishes flow-mediated dilation (FMD) and β1-adrenergic receptor (β1AR) dilation in coronary arterioles of aged female rats, reversible by SVF-mediated
reduction in oxidative stress. SVF attenuates aging-induced chronic accumulation of ROS
and prooxidant gene and protein expression with concomitant enhancement of
antioxidant gene and protein expression and glutathione, but not nitric oxide. FMD and
β1-AR-mediated dilation were diminished in aging, restored with SVF. FMD was
restored by a switch in the acute signaling mediator from hydrogen peroxide in aging to
peroxynitrite with SVF therapy. Vasorelaxation to β1-AR-agonism was mechanistically
linked to ROS and nitric oxide levels in an age-dependent manner via their effects on
desensitization and internalization. Exogenous ROS eliminates isoproterenol-mediated
dilation that is blocked by inhibition of pro-desensitization and internalization proteins
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GRK2 and dynamin (via paroxetine and dynasore). Exogenous nitrosylation,
paroxetine, and dynasore restore β1-AR-mediated dilation in aged vessels. We introduce
a novel mechanism by which ROS impacts β1-AR receptor trafficking; the ROS/RNSβ1-AR Desensitization and Internalization Axis (Fig A3.1). Aging induces oxidative
stress that shunts β1-AR trafficking from the plasma membrane into endosomes. SVF
reduces oxidative burden in this axis, restoring functional β1-AR. SVF reduces oxidative
stress and restores flow- and β1-AR-mediated vasodilation with aging. SVF represents a
promising alternative therapeutic strategy for CMD by addressing root cause of
pathology i.e., oxidative stress-mediated hyperconstriction.

This chapter is from the published work referenced as follows:
Tracy, E.P., M. Dukes, G. Rowe, J.E. Beare, A.J. LeBlanc, Stromal Vascular fraction
Restores Vasodilatory Function by Reducing Oxidative Stress in Aging-Induced
Coroanry Microvascular Disease. Antioxid Redox Signal, 2022. in revsion
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Introduction
Coronary microvascular disease (CMD) presents in a majority of postmenopausal, aging women with chronic angina due to microvascular hyperconstriction,
as opposed to atherosclerotic blockage seen typically in men [56]. Clinically, CMD is
defined as a coronary flow reserve (CFR) ≤ 2.5, endothelial dysfunction with constriction
to acetylcholine, and <20% coronary dilation to nitroglycerin [56]. Coronary perfusion is
compromised by ~43% in advanced age with a negative correlation between advancing
age and myocardial flow reserve, exacerbating CMD severity [52, 53]. Current treatments
are known to be minimally effective. Beta blockers may be utilized to preserve oxygen
consumption by reducing the workload of the myocardium but may inhibit vascular
dilative beta-adrenergic receptor (β-AR) function [128]. Conversely, beta agonists would
lead to habituation over time and would increase inotropic myocardial workload [128].
Although nitrates may provide acute relief of symptoms, there is little evidence of
reduced major adverse cardiac events (MACE) or mortality [129, 130]. Further, nitrates
cause rebound angina and increase oxidative stress, and are difficult to manage.
A novel strategy that can holistically treat each facet of CMD pathophysiology by
mending the pathologic microvessels themselves, rather than merely treating their
symptomatic consequences, is of significant clinical interest. Adipose-derived stromal
vascular fraction (SVF) represents a heterogenous population of cells with regenerative
potential, including mesenchymal and hematopoietic stem cells, microvascular
endothelial cells, pericytes, fibroblasts, B and T cells, natural killer cells, dendritic cells,
and macrophages [39]. We have previously shown that injected SVF incorporates into
carotid arteries and aorta, and to a lesser extent the myocardium, lung, and brain [39, 42].
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SVF therapy reverses aging-mediated reduction in CFR and perfusion (a clinical
determinant of CMD), improves maximal cardiac output one-week post-injection, and
reverses markers of diastolic dysfunction typical of aging [39, 42]. One possible
mechanism for the regenerative effects of SVF could be due to antioxidant effects [383,
384].
A cornerstone aspect of vascular aging is increased oxidative stress [50]. We
recently reviewed how aging-associated oxidative stress impacts mitochondrial
dynamics, FMD and β-AR function [121]. There is a known correlation between agingassociated oxidative stress and decline in functional vasodilation [50, 205, 385, 386],
although uncertainty remains as to whether this relationship is purely correlational or if
there is a causal link. If there is causality, then targeting oxidative stress in age-related
CMD may provide new therapeutic avenues to restore vascular function. In this study, we
examine the interplays of oxidative stress in aging and two mechanisms for maintenance
of microvascular patency: flow- and β-adrenergic-mediated dilation.
Increasing intraluminal flow causes shear stress that in youth activates endothelial
nitric oxide synthase (eNOS) to produce nitric oxide, leading to vasorelaxation [33].
During aging, this instead leads to production of hydrogen peroxide resulting in
hyperpolarization-mediated vasorelaxation [387]. Overall, it is thought that the
hyperpolarization-mediated pathways in aging are less efficient than nitric oxidemediated during youth. Indeed, reductions in FMD are correlated with advancing age,
which starts earlier in men but becomes more severe (steeper correlation) in
postmenopausal women [47]. Therefore, therapeutically restoring nitric oxide
bioavailability in aging vessels may restore effective FMD signaling.
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We previously showed decreased vasodilative β1-AR protein in aged coronary
microvessels, but not β2-3 AR or constrictive alpha 1-2 adrenergic receptor (α1-2 AR)
[39, 40]. Furthermore, β1-AR is rescued to young control levels by the SVF therapy in
aging female rats [40]. Aging leads to an overload of catecholamines, with compensatory
receptor degradation. Upon catecholamine-receptor binding, G-protein receptor kinase 2
(GRK2) causes desensitization by phosphorylation of β-AR, reducing dilation efficacy.
Beta-arrestin associates with the phosphorylated receptor, which initiates dynaminmediated internalization of the β-AR into endosomes for storage, eventual degradation, or
recycling back at the membrane. The protein expression of GRK2 and beta-arrestin are
known to increase in aging Fischer 344 rat aortas [266, 388], and we have recently shown
an age-related increase in myocardial and coronary microvascular protein expression of
GRK2 [40]. Intravenous SVF was not able to fully reverse this age-related discrepancy,
although it partially increased naturally inhibited GRK2 (phospho-GRK2) [40]. Since
SVF did not reduce expression of pro-desensitization and internalization proteins, yet
restored dilative βADR function, perhaps regulation of these proteins is altered with SVF
therapy.
Post-translational modification may also be in play, as S-nitrosylation sterically
inhibits GRK2 to block desensitization [20]. It is thought that thiol oxidation by ROS of
the βADR facilitates desensitization and/or internalization [389-391]. ROS activates
phosphatidylinositol 3-kinase gamma (PI3kγ) signaling, causing inhibition of protein
phosphatase 2A (PP2A)-mediated recycling of the β-AR back to the plasma membrane
[20]. Therefore, it may be possible to influence β-AR function by therapeutically
modulating oxidative stress and nitrosative potential. Frame et al. found that nitrosative
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exposure with sodium nitroprusside (SNP) can “uncover” β2-AR pools that increase
isoproterenol potency (albeit with reduced efficacy) through GRK2
nitrosylation/inhibition, leaving functional β2-AR at the plasma membrane [392].
Mitochondrial antioxidant therapy with mitoQ can improve endothelium-dependent
dilation and FMD [393, 394]. The role of mitochondrial redox dysfunction in aging
coronary microvascular β-AR- and FMD with therapeutic potential of antioxidative
strategies has yet to be elucidated.
We hypothesized that flow- and β1 adrenergic-mediated dilation are reduced with
aging, reversed by SVF therapy by attenuating oxidative stress and restoring protective
nitrosative signaling. Specifically, we predicted FMD will be restored in aging with SVF
via restored nitric oxide production (as well as reduced ROS that siphons nitric oxide).
Reduced ROS and enhanced nitrosative signaling will alleviate β1-AR desensitization
and internalization of the receptor according to our conceptually novel ROS/RNS β1-AR
Desensitization & Internalization Axis (Fig A3.1 Graphic Summary). The ability to
therapeutically modulate vasodilative mechanisms through manipulating redox dynamics
as shown in this study will provide exciting new avenues for addressing management of
diseases such as CMD.

Materials and Methods
Animal model, groups, and endpoint procedures.
Surgeries for all animals were carried out in accordance with approved protocols
from the University of Louisville Institutional Animal Care and Use Committee and the
NIH Guide for the Care and Use of Laboratory Animals [395]. Female Fisher 344 young
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control (YC, 3–6-month-old, Harlan Laboratories, Indianapolis, IN, USA) and aged (2324-month-old, National Institute on Aging, Bethesda, MA, USA) rats were housed in
pairs and allowed free access to food and water. Rats were accustomed to a regular 12hour light/dark cycle and acclimated to facility environment for at least one week prior to
endpoint procedures. Aged rats were randomly divided into two groups, old control (OC,
24 months) or old treated with SVF (OSVF). SVF was injected at 23 months of age, with
sacrifice at 24 months of age. Euthanasia was achieved by removal of the heart under
deep anesthesia (lack of tactile toe reflex and lower respiratory rate) consisting of 5%
inhaled isoflurane with 1.5-2.0 L/min O2 flow in an induction chamber.
SVF isolation and injection.
Young (3-6 mo) rats from a green fluorescent positive (GFP+) Fischer-344 colony
(original breeders obtained from University of Missouri RRRC, strain #307, colony
maintained in house) were utilized to obtain SVF cells as described before [39, 41, 42]. In
short, a 1:1 mixture of male epididymal and female ovarian fat pads was isolated. The fat
was harvested, washed, and finely minced with subsequent digestion in 0.75 mg/mL
Type 1 collagenase solution (Vitacyte, Indianapolis, IN, 011-1030) and 1 mg/mL DNAse
(Sigma, Burlington, MA 9003-96-9) in 0.1% BSA-PBS. Two centrifugation cycles at 400
rpm for 4 minutes were performed to separate and then remove buoyant adipocytes. The
SVF cell pellet was resuspended in 0.1% BSA-PBS followed by a second centrifugation
cycle for 5 minutes and removal of remaining supernatant. The cell pellet was
resuspended in 0.1% BSA-PBS once more, followed by gravity filtration through 20 µm
mesh. The final SVF solution was collected, and cells counted by hemocytometer,
followed by a final centrifugation, removal of supernatant, and resuspension in normal
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saline to allow for 1 mL injections with 10 million SVF cells. The SVF-saline solution
was warmed to 37°C and injected in the tail vein of rats under isoflurane anesthesia.
Heart and subepicardial arteriole isolation.
Hearts were isolated from each euthanized rat and coronary arterioles were
dissected and transferred to a vessel chamber pressure myography system. Each end of
the vessel was attached to a glass pipette and subjected to physiologic temperature (37°C)
and pressure (45 mmHg) as shown in Figure A3.2. Vessels were allowed to achieve
spontaneous tone of >20% constriction from initial diameter [39, 41, 42]. Whole heart,
left ventricle, total body weight, initial tone achieved, and maximum dilation were
acquired for each animal (Table A3.1).
Pressure myography with concentration or flow response.
The following experiments were randomized to each vessel. Baseline
concentration-response curves were generated for each group for dobutamine at 10-10-10-5
[M] (primary β1-AR agonist, partial β2-AR agonist, Sigma-Aldrich, Burlington, MA
D0676), isoproterenol 10-14-10-4 [M] (non-specific βADR, Sigma-Aldrich, Burlington,
MA I6504), and norepinephrine at 10-9-10-4 [M] (primary β1-AR, β2-AR, α1-AR, and
α2-AR agonist, Sigma-Aldrich, Burlington, MA A9512). Vessels were monitored for two
minutes at each concentration and diameter recorded manually using video calipers.
Percent dilation was calculated as ([intraluminal diameter at specific concentration –
diameter at baseline]/[maximal diameter – diameter at baseline]) x 100. Percent dilation
responses for norepinephrine and dobutamine were plotted against mean fluorescence
intensity (MFI) values for hydrogen peroxide, peroxynitrite, superoxide, nitric oxide, and
glutathione (described further later). Once experiments were concluded, vessels were

201

washed with calcium-free physiologic salt solution twice for fifteen minutes each time,
followed by sodium nitroprusside (SNP, 10-4 [M] Sigma-Aldrich, Burlington, MA,
13451, 2 minutes) to achieve maximum dilation. Tone was calculated as 1-(initial
diameter/maximum diameter) x 100.
Isoproterenol concentration-response curves were also generated for vessels from
YC and OSVF vessels pre-incubated for 1 hour with exogenous hydrogen peroxide (10-4
[M] Sigma-Aldrich, Burlington, MA, 7722841) plus menadione (superoxide donor, 10-5
[M], Sigma-Aldrich, Burlington, MA, 130-37-0) plus or minus dynasore (inhibits
dynamin-mediated internalization, 1.6 µM Abcam, Cambridge, United Kingdom,
120192) and paroxetine (GRK2 antagonist, 5 µM, VWR, Radnor, PA, 89160-896).
Additional isoproterenol concentration-response curves were generated for OC vessels
with either incubation of dynasore, paroxetine, or SNP pre-treatment. Vessels were
incubated with SNP (10-4 [M]) for one minute, followed by a fifteen-minute wash without
SNP, followed by isoproterenol concentration-response generation plus low-dose SNP
(10-9 [M]).
In a separate cohort, vessels from each group were incubated with inhibitors of
β1-AR recycling including okadaic acid (PP2A inhibitor, 10-9 [M], APeX Bio A4540)
and BEZ235 (PI3Kγ inhibitor, 10-6 [M] MedChemExpress, Monmoth Junction, NJ, HY50673), and concentration curves for isoproterenol were generated. In separate YC and
OSVF vessels, concentration curves for isoproterenol were generated with exogenous
hydrogen peroxide and menadione plus or minus BEZ235 co-incubation. A detailed
pathway of βADR desensitization, internalization, and recycling with inhibitors utilized
in this manuscript are illustrated in Figure A1.1, adapted from Tracy et al. [121].
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Percent dilation to varied flow rates (0, 5, 10, 15, 20, 25 µL/min, 2 minutes each)
were assessed in separate vessels from each group. Following baseline FMD, flow rates
were re-assessed with addition of uric acid (peroxynitrite scavenger, 1 mM SigmaAldrich, Burlington, MA, 69-93-2 for 20 min), catalase (hydrogen peroxide scavenger,
500 U/ mL, Sigma-Aldrich, Burlington, MA, C4963, 1 hour), and L-NAME (eNOS
inhibitor, 10-5 [M] Sigma-Aldrich, Burlington, MA, N5751 for 20 min), separately.
Pressure myography with fluorescence imaging.
Isolated coronary arterioles from each group were infused with fluorescent dyes
for superoxide (Mitosox, 0.1 µM, Invitrogen, Waltham, MA, m36008, 30 min),
peroxynitrite (Biotracker 515, 20 µM Sigma-Aldrich, Burlington, MA, SCT035, 30 min),
hydrogen peroxide (Mitopy1, 10-5 [M], Tocris, Bristol, United Kingdom, 1041634-69-8,
1 hour), nitric oxide (2,3-diaminonapthalene (DAN), 10-4 [M], Alfa Aesar, Haverhill,
MA, 771-97-1, 10 minutes), and glutathione (DSSQ SEMKUR-IM, 250 µM,
ProteinMods, Waunakee, WI, 1 hour). Experiments were carried out in physiologic salt
solution without albumin. Flow (10 and 25 µm/min) was applied to infused vessels plus
or minus either Diethyldithiocarbamic acid (DETC, 1 mM, Fisher, Hampton, NH 140-617, 1 hour) or 3-amino-1,2,4-triazole (AMT, 100 µM, Sigma-Aldrich, Burlington, MA,
A8506, 1 hour) with images taken after 2 minutes at each flow rate. Mean fluorescence
intensity (MFI) for each image was calculated from the average of two regions of interest
(ROI) of consistent size (20 x 100 µm) applied over the left and right vessel walls using
NIS Elements AR Analysis software (Nikon Instruments, Melville, NY, USA). For
Mitosox, cobalt chloride (generates superoxide through hypoxia-inducible factor 1, 0.5
mM, Sigma-Aldrich, Burlington, MA, 15862, 1 hour) represented positive control

203

whereas Tiron (superoxide scavenger, 10 mM, Acros Organics, Geel, Belgium,
174140250, 1 hour) represented a negative control. For Biotracker 515, menadione (10-5
[M], Sigma-Aldrich, Burlington, MA, 130-37-0) + SNP (10-4 [M]) for 1 hour represented
positive control, whereas Tiron (10 mM) + catalase (10 mM, 500 U/mL) for 1 hour
represented a negative control. For Mytopy1, exogenous hydrogen peroxide (10-4 [M],
20 minutes) represented positive control whereas catalase (500 U/mL, 1 hour)
represented a negative control. For DAN, exogenous SNP (10-4 [M], 2 minutes)
represented positive control whereas CPTiO flow (1 mM, Sigma-Aldrich, Burlington,
MA, C221, 20 minutes) represented a negative control. Simplified illustration of ROS
and the fluorescent labels, enzyme activator/donors, and inhibitors/scavengers are
summarized in Figure A3.3.
Immunofluorescence staining.
Vessel immunofluorescence staining was performed as previously described [39,
396]. Briefly, coronary arterioles measuring 750-1000 µm in length and <250 µm in
diameter were isolated and fixed in 2% paraformaldehyde for one hour. After fixation,
vessels were washed 2 x 15 minutes in DCF-PBS followed by 20 minutes in 0.5% TritonX/DCF-PBS, all at room temperature with mild rotation. Next, vessels were placed in
blocking solution containing 5% donkey serum, 0.5% BSA, and 0.5% triton X/DCF-PBS
for one hour followed by incubation with primary antibodies including manganese
superoxide dismutase (mSOD, 1:100, Novus Biologicals, Littleton, CO, NB100-1992SS),
catalase (1:100 dilution, Bioss, Woburn, MA, 980693W), NOX4 (1:100 Novus,
Littleton, CO NB110), heat shock protein 70 (1:100 Abcam, Cambridge, United
Kingdom, 2787), glutathione synthetase (1:100 Novus Biologicals, Littleton, CO NBP2-
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75513), S-nitrosocysteine (1:100 Abcam, Cambridge, United Kingdom, 268288), PP2A
(1:100 Abcam, Cambridge, United Kingdom, 81G5), I2PP2A (1:100 Santa Cruz
Biotechnologies, Dallas, TX, sc-133138), and PI3ky (1:100 Arigo Biolaboratories,
Hsinchu City, Taiwan, ARG43246) rotating at 4°C overnight. Normal rabbit serum
replaced primary antibody for negative control vessels. The following day, the vessels
were washed x3 times in DCF-PBS, followed by one-hour incubation in donkey antirabbit IgG Alexa Fluor 594 (1:300 Invitrogen, Waltham, MA, A21207) or goat antimouse IgG Alexa Fluor 488 (1:300 Abcam, Cambridge, United Kingdom, 150113) in
blocking solution. Nuclei were stained with DAPI (Life Technologies, Carlsbad, CA,
R37606). Vessels were placed on slides with mounting media and coverslip, then imaged
with Olympus FV1000 confocal microscope system (Olympus America, Center Valley,
PA, USA) with a 405 and 562 nm laser. The pixel density set for image capture was
1024x1024 with 2 µm Z-step with 20X magnification, with ~12 slices stacked together
post-image capture. Immunofluorescence intensity for each antibody were quantified
using the Nikon NIS Elements AR Analysis software using 20 µm x 100 µm area. ROI
boxes were placed on the right and left vascular walls (endothelial + smooth muscle)
excluding cardiomyocytes with MFI averaged.
RNA sequencing.
Additional coronary arterioles were allocated for RNA sequencing via flash
freezing; samples were stored at -80°C until samples from all groups were collected as
done previously [396]. Six isolated vessels were pooled from two animals in the same
group for n=3 biological replicates/group. RNA was harvested with RNAqueous Micro
kit (Invitrogen, Waltham, MA, AM1931) and quantified on a NanoDrop (ThermoFisher,
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Waltham MA, USA). Samples were sent to the University of Louisville Genomics Core
for quality control analysis using the Agilent Bioanalyzer 2100 system (Agilent
Technologies, Santa Clara, CA) and quantified using a Qubit fluorometric assay (Thermo
Fisher Scientific, Waltham, MA) as previously described [257]. Poly-A enrichments,
barcoding, and Illumina Next-Gen sequencing for library preparation were performed as
previously described [257, 258]. Gene transcripts were analyzed by the University of
Louisville Bioinformatics Core for differential expression analysis between group
comparisons as previously described [259].
Statistical analysis.
SigmaPlot 14 (Systat) was utilized for statistical analyses, with significance level
set at p ≤ 0.05 for all analysis. Concentration- and flow-response curves as well as MFI
evaluations were analyzed with Two-way Repeated Measures ANOVA with Bonferroni
or Holm-Sidak post hoc testing as appropriate. Data are presented as means plus or minus
standard error of the means as indicated. For pressure myographic fluorescence analysis,
20% of the data was re-analyzed by blinded inter- and intraobservers. Linear regression
and Bland-Altman Plots were generated to assess for bias in interpretation of data
(Supplemental Fig A1.3). For confocal images, the images were coded and analyzed in a
blind fashion with the code being broken only after all MFI quantifications were
acquired. Electronic laboratory notebooks were not used for this study.

Results
Animal characteristics.

206

Animal groups and experimental setup are illustrated in Figure A3.2. There was a
significant increase in body weight and total ventricular weight between young control
(YC) vs old control (OC) and YC vs old treated with SVF (OSVF) (p < 0.001 for all)
(Table A3.1). LV weight increased significantly with aging (p < 0.001) and was reduced
with SVF therapy (p = 0.026), albeit not to YC levels (p < 0.001). There was no
significant change in wall thickness, maximal diameter, or percent resting tone.

Stromal vascular fraction reduces aging-associated oxidative stress.
An illustrative guide for fluorescent dyes, inhibitors/scavengers, and activators of
key ROS/RNS and their mediators used in this section are shown in Figure A3.3. There
were significant increases in coronary microvascular hydrogen peroxide and peroxynitrite
in coronary arterioles from aged rats (p = 0.015 and p = 0.01, respectively), but no
significant increases in superoxide MFI at baseline (Fig A3.4). Hydrogen peroxide,
peroxynitrite, and superoxide MFI were all significantly decreased in OSVF compared to
OC (p < 0.001, p = 0.024, p = 0.004, respectively). Meanwhile, there were significant
decreases in nitric oxide (p = 0.024) and glutathione (p < 0.01) MFI between youth and
aging (Fig A3.4 D-E). SVF therapy was unable to significantly increase nitric oxide MFI,
but did significantly increase glutathione MFI compared to OC, although not fully
restored to YC levels (p = 0.017 vs. OC, p =0.014 vs. YC). The validity of the
fluorescent dyes was confirmed with positive and negative controls for each dye. Briefly,
mytopy1, Biotracker 515, Mitosox, 2,3-diaminonapthalene (DAN), and SEMKUR-IM
MFI were appropriately increased by exogenous hydrogen peroxide, cobalt chloride
(CoCl2), SNP, and tiron + catalase, respectively. Mytopy1, Biotracker 515, Mitosox,
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DAN, and SEMKUR-IM MFI were appropriately decreased by PEG-catalase, tiron,
CPTiO, and hydrogen peroxide, respectively. Further, repeatability was confirmed via
linear regression and Bland-Altman analysis with blinded inter- and intra-observer reanalysis of 20% of the data.
To elucidate the redox environments between youth, aging, and aging + SVF, we
utilized RNA sequencing to study gene expression and fluorescence staining to
extrapolate protein expression of various antioxidant and prooxidant enzymes (Fig A3.5).
Among prooxidant enzymes, xanthine dehydrogenase was increased by 21% in OC vs.
YC and 28% in SVF vs. YC (p = 0.042 and p = 0.006, respectively). Peroxisome
proliferator-activated receptor gamma (coactivator-related), known to increase oxidative
stress, was increased by 22% in OC vs. YC (p = 0.042). There were no significant
differences between groups for suspected prooxidant enzyme NOX4. SHC adaptor
protein 1 expression was 18.9% greater in OC vs. YC (p = 0.018).
Among antioxidant enzymes, there was significant increase in catalase by 19% (p
= 0.049), (extracellular) SOD3 by 22% (p = 0.007), thioredoxin reductase 1 by 23% (p =
0.014), and glutathione-S-transferase mu 1 by 24% (p = 0.019) and pi 1 by 31% (p =
0.025) in OC vs. YC. Antioxidant enzyme expression increases in YC vs. OC included
26% more oxidation resistance protein 1 (p = 0.035), 40% more COX20 assembly factor
(p = 0.002), and 15% and 21% more heat shock proteins 90 and 110 (p = 0.037 and p =
0.034, respectively). For OSVF vs. YC antioxidant enzymes, catalase was increased by
19% (approaching significance, p = 0.057), SOD3 by 20% (p = 0.012), glutathione
peroxidase 3 and 4 by 24% and 18% (p = 0.016 and p = 0.024, respectively), sirtuin 5 by
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20% (p = 0.038), thioredoxin reductase by 20% (p = 0.034), and peroxiredoxin 4 by 39%
(p = 0.015) albeit with 40% decreased heat shock protein 110 (p = 0.003).
Comparing antioxidant enzyme expression between OSVF vs. OC, glutathione
synthetase was increased by 28% (p = 0.018), thioredoxin-like protein 1 increased by
17.2% (p = 0.045), heat shock proteins 40 (member C7) and 70 increased by 21.4% and
22% (p = 0.01 and p = 0.07, respectively), and cytochrome oxidase assembly factor 3
increased by 21% (p = 0.032) in OSVF. A comprehensive listing of antioxidant and
prooxidant proteins are illustrated in the heat map in Figure A3.5 A.
We selected gene targets of most interest and potential impact/relevance to
evaluate protein expression utilizing fluorescence imaging of isolated coronary
microvessels (Fig A3.5 B-C). Antioxidant enzymes catalase, glutathione synthetase, and
heat shock protein 70 yielded no differences in MFI. mSOD MFI was reduced with aging
(albeit not significantly) but was significantly increased with SVF therapy (p = 0.041).
Prooxidant enzyme NOX4 was significantly increased with aging (p = 0.032) with
significant reversal to YC levels by SVF (p = 0.037). S-nitrosylation of proteins was
significantly reduced with aging (p = 0.012) but was not restored with SVF (p = 0.047
vs. YC).

Alterations of flow-mediated dilation signaling throughout the lifespan and with stromal
vascular fraction.
Introduction of intraluminal flow into isolated coronary microvessels in pressure
myography experiments elicited different signaling responses to induce FMD between
YC vs. OC vs. OSVF. In youth, flow elicited an increase in nitric oxide MFI (significant
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compared to OC at flow rate of 10 & 25 μL/min, p = 0.015 and p = 0.046, respectively)
(Fig A3.6 A). There was minimal change in nitric oxide MFI with flow in OC and OSVF
groups.
In all groups, flow induced an increase in hydrogen peroxide, but the increase was
greatest in the OC group (significant vs. YC at flow rate of 25 μL/min, p = 0.045) (Fig
A3.6 B). Inhibition of superoxide dismutase with diethyldithiocarbamic acid (DETC) led
to overall reduced hydrogen peroxide production with flow in all groups, with greater
reduction in OC than OSVF at 25 μL/min (p = 0.041) (Supplemental Fig A3.1).
Inhibition of catalase with 3-amino-1,2,4-triazole (AMT) without flow led to greater
hydrogen peroxide MFI increases in OSVF vs. YC and OC (p = 0.01 and p < 0.01,
respectively) (Fig A3.6 B). With AMT + flow at 10 and 25 μL/min, OSVF hydrogen
peroxide MFI was significantly greater than OC (p < 0.001 and p < 0.001, respectively)
and nearly significant vs. YC (p = 0.051 and p = 0.087, respectively). OC was nonsignificantly reduced compared to YC at all flow rates. These results with AMT suggest
significantly greater catalase function in OSVF vs. YC and OC.
Superoxide MFI decreased with intraluminal flow in all groups (Fig A3.6 C).
Inhibition of superoxide dismutase with DETC led to significantly greater superoxide
accumulation in YC and OSVF groups compared to OC at baseline (p = 0.035 and p =
0.011, respectively). With flow + DETC, OC exhibited less superoxide production at
flow rates of 10 (vs. YC and OSVF, p < 0.001, p = 0.008, respectively) and 25 (vs. YC, p
= 0.029) μL/min, suggesting greater SOD expression and/or function in youth than aging,
and that SOD function was restored with SVF therapy. DETC inhibition of SOD with
flow reduced hydrogen peroxide production in all groups as expected. Peroxynitrite MFI
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was increased with intraluminal flow at 10 and 25 μL/min in young control and
significantly so in OSVF compared to minimal peroxynitrite production in OC (p = 0.027
and p = 0.01, respectively) (Fig A3.6 D).
Glutathione is an essential antioxidant that reflects the redox balance of the cell,
quenching ROS such as hydrogen peroxide, superoxide, and peroxynitrite. The
SEMKUR-IM dye indirectly reports the ratio between reduced and oxidized glutathione,
with increased fluorescence changes indicating reduced glutathione, and decreased
changes indicating oxidized glutathione. At intraluminal flow rate of 10 μL/min,
glutathione MFI was increased in YC but significantly decreased in OC (p = 0.04) (Fig
A3.6 E). At intraluminal flow rate of 25 μL/min, there was a significant difference
between YC (p = 0.01) and OSVF (p = 0.013) MFI vs. OC. These results are consistent
with the results that flow in OC increased hydrogen peroxide (and superoxide transiently
before it was converted to hydrogen peroxide by SOD).
These data indicate that the FMD signaling mediator is nitric oxide during youth,
hydrogen peroxide in aging, and switching to peroxynitrite with SVF therapy. To
complement and strengthen the validity of these findings, we used pressure myography
with flow while recording percent vasorelaxation in each group with or without
inhibitors/scavengers/enzymes of these redox signaling mediators. Overall, the
effectiveness of FMD was significantly attenuated with aging at flow rates of 10, 15, 20,
& 25 μL/min (p < 0.01, p < 0.01, p = 0.024, and p < 0.01, respectively) but rescued to
YC levels in the SVF therapy group (p = 0.011, p = 0.006, p = 0.04, and p = 0.002,
respectively) (Fig A3.7 A). In youth, FMD was significantly attenuated by pre-incubation
with N-Nitro-L-arginine methylester (L-NAME), but not catalase or uric acid, at all flow
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rates (p = 0.005, p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively) (Fig A3.7
B). This signifies that nitric oxide production is responsible for FMD during youth, as LNAME inhibits eNOS-mediated nitric oxide production. During aging, FMD was not
further attenuated by L-NAME, uric acid, or catalase (Fig A3.7 C). OSVF’s
improvement in FMD was significantly abrogated by uric acid at all flow rates (p = 0.04,
p = 0.04, p = 0.04, p < 0.001, and p < 0.001, respectively) and L-NAME at flow rates
15-25 μL/min (p = 0.027, p = 0.014, and p = 0.012, respectively) (Fig A3.7 D). This
signifies that with SVF therapy, the FMD signaling mediator switches to peroxynitrite, at
least partially dependent on nitric oxide production.

Baseline oxidative and nitrosative stress are mechanistically linked with β1-AR-mediated
dilative function.
Consistent with our lab’s previous reporting, β1-adrenergic-mediated
vasorelaxation was reduced with aging and restored to YC levels in aging + SVF therapy.
Specifically, there were significant differences between YC vs. OC NE concentration
responses at 10-8-10-4 [M] (p = 0.022, p < 0.001, p < 0.001, p < 0.001, and p < 0.001,
respectively) and OSVF vs. OC at 10-8-10-4 [M] (p < 0.001 for all) (Fig A3.8 A).
Similarly, there were significant differences between YC vs. OC Dob dose responses at
10-9-10-5 [M] (p = 0.018, p < 0.001, p = 0.002, p = 0.001, and p < 0.001, respectively)
and OSVF vs. OC at 10-9-10-7 and 10-5 [M] (p = 0.043, p = 0.002, p = 0.004, and p <
0.001, respectively) (Fig A3.8 B). Since aging is associated with both increased oxidative
stress and reduced β-adrenergic function, we next endeavored to determine if there was a
true correlation between them.
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Using separate vessels from the same animal, we correlated percent relaxation to
norepinephrine 10-4 [M] with ROS/RNS/glutathione MFI. There were negative
correlations between percent vasorelaxation to NE and MFI of hydrogen peroxide and
superoxide, but not peroxynitrite (r(27) = -0.69, p < 0.001; r(15) = -0.505, p = 0.018;
r(20) = -0.24, p = 0.297, respectively) (Fig A3.8 C-E). There was a positive correlation
between increasing nitric oxide and glutathione with percent vasorelaxation to NE (r(19)
= 0.50, p = 0.021; r(18) = 0.50, p = 0.028, respectively) (Fig A3.8 F-G)

Exogenous ROS eliminates while RNS rescues β-AR vasodilation due to the ROS/RNS βAR desensitization & internalization axis.
For isoproterenol, there were significant differences between YC vs. OC
concentration responses at 10-8-10-4 [M] (p < 0.001 for all doses) and OSVF vs. OC at
10-11-10-4 [M] (p = 0.002, p = 0.002, p < 0.001, p < 0.001, p < 0.001, p < 0.001, p <
0.001, and p < 0.001, respectively) (Fig A3.9 A). Isoproterenol concentration response
was significantly abrogated in YC from doses 10-8-10-4 [M] (p = 0.003, p < 0.001, p <
0.001, p < 0.001, and p < 0.001, respectively) and OSVF at 10-8-10-4 [M] (p < 0.001 for
all doses) when pre-incubated with exogenous hydrogen peroxide and superoxide
donation via menadione (Fig A3.9 B and D). Post-experimentation, exposure to calciumfree solution + SNP still facilitated dilation, indicating ROS-attenuated dilation is βadrenergic specific (YC=78.39±9.76%; OSVF=88.88±6.37% dilation). In YC, the effect
from ROS was nullified when co-incubating with dynasore at 10-8-10-4 [M] (p = 0.005, p
< 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively), but not restored to YC levels
at 10-6-10-5 [M] (p = 0.037 and p = 0.003, respectively). Paroxetine also nullified the
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ROS attenuation of dilation at doses 10-8-10-4 [M] (p = 0.02, <.001, p < 0.001, p = 0.001,
and p = 0.001, respectively), albeit not completely restored to baseline levels for doses
10-7-10-4 [M] (p = 0.047, p = 0.011, p = 0.01, and p = 0.004, respectively). In OSVF +
ROS, dynasore and paroxetine pre-incubation also rescued function from doses 10-7-10-4
[M] (dynasore: p = 0.009, p = 0.0033, p = 0.005, and p = 0.007, respectively) and 10-510-4 [M] (paroxetine, p = 0.042 and p = 0.015, respectively). These reversing effects to
attenuate ROS-blunted adrenergic dilation were therefore the result of inhibiting GRK2mediated desensitization and dynamin-mediated internalization, respectively. Response
to isoproterenol in old control vessels was significantly rescued at doses 10-7-10-6 [M] by
pre-incubation with a one-minute high-dose SNP preincubation followed by fifteen
minutes of low-dose SNP and throughout the experiment (p = 0.004 and p = 0.023,
respectively) (Fig A3.9 C). The response was also rescued by pre-incubation with
dynasore at 10-8-10-4 [M] (p = 0.015, p < 0.001, p < 0.001, p < 0.001, and p = 0.004,
respectively) and paroxetine at 10-7-10-4 [M] (p < 0.001, p = 0.022, p = 0.019, and p =
0.004, respectively).

β1-AR recycling is necessary in aging, but not youth or OSVF for maximal dilation to
agonist.
To determine the contribution of β1-AR recycling (from endosome back to
plasma membrane), we inhibited recycling regulatory proteins PP2A (pro-recycling) with
okadaic acid, or PI3kγ (anti-recycling) with BEZ235 in a separate cohort of coronary
arterioles from each group. Okadaic acid did not significantly reduce YC dilation to
isoproterenol but did significantly reduce dilation in OC at 10-5-10-4 [M] (p = 0.01, p <
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0.001) and OSVF at 10-7-10-6 [M] (p = 0.005, p = 0.045) (Supplemental Fig A3.2 A-C).
Inhibition with BEZ235 did not alter aged dilation but did significantly reduce dilation in
YC at 10-7-10-4 [M] (p = 0.011, p = 0.002, p < 0.001, and p = 0.004, respectively) and
OSVF at 10-6-10-4 [M] (p = 0.045, p = 0.008, and p = 0.017, respectively). BEZ235
partially negated the effects of exogenous ROS incubation in YC at 10-5-10-4 [M] (p <
0.001, p = 0.004), although differences were also significant against baseline at those
doses (p < 0.001 for both) (Supplemental Fig A3.2 D). BEZ235 also negated the
attenuation of dilation from exogenous ROS in OSVF at 10-6-10-5 [M] (p=0.042, p =
0.017) (Supplemental Fig A3.2 E). There were no significant differences between
groups for MFI of PP2A, protein phosphatase 2A inhibitor 2 (I2PP2A), or PI3kγ
(Supplemental Fig A3.3).
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Table A3.1
Animal & Vessel
Characteristics
Age (Months)

YC (n=66)

OC (n=58)

OSVF (n=55)

3-6

24

24

Body Weight (g)
(n)

181.25 +/- 2.5 (65)
*#

249.97 +/- 3.795 (46)

246.82 +/- 2.99 (45)

Total Ventricular
Weight (mg) (n)

502.66 +/- 6.64 (66)
*#

651.47 +/- 16.31 (53)

653.89 +/- 6.74 (42)

LV Weight (mg) (n)

421.34 +/- 5.34 (66)
*#

566.55 +/- 3.74 (53)
^

530.32 +/- 14.51
(43)

Vessel Wall
Thickness (μm) (n)

12.58 +/- 0.4 (72)

16.22 +/- 1.68 (61)

15.39 +/- 1.75 (64)

Maximum Diameter
(n)

138.55 +/- 3.33 (72)

148.42 +/- 3.93 (62)

147.45 +/- 3.29 (67)

Average % Tone
(n)

30.65 +/- 1.52 (72)

29 +/- 1.62 (62)

32.71 +/- 1.81 (67)

Table A3.1: Rat anatomic, cardiac and vascular characteristics.
Significance set as p < 0.05 (* YC vs OC, # YC vs OSVF, ^ OC vs OSVF) via One-way
ANOVA with Bonferroni post hoc analysis.
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Figure A3.1

Figure A3.1: Simplified schematic model of ROS/RNS- β1-AR desensitization and
internalization axis.
Age-dependent accumulation of mitochondrial ROS may oxidize the β1-AR and reduce
nitric oxide-mediated nitrosylation of GRK2 to facilitate desensitization and
internalization into endosomes. SVF restores β1-AR mediated dilation within this axis
through antioxidation of mitochondrial ROS, which likely decreases β1-AR thiol
oxidation. However, GRK2 nitrosylation is likely not restored to youthful levels as SVF
does not restore nitric oxide or general protein SNO signaling. Overall, the results of this
manuscript explain the therapeutic effects of SVF in CMD to reverse hyperconstriction
by increased functional β1-AR at the plasma membrane in part due to antioxidative
effects. βAR: Beta Arrestin, CAT: catalase, GRK-2: G-protein Receptor Kinase 2, GSH:
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glutathione, GSNO: nitrosoglutathione, mSOD: manganese superoxide dismutase, NE:
norepinephrine, OH, thiol oxidation, S-NO: S-nitrosylation
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Figure A3.2

Figure A3.2: Outline of pressure myography methodology.
Female Fisher-344 rats in three experimental groups including young control (3-6 months
old), old control (24 months old), and old + SVF (OSVF, 24 months old) with SVF tail
vain injection (10 million cells) one month prior to sacrifice (A). At time of sacrifice,
hearts are removed and microvessels (100-200 μm) dissected and attached to glass
pipettes of a pressure myography rig allowing flow through the vessel via a flow pump at
0-25 μL/minute at 37°C and 45 mmHg (physiologic pressure) (B). Vessel fluorescence or
intraluminal diameter can be tracked in real time with examples at tone (C), dilation (D)
and constriction (E).
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Figure A3.3

Figure A3.3: ROS map illustrating experimental fluorescent labels (blue),
activators/donors (green) and inhibitors/scavengers (red).
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Figure A3.4

Figure A3.4: Changes in mitochondrial ROS, nitric oxide, and glutathione at
baseline with aging and SVF therapy.
Hydrogen peroxide, peroxynitrite, and superoxide Mean Fluorescent Intensity (MFI,
arbitrary units) are increased with aging, reversed by SVF (A-C). Nitric oxide and
Glutathione MFI are decreased with aging, with SVF partially restoring glutathione, but
not nitric oxide to youthful levels (D-E). Data presented as means±SEM. Significance
determined as p < 0.05 with One-way ANOVA with Bonferroni post-hoc analysis. Scale
bar represents 100 μm. OC: Old Control, OSVF: Old + Stromal Vascular Fraction, YC:
Young Control.
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Figure A3.5

Figure A3.5: Antioxidant and pro-oxidant gene and protein expression in youth,
aging, and SVF therapy.
RNA sequencing of isolated vessels with genes relevant to cellular and mitochondrial
redox balance (A). Protein MFI of isolated vessels for catalase, mSOD, glutathione
synthetase, HSP70, NOX4, and SNO (B) with representative confocal images (C). Nuclei
signified by DAPI. Data presented as means±SEM. Significance determined as p < 0.05
with One-way ANOVA with Holm-Sidak post-hoc analysis. Scale bar represents 200 μm
and ROI represents 20x100 μm with blue representing DAPI. GSH synth.: glutathione
synthetase, HSP70: Heat Shock Protein 70 mSOD: manganese Superoxide Dismutase,
NOX4: NADPH Oxidase 4, OC: Old Control, OSVF: Old + Stromal Vascular Fraction,
SNO: S-nitrosylation, YC: Young Control.
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Figure A3.6

Figure A3.6: Effect of intraluminal flow on ROS/NO/GSH MFI with and without
antioxidant enzyme inhibitors.
Nitric oxide signaling to flow is greatest with youth but minimal in aging and SVF
therapy (A). Hydrogen peroxide accumulation to flow is greatest in aging (B). Further,
blocking catalase with AMT yields greatest buildup of hydrogen peroxide in response to
flow with SVF therapy, indicating greatest catalase function in OSVF. There is no age- or
therapy-induced changes to superoxide response to flow at baseline, however, with
DETC there is significantly less buildup of superoxide to flow in aging, indicating greater
SOD function with youth/OSVF (C). OSVF has greater accumulation of peroxynitrite
with flow than young or old control (D). Flow leads to a significant decrease in
glutathione MFI in aging alone compared to youth or OSVF (E). Data presented as
means±SEM. Significance determined as p < 0.05 with One-way ANOVA with
Bonferroni post-hoc analysis. AMT: 3-amino-1,2,4-triazole, DETC:
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Diethyldithiocarbamic acid, OC: Old Control, OSVF: Old + Stromal Vascular Fraction,
YC: Young Control.
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Figure A3.7

Figure A3.7: Flow-mediated dilation changes in response inhibitors/scavengers of
ROS/RNS.
There is a significant decrease in FMD in aging, reversed by SVF therapy (A). During
youth, FMD is inhibited by L-NAME inhibition of eNOS nitric oxide production, but not
uric acid or catalase (B). During aging, there are no differences in FMD with
preincubation of L-NAME, uric acid, or catalase (C). With SVF therapy, FMD is
attenuated with L-NAME and uric acid scavenging of peroxynitrite (D). Data presented
as means±SEM. Significance determined as p < 0.05 with Two-way Repeated Measures
ANOVA with Bonferroni (A) or Holm-Sidak (B-D) post-hoc analysis. eNOS: endothelial
nitric oxide synthase, FMD: flow mediated-dilation, L-NAME: N-Nitro-L-arginine
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methylester, OC: Old Control, OSVF: Old + Stromal Vascular Fraction, YC: Young
Control.
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Figure A3.8

Figure A3.8: Link between β1-AR dysfunction and increased ROS and attenuated
nitric oxide, and glutathione concentration in aging.
Aging reduces β1-AR dilative response to norepinephrine and dobutamine, restored to
young control levels by SVF therapy (A-B). β1-AR dilation to norepinephrine (10-4 [M])
negatively and significantly correlates with hydrogen peroxide and superoxide, but not
peroxynitrite, while positively and significantly correlating with nitric oxide and
glutathione MFI (C-G). Data presented as means±SEM. Significance determined as p <
0.05 with Two-way Repeated Measures ANOVA with Bonferroni post-hoc analysis (AB) and Linear Regression (C-G). OC: Old Control, OSVF: Old + Stromal Vascular
Fraction, YC: Young Control.
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Figure A3.9

Figure A3.9: Effect of ROS/RNS on β1-AR desensitization & internalization
in youth, aging, and SVF therapy.
With aging there is a significant decrease in dilation to isoproterenol, reversed by SVF (*
= YC vs. OC, # = SVF vs. OC, ^ = YC vs. OSVF) (A). YC vessels exposed to exogenous
ROS (hydrogen peroxide 10-4 [M] and menadione superoxide donor 10-5 [M]) have
abrogated dilation reversed by paroxetine and dynasore inhibition of desensitization &
internalization (* = baseline vs. ROS, # = dynasore vs. ROS, ^ = paroxetine vs.
ROS) (B). OC vessels exposed to SNP, dynasore, and paroxetine have significantly
improved percent relaxation (* = baseline vs. SNP, # = baseline vs. dynasore, ^ =
baseline vs. paroxetine) (C). OSVF vessels exposed to exogenous ROS have ameliorated
dilation reversed by paroxetine and dynasore (* = baseline vs. ROS, # = dynasore vs.
ROS, ^ = paroxetine vs. ROS) (D). Data presented as means±SEM. Significance defined
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as p < 0.05 utilizing two-way repeated measures ANOVA with Bonferroni (A) or HolmSidak (B-D) post hoc analysis. OC; Old Control, OSVF: Old + Stromal Vascular
Fraction, ROS: Reactive Oxygen Species, SNP: Sodium Nitroprusside. YC: Young
Control.
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Supplemental Figure A3.1

Supplemental Figure A3.1: Hydrogen peroxide production with DETC superoxide
dismutase inhibition.
Data presented as means±SEM. Significance defined as p < 0.05 via One-way ANOVA
with Bonferroni post hoc analysis. DETC: Diethyldithiocarbamic acid. Old Control,
OSVF: Old + Stromal Vascular Fraction, YC: Young Control.
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Supplemental Figure A3.2

Supplemental Figure A3.2: Contribution of β1-AR recycling on dilative function
between groups.
Incubation with BEZ235, but not okadaic acid, attenuates dilation to isoproterenol in YC
(A). In YC, pre-incubation with ROS (hydrogen peroxide and menadione) leads to
abrogation of dilation, partially prevented by co-incubation with BEZ235 (B). OC
dilation to isoproterenol is significantly attenuated by okadaic acid, but not BEZ235 (C).
In OSVF, dilation to isoproterenol is diminished with okadaic acid at lower respective
doses and BEZ235 at higher respective doses (D). Pre-incubation of vessels with ROS
attenuates dilation to isoproterenol in OSVF, partially prevented by co-incubation with
BEZ235 (E). Data presented as means±SEM. Significance defined as p < 0.05 via twoway ANOVA with Bonferroni post hoc analysis.
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Supplemental Figure A3.3

Supplemental Figure A3.3: Protein expression of β-AR recycling mediators is
unchanged with aging or SVF therapy. There is no significant change in MFI of PP2A
(activates recycling) or its inhibitors I2PP2A or PI3ky (A). Representative confocal
images are shown (B). Data presented as means±SEM. Significance determined as p <
0.05 with one-way ANOVA. Scale bar represents 200 μm and ROI represents 20x100
μm. OC: Old Control, OSVF: Old + Stromal Vascular Fraction, YC: Young Control.
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Discussion
Aging induces a redox shift in coronary microvessels towards oxidative stress,
accompanied by a decrease in antioxidants glutathione and nitric oxide. Intravenous
treatment with SVF four weeks prior to explant reverses these trends in old rats, except
for nitric oxide. Oxidative stress occurs despite an age-related increase in gene expression
of several antioxidant proteins including catalase, superoxide dismutase 3, and
thioredoxin reductase. This likely indicates attempted compensatory regulation that
cannot compete with prooxidant processes, including gene expression of xanthine
dehydrogenase, monoamine oxidase A, and SHC1 (encodes p66SHC). These
consequences with aging include abrogated vasodilation through reduced FMD and β1AR signaling. We show for the first time that ROS levels negatively correlate whereas
nitric oxide and glutathione positively correlates with β1-AR function. The major
findings support that antioxidant effects of SVF cell therapy restores vasodilation in
aging by switching the acute mediator of FMD from hydrogen peroxide to peroxynitrite,
as well as by attenuating desensitization and internalization of the β1-AR.
Immunofluorescence staining found greater NOX4 protein MFI with aging albeit
no increase in gene expression. NOX4-derived hydrogen peroxide can lead to ROSinduced ROS release in part through activation of p66SHC [397]. The MFI of mSOD was
reduced with aging and reversed by SVF, despite no genetic expression changes.
Interestingly, p66SHC (increased gene expression in OC) can inactivate FOXO3, causing
mSOD downregulation [398]. p66SHC overexpression is also known to reduce dilation to
acetylcholine and nitric oxide bioavailability, while the opposite is true in knockout
models [399-401]. Therefore, greater NOX4 and p66SHC could be a major driver of
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ROS production in aging coronary microvasculature. One explanation for SVF’s
antioxidant effects could be to reduce signaling from NOX4/p66SHC. NOX4 MFI was
reduced to YC levels by SVF and there was no expressional difference in p66SHC
between YC and OSVF. Moreover, SVF upregulated gene expression of additional
antioxidant proteins such as glutathione synthetase, Sirt5, thioredoxin-like 1,
glutaredoxin-like protein, selenophosphate synthetase 1, and several heat shock protein
subunits compared to OC. Although there was no increase in glutathione synthetase
protein MFI, glutathione itself was increased with SVF to YC levels.
It has previously been reported that the mediator of FMD shifts throughout the
lifespan from prostaglandin during youth, to nitric oxide during young adulthood, to
hydrogen peroxide in coronary artery disease [387]. Our data confirms this trend, as
youth produced significant nitric oxide MFI and FMD was inhibited by L-NAME,
whereas in aging hydrogen peroxide MFI was most significantly increased with flow.
Catalase did not inhibit FMD in aged vessels because dilation was minimal to begin with.
With flow plus DETC inhibition of superoxide dismutase, superoxide MFI was greater in
YC and OSVF compared to OC. This suggests that there is reduced mSOD expression or
function in aging, reversed by SVF therapy. Although RNAseq showed no difference in
mSOD transcription, immunofluorescence showed increased mSOD availability in OSVF
compared to OC. Other than expression changes in mSOD described above, function of
mSOD in aging can be inhibited by peroxynitrite-mediated tyrosine nitration (and chronic
baseline peroxynitrite MFI was increased in OC) [402]. Inhibiting catalase with AMT led
to greater hydrogen peroxide in YC and OSVF compared to OC, indicating a reduction in
catalase expression/function with aging that is restored by SVF. Interestingly, RNAseq
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showed increased catalase gene expression in the aged groups, OC and OSVF, when
compared to YC, while immunofluorescence showed no difference between groups.
Catalase function can be activated by phosphorylation of catalase at tyrosine 231 and
386, and can be ubiquitin degraded, which may explain these findings [403].
With SVF there was increased peroxynitrite MFI in response to flow, and FMD
was inhibited by uric acid scavenging of peroxynitrite as well as L-NAME. This goes
against our initial hypothesis, as we believed nitric oxide would be restored to YC levels
and would mediate FMD in OSVF vessels [404]. However, as nitric oxide is required to
produce peroxynitrite (in combination with superoxide), and L-NAME inhibited FMD, it
stands to reason that peroxynitrite FMD response is dependent on enough nitric oxide
production to combine with superoxide resulting in significantly increased peroxynitrite.
Although peroxynitrite is a ROS, it has been speculated to have functional significance in
geriatric populations as a “new healthy vascular endothelium redox status” because
peroxynitrite can donate nitric oxide, thereby acting as a reservoir and eliciting FMD,
possibly without the pro-atherogenic effects of hydrogen peroxide [405]. To emphasize,
the increase in OSVF peroxynitrite is acute, and limited to periods of FMD. During
baseline (chronic status), aged vessels had greater peroxynitrite MFI than YC or OSVF.
These acute vs. chronic redox signaling changes are likely of significance to cellular
health.
β1-AR-mediated dilation with dobutamine, norepinephrine, and isoproterenol
were reduced with aging, restored by SVF therapy. Using two vessels from the same
animals, we determined there is negative correlation between oxidative stress and β1-AR
dilative function (albeit not for peroxynitrite) and a significant positive correlation
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between glutathione and nitric oxide with β1-AR function. Thus, oxidative stress reduces
functional dilation with aging. Incubating vessels with exogenous hydrogen peroxide and
superoxide (mimicking aging conditions) completely attenuated YC and OSVF β1-AR
dilation to isoproterenol. This effect was diminished if co-incubating the ROS with
dynasore (inhibiting dynamin i.e internalization) or paroxetine (inhibiting GRK2 i.e.
desensitization). OC vessels pre-incubated with SNP (mimicking YC nitrosylation
status), dynasore and paroxetine significantly improved β1-AR dilation to isoproterenol.
These results indicate a role for ROS and RNS in β1-AR trafficking.
It has been speculated that the β1-AR can be influenced to internalize upon thiol
oxidation, and receptor recycling from the endosome is known to be inhibited by ROS
[20, 406]. We found that inhibition of PI3kγ (which activates I2PP2A to inhibit PP2Amediated β1-AR recycling) with BEZ235 countered the poor dilatory effects produced by
exogenous ROS YC and OSVF vessels. This is consistent with what others have found,
specifically that ROS can influence β1-AR recycling [20, 406]. This did not translate to
BEZ235 improving OC vessel dilation. Interestingly, inhibiting β1-AR recycling with
okadaic acid led to significant reduction in isoproterenol-mediated dilation in OC but not
in youth. This signifies that recycling is not necessary in youth for successful maximal
response to agonist, likely due to plentiful receptor density at the plasma membrane. This
is not the case in aging, indicating that greater density of receptor has been desensitized
and internalized, and maximal dilative response to agonist depends in part on recycling.
OSVF vessels exhibit partially attenuated dilation with okadaic acid, but at high doses of
isoproterenol this is not significant. Overall, this indicates OC vessels are most reliant on
recycling, followed by OSVF, then YC. Supporting these observations, we found that
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protein levels (evaluated by MFI) of PP2A, I2PP2A, and PI3kγ were unchanged with
aging or SVF therapy, indicating the mechanisms of recycling themselves are unchanged.
SNP-mediated improvement in β1-AR function has been attributed to
nitrosylation and inhibition of GRK2 [392]. We analyzed general protein nitrosative
status using a fluorescent S-nitrosocysteine antibody, believing SVF may restore β1-AR
function by reducing ROS which would alleviate nitric oxide bioavailability to
nitrosylate/inhibit GRK2. Instead, we found that S-nitrosylation status is significantly
reduced in aging and OSVF compared to youth. This complements our findings that SVF
does not restore nitric oxide bioavailability. Therefore, we conclude that in the ROS/RNS
β1-AR Desensitization and Internalization Axis, young vessels experience limited ROS
and plentiful nitric oxide bioavailability, resulting in functional β1-AR at the plasma
membrane potentially via greater GRK2 nitrosylation, less β1-AR thiol oxidation, and
less ROS-mediated blockade of receptor recycling. In aging, this axis shifts such that
there is reduced nitric oxide bioavailability, allowing functional GRK2 to influence
desensitization and internalization, and there is greater accumulation of ROS to oxidize
β1-AR-thiols and inhibit recycling. With SVF therapy, although nitric oxide
bioavailability is not restored, ROS are reduced to alleviate β1-AR thiol oxidationmediated desensitization/internalization and restored receptor recycling.
Future directions should confirm these findings by studying β1-AR trafficking
through qualitative and quantification studies. For example, in living vessels or in
endothelial cells, fluorescently tracking the trafficking of the β1-AR in response to ROS,
SNP, paroxetine, and dynasore in YC, OC, OSVF would qualitatively confirm and
support our findings [392, 407]. β1-AR trafficking can also be quantified by western
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blotting of plasma membrane and endosomal β1-AR [408]. Finally, the constituents of
SVF that are responsible for restoration of redox balance, FMD, and adrenergic
homeostasis should be determined. Differentiating between which cell type(s) and/or
paracrine factors (exosomal or exocytosed proteins, miRNA, etc.) induce the observed
changes would be of benefit for therapeutic development. It would be of interest if SVFderived exosomes could be used in lieu of cells [409]. Indeed, adipose SVF-derived
mesenchymal stem cell exosomes have antioxidant effects and protect against ischemia
and apoptosis, encourage angiogenesis, and restore mitochondrial health [383, 384, 410,
411].
In conclusion, we hypothesized that flow- and β1-AR-mediated dilation are
reduced with aging and reversed via SVF therapy by attenuating oxidative stress and
restoring protective nitrosative signaling. FMD and β1-AR were significantly reduced in
aging with reversal by SVF therapy. However, nitric oxide bioavailability was not
restored by SVF cell therapy to YC levels; instead, peroxynitrite was the mediator of
improved FMD. Β1-adrenergic dilative function was restored in SVF correlating with
reduced ROS and increased antioxidant glutathione. Our conceptual ROS/RNS β1-AR
Desensitization and Internalization Axis is supported since exogenous SNP or blockade
of desensitization/internalization restored β1-AR function in aging, and exogenous ROS
attenuated β1-AR function in youth/OSVF unless simultaneously blocking
desensitization/internalization. In conclusion, aging-mediated microvascular dysfunction
and hyperconstriction can be ameliorated by targeting oxidative stress. SVF therefore has
significant translational potential for patients with CMD and is theoretically superior over
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current clinical standards (e.g., beta blockers) that treat symptoms but do not address the
pathologic cause of microvascular dysfunction and hyperconstriction.
Innovation
Current therapeutic options for coronary microvascular disease are of limited
effectiveness, however, SVF therapy in a female rodent model reverses hyperconstriction
by restoring effectiveness of flow-mediated and β1ADR-mediated dilation. SVF’s
mechanism of action is to reduce chronic oxidative stress, which restores β1-AR function
according to our novel conceptual ROS/RNS-β1-AR Desensitization and Internalization
Axis (Fig A3.1). SVF also facilitates an acute substrate switch in response to intraluminal
flow from pro-atherogenic hydrogen peroxide-mediated FMD in aging to peroxynitritemediated FMD with SVF. This switch of FMD mediator is associated with FMD restored
to levels seen in young control animals.
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APPENDIX 4
VIEWING STROMAL VASCULAR FRACTION DE NOVO VESSEL FORMATION
AND INTEGRATION WITH HOST MICROVASCULATURE USING THE RAT
MESENTERY CULTURE MODEL

Overview
The objective of the study is to demonstrate the innovation and utility of
mesenteric tissue culture for discovering the microvascular growth dynamics associated
with adipose-derived stromal vascular fraction (SVF) transplantation. Understanding how
SVF cells contribute to de novo vessel growth (i.e., neovascularization) and host network
angiogenesis motivates the need to make observations at single cell and network levels
within a tissue. SVF was isolated from the inguinal adipose of adult male Wistar rats,
labeled with DiI, and seeded onto adult Wistar rat mesentery tissues. Tissues were then
cultured in MEM + 10% FBS for 3 days and labeled for BSI-lectin to identify vessels.
Alternatively, SVF and tissues from green fluorescent positive (GFP) Sprague Dawley
rats were used to track SVF derived versus host vasculature. SVF treated tissues
displayed a dramatically increased vascularized area compared to untreated tissues. DiI
and GFP+ tracking of SVF identified neovascularization involving initial segment
formation, radial outgrowth from central hub-like structures, and connection of segments.
Neovascularization was also supported by the formation of segments in previously
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avascular areas. New segments characteristic of SVF neovessels contained
endothelial cells and pericytes. Additionally, a subset of SVF cells displayed the ability to
associate with host vessels and the presence of SVF increased host network angiogenesis.
The results showcase the use of the rat mesentery culture model as a novel tool for
elucidating SVF cell transplant dynamics and highlight the impact of model selection for
visualization.

This chapter is from the published work referenced as follows:
Hodges, N.A., A.O. Lampejo, H. Shang, G. Rowe, A.J. LeBlanc, A.J. Katz, W.L.
Murfee, Viewing Stromal Vascular Fraction De Novo Vessel Formation and
Integration with Host Microvasculature Using the Rat Mesentery Culture Model.
Microcirculaiton, 2022.
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Introduction
The isolation of adipose stromal cells with multi-lineage differentiation potential
was first reported in the peer-reviewed literature in 2001 [179]. In recent years, the use of
stromal vascular fraction (SVF) has emerged as an alternative therapeutic strategy to
form new vessels, with its use in clinical trials growing exponentially [184]. SVF has
become an ideal candidate in vascular therapeutics due to the ability to leverage a realtime autologous point-of-care therapeutic approach, thereby avoiding excessive costs
related to good manufacturing practice and logistical obstacles related to cell transport,
storage, tracing, and inventory. SVF includes multiple cell types and can be thought of as
a heterogeneous mixture of leukocytes, erythrocytes, stromal cells, progenitor cells,
endothelial cells, endothelial progenitor cells, pericytes, and other cells of the
perivascular niche [412, 413]. Though SVF as a therapeutic has entered into clinical
testing for a variety of pathologies such as osteoarthritis [181], chronic heart ischemia
[183], angina [414], and pulmonary fibrosis [182], none to date are approved by the Food
and Drug Administration (FDA). While these clinical trials have shown beneficial effects
of SVF administration, questions regarding treatment timing, cell dose, and duration
remain. There is also a need to better understand how SVF cells spatially and temporally
contribute to neovascularization and blood flow within a vascular bed. The ultimate goal
is to deliver cells to influence and promote microvascular growth and function. Since
microvascular remodeling is a complex process involving multiple cell types, a
heterogeneous cell therapy such as the SVF may be more conducive to vascularization
than single homogenous cell approaches. A heterogeneous cell composition might
provide the unknown optimal milieu of environmental cues [186]. As of now, we know
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that SVF can dramatically affect the presence of new vessels both in vivo and in vitro
[191, 307], possibly due to engraftment into the host vasculature [42] or release of
angiogenic growth factors.13 This study will examine the former of the two paradigms
and address the knowledge gaps concerning how SVF spatially and temporally
incorporates within living tissues and promotes microvascular growth and remodeling.
The identification of SVF dynamics during neovessel formation and integration
with host microvascular networks can be thought of as an imaging challenge. Meeting
this challenge requires the ability 1) to view SVF cell populations in a real tissue
environment at the single cell level and 2) to view changes of the existing vasculature
over time. These experimental challenges thus require investigators to make decisions
related to the imaging technology and the experimental model. Potential in vivo models
include two-photon imaging of brain vasculature (cranial window) or the use of dorsal
window chamber models via intravital microscopy [415, 416]. These models incorporate
the necessary complexity of microvascular networks in situ, however these models have
yet to be used for SVF characterization because of the technical difficulties associated
with SVF transplantation, repeated imaging, and the need for invasive survival surgeries
[417]. In comparison, in vitro studies involving culturing SVF in two-dimensional or
three-dimensional substrates represent a simplified environment that allows for easier
time-lapse imaging needed to track vessel formation dynamics. Such methods have also
proven valuable for reductionist studies focused on concentration-dependent and matrixdependent effects [191, 338]. However, in vitro methods do not offer a view of an intact
host microvascular network and the impact of host-derived cell signaling factors is not
considered.
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Within the last decade, our laboratory has developed the rat mesentery ex vivo
culture model to bridge the gap between in vitro and in vivo (Fig A4.1). Traditionally
used for intravital microscopy because it is 20 – 40 µm thick, the rat mesentery is
relatively easy to image with common epifluorescent microscopes. The thinness also
makes it ideal for continued culturing and despite being excised, mesenteric windows
survive up to at least 7 days [294]. We have shown that the culture model enables timelapse investigation of cell-cell interactions at specific locations across blood and
lymphatic microvascular networks [294, 418, 419]. The physiological relevance of the
model is supported by demonstration of the functional effects of pericytes on endothelial
cell sprouting, smooth muscle cell contraction along arterioles, and the maintenance of in
vivo-like endothelial cell phenotypes along capillary sprouts during angiogenesis [294,
296, 420]. The objective of this study was to showcase the use of the rat mesentery
culture model as a platform for visualizing SVF cell dynamics and effects on the host
vasculature (Fig A4.1). Our results confirm that SVF can be translated onto the
mesentery tissue and integrate into the networks when cultured for 3 days, thus offering a
new view for SVF derived vasculogenesis and interactions with the host vasculature. The
SVF formed unique networks that connected with the pre-existing host networks. In
addition, SVF induced host microvascular network angiogenesis and examples of
individual cells were observed to be integrated along individual host vessel segments.
This study demonstrates the therapeutic potential of SVF and the importance of SVF
interaction with the host microvascular network. The results further showcase the use of
the rat mesentery culture model for visualizing SVF neovessel formation, time-lapse
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dynamics, and SVF effects on a live tissue. The comprehensive readouts will serve to
guide our understanding of SVF transplantation.

Materials and Methods
Animal model.
The University of Florida Animal Care and Use Committee approved all
experimental protocols. Adult male Wistar rats were anesthetized via intramuscular
injection with ketamine (80 mg/kg body weight) and xylazine (8 mg/kg body weight).
Adult male Wistar rats were used to be consistent with previous published studies in our
laboratory using the rat mesentery culture model. Sprague Dawley EGFP rats (Rat
Resource and Research Center; 800‐1000 g) were anesthetized via isoflurane. The
specific strain and weight of Sprague Dawley EGFP rats were used because of
availability through a collaboration at the time of the study. Adult Fischer 344 rats were
used for immunolabelling for endothelial cells and pericytes; rats were anesthetized via
intramuscular injection with ketamine (80 mg/kg body weight) and xylazine (8 mg/kg
body weight). Post tissue harvesting and/or SVF isolation, all rats were euthanized by
intracardiac injection of Beuthanasia (0.2 ml).

Rat mesentery tissue harvesting, SVF transplantation, and culture.
Rat mesenteric tissues were harvested and cultured according to a previously
established protocol [301, 418]. To harvest mesenteric tissues, the abdominal region was
shaved then sterilized with 70% isopropyl alcohol before an incision was made along
the linea alba. The mesentery was exteriorized onto a sterile plastic stage using cotton tip
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applicators to first remove the cecum and subsequently the ileum and jejunum.
Vascularized mesenteric tissues were excised and rinsed once in sterile saline with 0.9%
NaCl (Baxter; Deerfield, IL) and immersed in minimum essential media (MEM; Gibco;
Grand Island, NY) containing 1% Penicillin-Streptomycin (PenStrep; Gibco; Grand
Island, NY) at 37°C. Isolated SVF cells were suspended in 10% FBS + MEM solution at
a concentration of 10 million cells/mL. Tissues were then spread onto a polycarbonate
filter membrane (pore size = 5 µm) on a cell crown. 100 µL of SVF solution was
transferred to the surface of each mesenteric window before incubating for 20 min so the
SVF cells attached to the tissue (Fig A4.1). Cell crowns were then inverted into a 6-well
plate with the fat of the tissue pressing against the bottom of the well. 3 mL of culture
media composed of 10% FBS + MEM was then added to each well on top of the filter.
Tissues were cultured in standard incubation conditions (5% CO2, 37°C) for three days.
Adipose tissue harvest and SVF isolation.
A scalpel was used to make a Y shaped incision into the skin from the bottom of
the previous incision of the linea alba to each of the inner thighs along the midline,
stopping above the knee. The skin was carefully removed from the subcutaneous adipose
and muscle layers using the scalpel and microscissors. Hemostats were used to hold the
skin back as the separation was advanced to the coxal region. The center skin flap of
pelvic region was removed in a similar fashion. The inguinal fat pad was removed in a
continuous strip from one hip and leg to the other and placed in a 50 mL conical tube
containing sterile saline at 37°C.
Fat was placed onto a large petri dish and diced into fine pieces before transfer
into an empty 50 mL conical tube for weighing. Once weight was measured, a 0.15%
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collagenase type 1 (Thermo Fisher; Waltham, MA) and DPBS solution heated to 37°C
was prepared. Collagenase solution was pushed through a 0.22 µm filter with a syringe
for sterilization at a ratio of 2 mL per 1 gram of fat. In the event that the fat weighed less
than 3 grams, 5 mL was used to ensure enough volume was in the conical tube containing
the diced adipose. The collagenase/adipose mixture was then transferred to a shaker set to
150 RPM and digested for 45 min at 37°C. After digestion, the mixture was centrifuged
for 10 min at 600 G to separate the cells from the collagenase and the undigested fat. The
top layer of undigested fat was transferred to a new conical tube containing the same
volume of fresh filtered collagenase and transferred back to the incubator for a second
digestion. The collagenase solution was then removed from the centrifuged tube and the
bottom layer of cells was resuspended in 5 mL of 5% FBS + DPBS. The resuspended
mixture was filtered through a 250 µm cytostrainer into a new 50 mL conical tube then
centrifuged at 600 G for 5 min. Media was removed and 5 mL of ACK lysing buffer
(Thermo Fisher; Waltham, MA) was added to the cells through a 0.22 µm filter for
sterilization. The solution was then gently shaken in the dark at room temperature for 3
min. Immediately afterwards, 5 mL of 5% FBS + DPBS was added to the solution to
neutralize the lysing buffer. This solution was filtered through a 70 µm filter into a new
conical tube and the centrifuged for 5 min at 600 G. The media was removed, and the
remaining SVF was resuspended with 1 mL of 5% FBS + DPBS. 10 µL of the SVF
solution was added to 10 µL of trypan blue, mixed, and then added to a disposable slide
for cell counting with a CountessTM II Automated Cell Counter (Thermo Fisher;
Waltham, MA).
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Immunohistochemistry.
Cultured tissues were fixed in methanol for thirty minutes at -20°C. Tissues were
spread on glass slides before being rinsed 3 times for 10 minutes in PBS +0.1% saponin.
Fat around window was removed and a hydrophobic barrier was applied around the tissue
before being labeled for either platelet endothelial cell adhesion molecule (PECAM;
endothelial cell marker) or PECAM plus Neuron-glial antigen 2 (NG2; pericyte marker):
Tissues were incubated for 1 hour at room temperature with a primary antibody solution
of 1:200 mouse monoclonal biotinylated anti-PECAM antibody (CD31 antibody,
BD Pharmigen; San Diego, CA) with 1:100 rabbit polyclonal anti-NG2 antibody
(Millipore/Chemicon, Billerica, MA). Tissues were then incubated for 1 hour at room
temperature with a secondary antibody solution of 1:500 CY3-conjugated Streptavidin
secondary (Jackson Immunoresearch Laboratories) and 1:100 goat anti-rabbit CY2conjugated antibody (Jackson Immunoresearch Laboratories). Antibodies were diluted in
antibody buffer solution comprised of phosphate-buffered solution (PBS; Sigma-Aldrich)
+ 0.1% saponin (Sigma-Aldrich) + 2% bovine serum albumin (BSA;
Jackson Immunoresearch Laboratories) + 5% normal goat serum
(Jackson Immunoresearch Laboratories). After each antibody incubation period, the
tissues were submerged in PBS + 0.1% saponin for 3 x 10 min washes. The
representative images shown in Figure A4.2 were obtained from experiments involving
tissues and SVF harvested from adult Fischer 344 rats.

Cell and vascular network tracking studies.
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In order to investigate the fate of the stromal vascular fraction and the
microvascular networks to which they were transplanted, cell tracking models were
implemented. For the first experimental model, DiI solution was mixed with MEM to
make a 5 µL/mL labeling solution. Isolated adult male Wistar SVF cell suspension was
centrifuged, aspirated, and resuspended in the DiI solution. The SVF was then
incubated for 5 min at 37°C followed by 10 min incubation at 4°C. The SVF suspension
was centrifuged at 600 G for 5 min and the labeling media was replaced with suspension
media. Cell were then centrifuged again and washed for 2 more times before being
seeding onto Wistar tissues according to the protocol above. After 3 days, BSI-Lectin
conjugated to FITC (Sigma-Aldrich; St. Louis, MO) was added to media in a 1:40 ratio,
transferred to the well containing the seeded tissue, and incubated for 30 min at 37°C.
After incubation, the supplemented media was removed, and the tissues were
subsequently rinsed with label free media. To preserve DiI labeling, tissues were fixed in
methanol-free 4% formaldehyde solution for 10 min at room temperature.
In another experiment, SVF from GFP rats was transplanted onto unlabeled Adult
Wistar tissues. The 6-well plates containing these tissues were then placed into a culture
chamber mounted on a microscope stage to maintain a temperature of 37 °C. Two to four
microvascular networks were imaged per tissue every 24 hours using an
inverted epifluorescent microscope. After 3 days, tissues were labeled with TRITC lectin
according to the same protocol above and imaged again.
The third tracking experimental group used adult male Wistar SVF on GFP
tissues. The time lapse was performed as described above. Following a 3-day culture,
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TRITC lectin labeling of the whole tissue was performed as described above and imaged
again.

Image acquisition.
Images were acquired using 4x (dry, NA = 0.1), 10x (dry, NA = 0.3), and 20x
(oil, NA = 0.8) objectives on an inverted microscope (Nikon Eclipse Ti2) coupled with an
Andor Zyla sCMOS camera. Image analysis and quantification were done using ImageJ
2.0.0-rc-54 (U.S. National Institutes of Health, Bethesda, MD).

Statistical analysis.
Two statistical comparisons were made in this study. In order to evaluate the
effects of SVF on tissue vascular area, a comparison was made using a two-tailed
Student’s t-test between 2 experimental groups: FBS alone (control) and SVF + FBS. In
order to evaluate the effects of SVF, a comparison was made using a paired t-test
between the vascularized areas of native vessels in GFP tissues at day 0 and day 3.
Results were considered statistically significant when p < 0.05. Statistical analysis was
performed using SigmaStat ver. 3.5 (Systat Software, San Jose, CA, USA). Values are
presented as mean ± standard error of the mean (SEM).

Results
SVF formation of new vessels via neovascularization.
Visualization of microvascular growth dynamics using the rat mesentery culture model
enables identification of SVF derived neovascularization. Lectin labeling of tissues after

250

DiI positive SVF transplantation and culture for 3 days revealed clusters of vessels with a
central hub and radial outgrowth (Fig A4.2 A-C). This unique pattern was unlike the
typical branching hierarchy of mesenteric vessels and resembled the aggregation and
sprouting dynamics reported for SVF vessel formation in vitro [191]. Positive
DiI labeling identified the central hub structure and the radial spoke structures indicating
SVF origin (Fig A4.2 B). Lectin co-labeling of the radially patterned segments isolated
from nearby host networks characterized by hierarchical branching suggests that the
segments were SVF derived. PECAM and NG2 labeling of the apparent hub and spoke
patterned structures confirmed that vessel segments contained endothelial cells and
vascular pericytes (Fig A4.2 D-F). NG2 labeling revealed pericytes along vessels
extending from the central hub aggregates and the branching vessels that connected the
hubs (Fig A4.2 E). After 3 days of culture, the SVF treated tissues displayed a dramatic
increase in percentage of vascularized area, indicative of new vessel formation (Fig A4.2
G-I). The vascular coverage increased nearly two-fold compared to serum stimulation
alone ((88.5 ± 2.2% vs. 45.9 ± 6.9%, p = 0.0004) (Fig A4.2 G-I). Lectin labeling of the
networks in the SVF transplanted tissues identified an intact network with no apparent
distinction between the host and SVF derived vessels. The apparent increased
vascularized areas were also covered with branching capillary networks. SVF
neovascularization is further supported by comparing the locations of host vessels versus
host and SVF vessels. Such a comparison was made possible by transplantation of wild
type SVF on GFP tissues. After 3 days in culture, areas void of GFP positive vessel
segments were observed between GFP positive host networks. This same region
contained GFP negative, lectin positive vessels, indicating SVF neovascularization had
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formed connections between the networks (Fig A4.3). SVF derived neovascularization is
also supported by time-lapse imaging of SVF from transgenic GFP rats which was used
to track vasculogenesis over time (Fig A4.4). SVF tracking revealed 3 phases involved in
initial vessel formation: initial segment formation, segment network formation, and the
connection of branched segment networks (Fig A4.4). Segments were defined by the
apparent elongation of individual cells and segment networks were classified as networks
made up of two or more connected segments.

SVF association with host vessels and effect on angiogenesis.
The visualization of microvascular growth dynamics using the rat mesentery
culture model also enables SVF association with host vessels and SVF effects on
angiogenesis. In support of the potential for SVF association along host vessels, examples
of DiI positive SVF cells were observed along lectin vessels (Fig A4.5 A-C). DiI positive
cells were also observed in the interstitial space not associated with vessels. These cells
associated with vessels were only observed to be present along capillaries and not
observed along larger diameter arterioles, larger diameter venules, or initial lymphatic
vessels (data not shown). The different vessel types were identified based on previously
described characteristic morphologies and position within a network consistent18,21.
Finally, to determine the effect of SVF on host tissue angiogenesis, vascularized area
measurements were compared for GFP host tissues with wild type SVF versus no SVF
transplantation control groups (Fig A4.5 D-G). For this experiment, GFP only identified
the native, host derived networks and comparison of Day 0 versus Day 3 vascularized
area per tissue allowed for the quantification of network expansion due to angiogenesis.
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Day 3 tissues treated with SVF displayed a significant increase in vascular coverage
compared to tissues treated with serum alone (25.3 ± 4.2% vs. 13.0 ± 3.2%, p = 0.0017)
indicating a proangiogenic effect (Fig A4.5 H).
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Figure A4.1

Figure A4.1: The rat mesentery culture model enables the visualization of SVF
effects on microvascular growth.
A gap in complexity exists between common three-dimensional in vitro cell culture
methods and in vivo systems. The rat mesentery culture model fills this gap by
maintaining tissue complexity, while enabling observation over a short time course. For
the visualization of SVF dynamics, SVF can be pipetted onto tissues prior to culture.
Mesenteric tissues are surgically removed, rinsed in buffered saline, and placed in media.
Post cell seeding, tissues are inverted into a culture well and covered with media.
Readouts include SVF neovascularization, time-lapse imaging, SVF integration with host
vessels, and effects on host network angiogenesis.
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Figure A4.2

Figure A4.2: SVF formation of new vessels via neovascularization.
Example of cluster and outgrowth pattern of SVF derived cells after 3 days in culture. DiI
labeled SVF cells identify lectin positive central hubs with spoked vascular branching (A-
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C). PECAM and NG2 labeling of SVF formed vessels indicating the presence of
endothelial cells and vascular pericytes (D-F). Images comparing the vascular area per
tissue area for tissues cultured with serum and serum plus SVF. Green outline indicates
vascularized area. Red outline indicates avascular area (G-H). Quantitative analysis of
percent vascularized area was significantly higher in the SVF treated tissues compared to
serum alone (n= 4 tissues from 2 rats per group) (I). * represents p < 0.05. Values are
shown as mean ± SEM. Scale bars = 100 µm (A-F), 2 mm (G-H).
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Figure A4.3

Figure A4.3: Observation of host microvasculature versus SVF derived vessels
confirms neovascularization. Images of GFP positive host vessels and all vessels in the
same tissue region after 3 days in culture. Tissues were harvested from GFP transgenic
rats allowing for identification of host tissue vessel segments. Lectin labeling identifies
all vessels including the host vessels and new SVF derived vessels. GFP negative, lectin
positive segments indicate SVF origin (A-B). Corresponding processed images more
clearly show connected vessel segments because lectin and GFP labeling also identifies
non-vascular interstitial cells. Vessel segments were defined by continuous labeling and
connection within a network. Observation of lectin positive segments spanning the gap
between GFP positive vessel labeling supports the formation of SVF derived vessels (CD). Scale bars = 100 µm.
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Figure A4.4

Figure A4.4: Time-lapse imaging of initial SVF vessel formation.
Example images of GFP positive SVF cells over the initial vessel development time
course. GFP sourced SVF was seeded onto tissues at the start of the culture duration (AC). At 24 hours the GFP cells appeared unassembled (A). By 48 hours GFP structures
were observed in assembled segments (B). By 72 hours assembled segments formed
connections. In some regions, a central hub with outward radial segment growth was
identified (C). Scale bars = 250 µm.
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Figure A4.5

Figure A4.5: SVF can associate with host vessels and stimulate host network
angiogenesis.
Example of DiI positive SVF derived cells along DiI negative, lectin positive vessel
segments (A-C). Analysis of the effect of SVF on host network angiogenesis. DiI positive
cells can also be observed not associated with vessels in the interstitial space.
Representative network images of tissues harvested from GFP transgenic rats at 0 hours
and 72 hours for 2 experimental groups: cultured with serum (FBS) and cultured with
serum (FBS) + wild type SVF. Outlines identify circumscribed vascular areas per
network (D-H). Quantification of the percent increase in the vascularized area of native
GFP vessels after 3 days in culture with serum alone or serum plus SVF (n= 6 tissues
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from 2 rats per group) (H). * represents p < 0.05; values are shown as mean ± SEM.
Scale bar = 50 µm.
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Figure A4.6

Figure A4.6: Summary schematic of observed SVF effects on microvascular
network growth using the rat mesentery culture model.
On day 0, before SVF and host network remodeling, SVF cells were transplanted onto
cultured tissues. The rat mesentery culture model enabled the viewing of SVF and host
network cells over time. Characterization of cell, vessel, and network dynamics during
culture supports that SVF can contribute to microvascular growth via 1) de novo vessel
formation, 2) integration or association of individual cells along host vessels, and 3)
stimulation of host network angiogenesis.
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Discussion
SVF implantation in vivo has been shown to result in the formation of patent
microvessels [41, 364, 421]. Yet current SVF therapies have not reached their full
potential due to the lack of understanding concerning the processes related to how SVF
contributes to the growth and remodeling of a vascular network. The infancy of SVF
research and our lack of information surrounding the mechanisms of SVF function
motivates the need to view the relative contributions of SVF effects on host network
angiogenesis, host vessel integration, and neovessel formation. Discovery of SVF
dynamics will guide new paradigms for research and therapeutic design.
Visualizing cell dynamics across temporal and spatial scales is a key challenge in
advancing our understanding of the microvasculature. Imaging cellular in vitro systems
does not accurately mimic the complexity of real vascular networks and imaging of in
vivo systems is often limited to end time points. To this end, in vitro models are valuable
for reductionist experiments investigating what players are important for vessel formation
and in vivo models are essential for evaluating functional effects. For example, in vitro
studies have shown the importance of the extracellular matrix environment; SVF cultured
on collagen, gelatin, and laminin formed monolayers while SVF cultured on Matrigel
formed microvascular networks [191]. As an in vivo example, a study by Koh et al.
demonstrated that SVF injection can cause neovascularization via cell re-assembly and
increase blood perfusion post hind limb ischemia [364]. Previous studies utilizing SVF
therapy to improve tendon, cardiac, and nerve regeneration also emphasize the ability of
SVF to form new vessels and integrate with nearby host vasculature [183, 422, 423].
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Questions regarding how cell assembly dynamics and contributions of new vessel
formation effect angiogenesis motivate the need to visualize SVF during these processes.
This study presents the rat mesentery culture model as a tool for visualizing SVF
during microvascular growth in real, intact, multi-cellular microvascular networks over
the time course of a few days. Advantages of the tissue culture model include the ability
to view an entire microvascular network, the use of a standard epifluorescent microscope,
the ease of adding SVF cells, and the use of multiple tissues per rat. As a thin (20 - 40
µm), translucent tissue, the mesentery provides an intact tissue ideal for observation at
the whole tissue, network, and cellular levels. Observation of DiI and GFP labeled SVF
identified segment formation and structures consisting of a central hub with segments
projecting radially. These central aggregates of cells and their projections labeled
positively for endothelial and pericyte markers. Important for the utility of the mesentery
culture model, the process occurs over several days. SVF derived hubs interconnect with
each other and establish branching capillary network. The characterization of the DiI and
GFP derived segments as vessels is supported by cell 1) the formation of similar DiI
positive SVF segments and structures in initially avascular areas, 2) the co-labeling of
these structures for lectin and PECAM, and 3) similar evidence of SVF vessel segment
formation dynamics observed in vitro [191].
Labeling of SVF versus the host microvasculature enabled the visualization of
SVF neovasculogenesis. This is important because chronic in vivo cell therapy studies
involving transplantation or injection of mesenchymal stem cells or circulating stem cell
types have suggested cells incorporate into the existing vasculature at rates of ~ 0% –
10%, but do not assemble to form new vessels [188, 314, 315, 361].
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In comparison, our results show that SVF derived vessels can cause a dramatic
increase in vascular area in a tissue via cell assembly. We speculate that since SVF
contains various stem cell populations, the dramatic differences in effects on
microvascular growth might be attributed to SVF’s mixture of multiple cell types. These
differences motivate future studies to 1) compare the advantages between specific stem
cell therapy approaches and 2) elucidate the roles of specific sub-cell populations [320].
Our results also support the ability of SVF cell to associate with host vessels,
though future studies will be needed to quantify the percentage of integration per host
vessel type and the percentages of integration of vascular pericytes or endothelial cells.
Isolated GFP positive vessel segments derived from GFP SVF were observed
interconnecting with lectin positive, GFP negative network regions (data not shown),
suggesting that SVF cells can also integrate with host networks as pre-assembled
endothelial segments. As support for integration as pericytes, examples of DiI positive
SVF cells were observed wrapping and elongated along lectin positive vessels in
characteristic pericyte locations. Interestingly, SVF cells were not observed on vessels
with larger diameters (arterioles and venules) nor lymphatic vessels (data not shown).
These findings were made possible by viewing the hierarchy of intact microvascular
networks. Additional studies are needed to evaluate the percentages of integration and
whether SVF preferably integrate as one cell type or another.
The SVF effects on microvascular growth observed in this study (Fig A4.6)
further emphasize the need to also evaluate the relative contributions of
neovascularization, vessel integration, or host network angiogenesis. Comparison of the
quantification of SVF presence on vascularized tissue area (Fig A4.2) and host network
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vascular area growth (Fig A4.5) suggests that neovascularization might be the most
dramatic contributor to microvascular growth. However, questions regarding the relative
dynamics remain. How does, for example, initial microvascular network size or the area
of initial avascular regions influence SVF dynamics? Do SVF cells prefer to populate
avascular regions? What are the paracrine mechanisms for interstitial residing SVF cells
on host network angiogenesis? How far can SVF cells migrate? Our examples of
visualizing SVF in the current study provide some information and highlight the
utilization of the model for follow up studies focused on further characterization of cell
dynamics.
The scope of this study focused on demonstrating the capability of the rat
mesentery culture model for viewing the locations of SVF neovascularization, SVF timelapse vessel segment assembly, and SVF effects on the host microvasculature. As SVF
related areas of research are still in their early stages, these types of images are highly
valuable. Novel findings reported herein show that SVF can assemble into new vessels
that fill avascular tissue regions and connect to host networks. In vitro studies have
suggested that SVF forms aggregates that develop into a central hub structure from which
radial vessels sprouting occurs [191]. Our ex vivo results support these initial dynamics
and subsequently show that these hubs can interconnect with other nearby hubs, form
networks, and connect to the host microvasculature. Consequently, our view of SVFs
effect on microvascular growth help link in vitro observations to an intact microvascular
system. The results of the current study motivate follow-up evaluation of SVF derived
vessel functionality, endothelial junctional structure, the size of SVF derived vessels, and
additional microvascular remodeling metrics. Another advantage of the tissue culture
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model is the presence of lymphatic vessels, immune cells, and nerves [294, 419, 424].
Additional follow up studies could also include investigation of SVF fate and functional
relationships within these systems.
Use of the rat mesentery culture model allows for the incorporation of a variety of
methods used to investigate the microvascular dynamics of SVF transplantation. Despite
the unique view the mesentery culture model provides, there are still several challenges
associated with the characterization of SVF dynamics. DiI labeling of cells is valuable for
tracking the original transplanted cells but as a membrane marker, each new generation of
cell has less vibrant labeling which makes long-term observation difficult. Other
limitations are the lack of perfusion and the limited options for transgenic rats. In a recent
study, we demonstrated the ability to perfuse the networks in culture, yet future studies
are needed to incorporate perfusion with SVF transplantation. Model development can
also include the culturing of SVF on mouse mesentery tissue. The mouse mesentery
tissue is typically avascular, yet our laboratory has recently demonstrated a method to
stimulate vascularization and the feasibility of culturing the tissues analogous to the rat
mesentery culture model [425]. Finally, using cell specific lineage or knockout transgenic
mice strains, studies could probe the roles of specific SVF cell populations. Future work
can also adapt the model to investigate pathological conditions or the influence of
aging. For example, whether in rat or mouse, tissues and/or SVF can be harvested from
disease strains to evaluate cell versus host tissue effects. Regarding aging, a study by
Aird et al. showed that SVF constructs from old donors had reduced perfused vascular
networks compared to SVF taken from young donors following 4-week subdermal
implantation [154]. Utilization of the multiple readouts made possible by the rat
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mesentery culture model would allow for determination of what SVF effects might be
compromised.

Perspective
SVF transplantation represents a promising microvascular growth platform and
advancing our understanding of SVF effects requires the ability to visualize SVF
integration during microvascular growth. The challenges associated with dynamically
viewing multiple cell types across an intact network motivates the need for models that
fill the gap created by in vivo and in vitro limitations. In this study, we demonstrate the
ability to visualize SVF de novo vessel formation and integration with a host
microvasculature via time-lapse observations of mesenteric tissues in an ex vivo setting.
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